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Monoclonal antibodies (mAbs) have emerged over the last 20 years as an invaluable 
biosensing, diagnostic, and therapeutic tool for targeting cancer. With their tight 
antigen binding and specificity, mAbs are a modular platform for a host of therapeutic 
modalities, most recently in bioconjugates. Bioconjugates are broadly defined as 
biological targeting moieties covalently linked with therapeutic molecules and are 
useful in targeting potent therapeutics to specific cells and tissues. In this work, we 
develop and investigate mAb bioconjugates for targeted delivery of small molecules, 
nucleic acids, peptides, and proteins. First, we establish methods for in-house 
expression, purification, and characterization of mAbs that undergo lysosomal and fast 
recycling endocytosis pathways upon binding to a target antigen. We then utilize 
biorthogonal reaction pairs to append various cargo to the mAbs. With an eye toward 
short-interfering RNA (siRNA) delivery, we conjugate siRNA and membrane 
disrupting agents to antibodies for co-delivery, targeted cytosolic localization, and 
gene knockdown of a luciferase reporter gene. Finally, we engineer antibodies with 
two, orthogonal conjugation sites and to attach sequentially cleavable cargos to a 
single mAb. With this, we demonstrate controlled, site-specific, dual-labeled 
antibodies with extracellular and intracellular cargo release mechanisms that can be 
implicated for sequential release antibody drug conjugates (ADCs). 
 iv 
BIOGRAPHICAL SKETCH 
Dana Nicole Thornlow was born on November 2nd, 1991 and spent her childhood in 
Sayville, New York. She began dancing at age 4 and believed she would grow up to 
be a dancer, until she realized she couldn’t make a career out of it and discovered she 
was actually pretty good at science. She graduated from Sayville High school in 2009 
with a newfound love of chemistry. 
In September 2009, she moved to Amherst, Massachusetts for her B.S. in Chemical 
Engineering with a concentration in biochemical engineering. In her freshman year, 
she joined the UMass dance team to maintain her sanity in the midst of lots of 
homework. In her sophomore year, she pursued undergraduate research under Prof. 
Neil S. Forbes, studying Salmonella typhimurium motility in tumor tissue, and 
continued throughout her undergraduate career.  
In August 2013, she moved to Ithaca, New York to start her PhD research as the first 
cohort of students in Prof. Christopher A. Alabi’s Lab. Under his direction, she 
worked on a variety of projects related to building antibody conjugates for delivering 
short-interfering RNA, as well as pioneering laboratory efforts to screen synthetic 
antimicrobial oligomers. In 2014, she received the NSF graduate research fellowship, 
followed by the inaugural Fleming Family Fellowship in 2015, and culminated her 
PhD by receiving the Austin Hooey Research and Service Award in 2018. She 
continued her passion for dance at Cornell when she literally stumbled upon the 
audition for Shadows Dance Troupe in 2013 while looking for the locker room in 
Teagle. She danced with Shadows for 10 semesters. 
After her PhD, she will begin a postdoctoral research position in Prof. Judy 
Lieberman’s Lab at Harvard Medical School, designing RNA aptamer conjugates for 
targeted siRNA delivery. She will also undoubtedly continue to dance. 
 
 v 
 
 
 
 
 
 
 
 
 
 
For all the people at Cornell and elsewhere that made all of this possible. And to CTB 
for all the hazelnut coffee (and chapples).
 vi 
ACKNOWLEDGMENTS 
I would first like to acknowledge Prof. Chris Alabi for taking me on as a student and 
giving me the freedom to make this project my own. Though it was difficult, I learned 
a huge range of skills that have prepared me well for the next challenge I face after 
this PhD. He has been a constant source of ideas and none of this would be possible 
without his guidance. 
Next, I would like to acknowledge my committee members, Prof. David Putnam and 
Prof. William Brown for their helpful feedback throughout this process. Though I 
should have utilized them much more, I appreciate their help in making this process as 
smooth and painless as possible. 
I would like to also acknowledge the National Science Foundation, the PhRMA 
Foundation, and Sam and Nancy Fleming for their financial support of me and my 
work.  
The entire Alabi Lab, past and present, have been an invaluable resource of knowledge 
and friendship throughout this PhD process. I would not be where I am now without 
the helpful conversations I’ve had with all of my lab mates, about experiments or 
otherwise, that have kept me moving forward over the past 5 years.  
Additionally, I would like to acknowledge the several undergraduate researchers I’ve 
had the pleasure of mentoring and working with: Katherine Fein, Madeline Dalziel, 
Bryan Thornlow, Masoom Chainani, and Jacqueline Plesset. They have taught me 
how to be a mentor and dealt with my learning process along the way. I hope I was 
able to insight as much in them as they have in me. 
Particular members of the fellow “bio” CBE groups have been invaluable to my 
success, including Emily Cox, Morgan Ludwicki, and Carolyn Shurer. I am very 
proud to be a part of this group of women who are incredible scientists, and I believe 
 vii 
that all of us have helped each other immensely in science and otherwise during our 
time in Ithaca. 
I would like to also acknowledge all of the other Cornell students and post-docs that 
have helped me along the way, particularly the 2013 PhD cohort. I have made the best 
of friends that I know will stay with me long after we all leave Ithaca. I cherish all the 
time we’ve spent together, from long homework sessions in the penthouse, attending 
A exam practices and presentations, outreach events, and organizing committees, to 
beers at the Chapter House (RIP), summer kickball, birthday parties, and every single 
one of my dance performances.  
I would also like to thank Shadows Dance Troupe for welcoming me as an old lady 
grad student to practice and perform with you all. Thanks for keeping dance as a 
constant source of joy in my life. 
To Nick Lamson, who provided love, support, and a plethora of coffee shops for thesis 
writing. 
Also, to the entire CBE family, for which I have truly felt a welcome member. 
And finally, to acknowledge my parents, Dan and Robin Thornlow, and brother, 
Bryan Thornlow, for all of their support for as long as I can remember. They 
encouraged me to pursue this PhD and I know they will continue to support me 
beyond it. 
 
 
 
 
 
 
 
 viii 
TABLE OF CONTENTS 
BIOGRAPHICAL SKETCH ......................................................................................... iv 
TABLE OF CONTENTS ............................................................................................ viii 
LIST OF ABBREVIATIONS ....................................................................................... ix 
LIST OF FIGURES ....................................................................................................... xi 
LIST OF TABLES ...................................................................................................... xiii 
CHAPTER 1 – INTRODUCTION: PROTEIN CONJUGATES IN TARGETED 
DELIVERY OF BIOLOGICS ...................................................................................... 14 
CHAPTER 2 – ANTIBODY EXPRESSION AND CONJUGATION METHODS .... 26 
CHAPTER 3 – ANTIBODY-siRNA CONJUGATES ................................................. 52 
CHAPTER 4 - MEMBRANE DISRUPTING AGENTS FOR ENDOSOMAL 
ESCAPE ....................................................................................................................... 78 
CHAPTER 5 – ANTIBODY CONJUGATES FOR DUAL-DELIVERY ................. 110 
CHAPTER 6 – DUAL-LABELED ANTIBODY DRUG CONJUGATES FOR 
ORTHOGONAL CARGO RELEASE ....................................................................... 129 
CHAPTER 7 – CONCLUSIONS AND FUTURE DIRECTIONS ............................ 152 
APPENDIX ................................................................................................................ 156 
REFERENCES ........................................................................................................... 186 
 
 ix 
LIST OF ABBREVIATIONS 
 
MW – Molecular Weight 
PEG – Polyethylene Glycol 
LLO – Listeriolysin O 
PFO – Perfringolysin O 
MAL – Maleimide 
OPSS – Ortho pyridyl disulfide 
RP-HPLC – Reverse-phase High Performance Liquid Chromatography 
HIC – Hydrophobic Interaction Chromatography 
LCMS – Liquid chromatography-mass spectrometry 
CDC – Cholesterol-dependent cytolysin 
DTT – Dithiothreitol 
bME – Beta-mercaptoethanol 
DMSO – Dimethyl Sulfoxide 
DMF – Dimethyl Formamide 
SDS-PAGE – Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
THF – Tetrahydrofuran 
TFA – Trifluoroacetic Acid 
MMP-2 – Matrix Metalloproteinase-2 
CatB – Cathepsin B 
siRNA – short interfering RNA 
EEA – Endosomal Escape Agent 
Ab – Antibody 
mAb – Monoclonal Antibody 
HC – Heavy chain 
LC – Light chain 
GalNAc – N-acetyl galactosamine 
ASGPR – Asialoglycoprotein receptor 
Tf – Transferrin 
TfR – Transferrin Receptor 
Tub – Tubulin  
ASO – antisense oligonucleotide 
CQ – Chloroquine 
ADC – Antibody-drug conjugate 
ADCC – Antibody-dependent cell-mediated cytotoxicity 
CDC – Complement-dependent cytotoxicity 
ADCP – Antibody-dependent cellular phagocytosis 
NK – Natural Killer 
mTG – Microbial Transglutaminase 
LplA – Lipoic Acid Ligase A 
LAP – LplA Acceptor Peptide 
HEK – Human Embryonic Kidney 
DOL – Degree of Labeling 
DAR – Drug-Antibody Ratio 
 x 
KD – Knockdown  
MAL – Maleimide 
SS – Disulfide 
NHS – N-hydroxy succinimide 
TCO – Trans cyclooctene 
MeTzine – Methyl tetrazine 
DBCO – Dibenzyl cyclooctyne 
Az – Azide 
DNA – Deoxyribonucleic Acid 
RNA – Ribonucleic Acid 
dsDNA – double-stranded DNA 
dsRNA – double-stranded RNA 
ssDNA – single-stranded DNA 
ssRNA – single-stranded RNA 
aa – Amino acid 
His – Histidine  
EtOH – Ethanol 
MeOH – Methanol 
EtOAc – Ethyl Acetate 
IPA – Isopropanol  
PBS – Phosphate-buffered saline 
DMEM – Dulbecco’s Modified Eagle Media 
FBS – Fetal Bovine Serum 
AF488 – Alexa Fluor 488 
AF647 – Alexa Fluor 647 
MDR – Multi-drug resistant 
MMAE – Monomethyl auristatin E 
MMAF – Monomethyl auristatin F 
WT – Wild-type 
Mut – Mutant 
KD – Dissociation Constant 
kD – Kilodalton 
CEA – Carcinoembryonic Antigen 
EGFR – Epidermal growth factor receptor 
 xi 
LIST OF FIGURES 
 
Figure 1.1 Antibody Structure and Function (adapted from Carter et. al1)  (15) 
 
Figure 1.2 Antibody Therapeutic Mechanisms (adapted from Weiner et. al2) (16) 
 
Figure 2.1 Hybridoma Antibody Culture, Expression and Purification   (31) 
 
Figure 2.2 Trastuzumab Antibody Cloning, Expression, and Purification from HEK 
293F Suspension Cells        (33) 
 
Figure 2.3 Uptake of Purified Antibodies in Target Cells    (35) 
 
Figure 2.4 Schematic of conjugation reactions     (36) 
 
Figure 2.5 Non-specific and Site-Specific PEGylation of Purified Antibodies (38) 
 
Figure 3.1 Luciferase Expression via Viral Transduction    (56) 
 
Figure 3.2 RNA Chemical Stability Modification     (58) 
 
Figure 3.3 Transferrin-Nucleic Acid Conjugation and Purification   (60) 
 
Figure 3.4 Functionalized Nucleic Acids with Heterobifunctional Crosslinkers (62) 
 
Figure 3.5 Conjugation and Uptake of Antibody-nucleic acid conjugates  (63) 
 
Figure 4.1 Peptide Endosomal Escape Agents with Amine Chemistry  (82) 
 
Figure 4.2 Peptide Endosomal Escape Agents with Thiol Chemistry  (85) 
 
Figure 4.3 Melittin Conjugation to Transferrin (Tf) Protein    (86) 
 
Figure 4.4 Peptide Conjugations with Chemical Linkers    (88) 
 
Figure 4.5 Characterization and Conjugation of R9K    (90) 
 
Figure 4.6 Conjugation of Peptides to Antibodies     (92) 
 
Figure 4.7 Perfringolysin O (PFO) Characterization     (93) 
 
Figure 4.8 Listeriolysin O (LLO) Characterization     (96) 
 
Figure 4.9 LLO Surface PEGylation- Studies on surface PEGylating LLO for reduced 
interaction with the outer cell membrane.      (98) 
 
 xii 
Figure 4.10 LLO-Antibody (Ab) Conjugation and Uptake into Mammalian Cells 
(SKOV3 Cells)                  (101) 
 
Figure 5.1 Schematic of Proposed Antibody Dual-Conjugate Delivery System     (112) 
 
Figure 5.2 Early Endosomal Fusion and Co-localization of TfR Antibody Conjugates
                   (114) 
 
Figure 5.3 Melittin-siRNA complexation for Luciferase Knockdown          (115) 
 
Figure 5.4 Transferrin (Tf)-siRNA and Tf-Melittin Conjugate Co-Delivery          (116) 
 
Figure 5.5 Antibody-siRNA Conjugate Delivery with Chloroquine Treatment     (118) 
 
Figure 5.6 Her2Ab-siRNA Conjugate Delivery with Chloroquine Treatment       (119) 
 
Figure 5.7 CD63Ab-siRNA and LLOmut Conjugate Co-Delivery: Simultaneous and 
Sequential Addition                (121) 
 
Figure 5.8 Conjugated LLOmut-siRNA Delivery            (123) 
 
Figure 5.9 Her2Ab-R9K-siRNA Non-covalent conjugate delivery          (124) 
 
Figure 6.1 Schematic for Dual-Labeled Antibody Conjugates and Orthogonal 
Cleavage                (130) 
 
Figure 6.2 LAP-Tag incorporation into pVitro vector for simultaneous transfection and 
expression of light chain (LC) and heavy chain (HC) tagged Trastuzumab        (132) 
 
Figure 6.3 Efficient conjugation of antibodies with pAz and TCO substrates and Click-
able PEGs (PEG-Tz and PEG-DBCO) via LplA           (133) 
 
Figure 6.4 Dual-Labeled Antibodies via mTG and LplA          (134) 
 
Figure 6.5 Enzymatic Cleavage of Linkers via CatB and MMP-2         (137) 
 
 xiii 
LIST OF TABLES 
 
 
Table 3.1 of Dissociation Constants of Parent Antibodies and Antibody-DNA 
Conjugates          (64)
 14 
CHAPTER 1 – INTRODUCTION: PROTEIN CONJUGATES IN TARGETED 
DELIVERY OF BIOLOGICS 
 
Antibodies as a Cancer Therapeutic Class 
Monoclonal antibodies (mAbs) have become an invaluable scientific tool in laboratory 
and pathological diagnosis since their discovery in 1975.3 With their strong antigen 
specificity and affinity, antibodies are utilized in laboratory cell and tissue analysis, as 
well as a diagnostic tool for a host of disease biomarkers.  
 
An antibody is a Y-shaped, tetrameric protein consisting of two identical heavy and 
light chains with constant and variable domains linked via disulfide bonds (Figure 
1.1).1 The constant region of the antibody contains 3 heavy chain domains (CH1, CH2, 
and CH3) and one light chain domain (CL), whereas the variable region consists of one 
heavy (VH) and one light (VL) chain domain. CH2 and CH3 domains exist in the Fc or 
“stem” region of the protein, and dictate the immunological response triggered by the 
antibody. This region also contains a conserved, single glycosylation site at Q297 
which is vital for effector function. The Fab or “arm” region of the protein contains 
the CH1, CL, and variable domains, which dictate the antigen binding specificity and 
affinity. Manipulating and engineering the antibody structure can determine the 
mechanism and efficiency at which it can be used in cancer treatment. 
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Figure 1.1  Antibody Structure and Function (adapted from Carter et. al1) - 
Schematic of full length IgG1 and Fc region glycosylation (not to scale). Zoom of 
symmetric half of IgG containing constant (dark blue, red) and variable (light blue, 
orange) domains. These two symmetric halves are connected via disulfide bonds in the 
CH2 domain. A single glycosylation site is present at the CH2 domain at Q297.  
 
Monoclonal antibodies can be used in a variety of ways to treat cancer depending on 
the given antigen and cell type. The holy grail of monoclonal antibodies in treating 
cancer would be to identify a single antigen that is uniquely and abundantly present on 
cancerous tissue over normal tissue. However, this cancer-specific antigen has yet to 
be found. Nevertheless, a host of antibodies that bind cancerous cells specifically have 
been identified and have the highest tumor specificity of any other targeted therapy to 
date.4 
 
In treating cancer, monoclonal antibodies can function via three main mechanisms:5 
Blocking/changing receptor function, modulating the immune system, or delivering a 
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chemotherapeutic cargo (Figure 1.2). Depending on the mechanism being targeted, the 
antibody-antigen pair requires a different set of properties. For example, antibodies 
eliciting an immune effector function response should bind to a highly abundant, non-
internalizing, surface antigen; whereas antibodies carrying a chemotherapeutic drug 
need not be as abundant but should be highly specific and internalize rapidly via 
endocytosis. Several antibodies have been developed utilizing these mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Antibody Therapeutic Mechanisms (adapted from Weiner et. al2) - 
Schematic of antibody therapeutic mechanisms on target cells including secondary 
effector responses (ADCC and CMC) and Antibody Drug Conjugates (ADCs). mAbs 
can signal effector cells through immunoreceptor tyrosine-based activation motifs 
(ITAMs), that recruit natural killer (NK) cells to secrete perforin and granzymes and 
induce apoptosis in the target cell for antibody-dependent cellular cytotoxicity 
(ADCC). mAbs can also induce complement-mediated cytotoxicity (CMC) in which 
the classical complement pathway is triggered and a membrane attack complex 
(MAC) is formed. Antibody drug conjugates (ADCs) can also induce cell killing by 
endocytosis of the ADC followed by release of the cytotoxic drug and subsequent cell 
death.  
Antibody Drug
Conjugate (ADC)
NK Cell
Antibody-Dependent
Cellular Cytotoxicity (ADCC)
Complement-
Mediated Toxicity (CMC)
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The most straight-forward mechanism for mAb-induced cancer cell killing is through 
direct transmembrane signaling, in which the antibody binds to its target and triggers a 
signaling cascade to induce apoptosis.2 Rituximab is an FDA-approved chimeric 
antibody targeting the CD20 molecule for treatment of non-Hodgkin’s lymphoma that 
functions via this mechanism.6 Though it also works through a variety of other 
mechanisms, Rituximab binding was shown to induce activation of apoptosis-
associated caspases 3 and 9 and a subsequent reduction in circulating lymphocytes.7 
This is one example of how the antibody can induce apoptosis directly, but more often 
the cell killing comes through a secondary response. 
 
Antibodies can target cancer cells indirectly by recruiting effector cells to specifically 
kill cancerous cells. The Fc region of antibodies can trigger an effector cell response 
through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-
dependent cytotoxicity (CDC), or antibody-dependent cellular phagocytosis (ADCP).1 
These mechanisms bring in effector cells such as natural killer (NK) cells, which 
secrete granzymes to a target and induce apoptosis, or macrophages that can 
phagocytose, or engulf, the target cell. Antibodies can also manipulate the immune 
system by setting up an immunological checkpoint blockade. Antibodies like 
Ipilimumab block the CDLA4 receptor, which is expressed on the cell surface of T 
cells and stops T-cell activation and survival signals mediated by CD28. By blocking 
CTLA4 with Ipilimumab, activated T cells could now tag tumor cells for apoptosis, 
which lead to improved survival in patients with metastatic melanoma.8 
 
The third mechanism in which antibodies can be used to kill cancer cells is through 
antibody drug conjugates (ADCs), in which a cytotoxic payload is covalently attached 
to a targeted antibody. Following antigen binding and internalization of the ADC into 
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the target cell, the drug is released and can induce cell death.9 A notable example of a 
successful antibody drug conjugate is Trastuzumab-emtansine (T-DM1 or trade name: 
KadcylaTM), which delivers the cytotoxic drug, DM1, as a potent tubulin inhibitor to 
Her2+ breast cancer cells, a particularly aggressive form of breast cancer.10 ADCs are 
a relatively new class of antibody-based drugs and requires specific antibody and 
linker design to make them effective. 
 
Antibody Drug Conjugates 
ADCs have gone through several generations of conjugation strategies and linker 
designs since the first ADC was approved in 2000. This first-generation ADC, 
Gemtuzumab ozogamicin (Mylotarg®), used a CD33 targeted antibody conjugated to 
calicheamicin, a bacterial-derived antitumor agent that causes double-stranded DNA 
breaks,11 for treatment of patients with acute myeloid leukemia (AML). The drug was 
connected to the antibody via an acid-labile hydrazone linker attached randomly to 
surface-exposed lysine residues on the protein, yielding an average drug:antibody ratio 
(DAR) of ~2-3. In 2010, this ADC was withdrawn from the market for high toxicity, 
presumably due to the heterogeneity of the conjugate and linker instability. However, 
Mylotarg was later re-introduced and re-approved in 2017 after modifications were 
made to the dosing regimen.12 The next generation of ADCs, such as Brentuximab 
vedotin and Trastuzumab emtansine, incorporated more stable linkages such as 
thioether linkages, and protease specific release mechanisms such as endolysosomal 
protease-cleavable sites for targeted drug release.86 Though these have been 
successful, they still utilized random conjugation to surface lysine residues or hinge 
region thiols, which result in statistical heterogeneous mixtures. The third generation 
of ADCs utilize engineered cysteine residues for site-specific conjugation to the 
constant heavy domain of the antibody, yielding conjugates with a fixed DAR and 
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homogeneous composition. By continuously improving conjugate homogeneity and 
reducing drug deconjugation in serum, ADCs can have an increased efficacy toward 
the target cells, reduced off-target effects, and increased tolerability.13,14  
 
With a proven increase in tolerability of site-specific ADCs, researchers have explored 
several methods to site-specifically conjugate cargo to antibodies. With the rise of bio-
orthogonal chemistry and chemoenzymatic ligation, research groups have developed 
chemo-enzymatic peptide tags15-17 and non-natural amino acids18-21 that can be 
incorporated into antibodies for site-specific conjugation. Beyond reactive thiol 
groups, as utilized in THIOMAb technology,14 researchers have incorporated >50 non-
natural amino acids into proteins.19 Most commonly, p-acetophenylalanine (pAcF) and 
p-azidophenylalanine (pAzF) have been incorporated for oxime ligations or “click” 
reactions with ketone or alkyne functionalized substrates, respectively. However, 
codon optimization of efficient incorporation and expression can be difficult; 
therefore, chemoenzymatic tags can be an attractive alternative. 
 
Chemoenzymatic ligation involves the ligation of a chemical substrate via an enzyme 
to a specific amino acid tag. These tags can vary in length and can be incorporated 
internally or terminally to the protein, depending on the tag. Many of these tags 
involve post-translational protein modification, in which the protein is modified with a 
substrate and enzyme after it is expressed and purified. For example, lipoate acid 
ligase,22 transglutaminase,23 and sortase24 enzymes can incorporate a wide variety of 
substrates to a short tag incorporated into a target protein. The Bertozzi group has 
pioneered a co-translational enzymatic ligation method via formylglycine-generated 
enzyme (FGE), which oxidizes the cysteine residue in the CXPXR pentapeptide 
sequence to a reactive aldehyde residue.25 This method is unique in that the enzymatic 
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ligation occurs co-translationally, thus eliminating a purification step in making the 
protein tag. 
 
These site-specifically tagged antibodies have been utilized in various applications 
beyond ADCs. Antibodies tagged with fluorescent and radioactive molecules have 
become vital in cellular labeling in microscopy applications and immuno-PET.26-29 
Additionally, nucleic acids could be efficiently conjugated to antibodies for 
applications in immuno-PCR.30,31 In addition to analytical applications, these 
conjugation strategies could be applied to other therapeutic cargo, like RNAs. These 
function similarly to ADCs for intracellular delivery of nucleic acids to target cells. 
 
Nucleic-Acid Therapeutics 
Oligonucleotide therapeutics, particularly RNA-based, provide a unique opportunity 
for transient genetic manipulation of target cells. Unlike CRISPR technologies that 
permanently edit the genome of cells and tissues and incur a host of ethical 
conundrums,32 RNA therapeutics provide a means for transiently down or 
upregulating gene expression with antisense oligonucleotides (ASOs), short interfering 
RNAs (siRNAs), and mRNAs.33 ASOs and siRNAs work by binding to a target 
mRNA and knocking down gene and protein expression through endonuclease-
mediated transcript knockdown34-36 or Ago2-mediated mRNA splicing.37,38 mRNA 
delivery works through upregulating the expression of a target protein by introducing 
more transcript into the cell. Despite the promise of all of these strategies for gene and 
protein regulation, the main barrier to therapeutic efficiency is inefficient cytosolic 
localization, as the mRNA and target machinery are only present in the cell cytosol. 
Though all nucleotide-based therapeutics run into delivery problems crossing the cell 
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lipid bilayer, we will focus on ASOs and siRNAs as they are more accessible to 
conjugate-based delivery strategies.  
 
ASOs and siRNAs have two major barriers in their efficiency of delivery: their serum 
instability and inability to diffuse through the cell membrane due to its size, charge, 
and hydrophilicity. To combat serum instability, there has been a wealth of research 
into chemical modifications to the nucleotide bases and phosphodiester backbone.39,40 
Most notably, modifications to the 2’ base position, such as 2’-OMe and 2’-F base 
modifications, are biophysically similar to the native 2’-OH group, and can still load 
efficiently into the RNAi machinery, but stabilize the RNA from RNAse degradation 
and immune activation.41 Additionally, changing a single oxygen in the backbone 
phosphodiester bond to a sulfur yields a phosphorothioate linkage,42 which decreases 
susceptibility to phosophodiesterases and increases hydrophobicity and subsequent 
membrane permeability for ASOs.43 Though these modifications were sufficient for 
ASO translocation, double-stranded siRNAs were still too hydrophilic for direct 
cellular uptake. 
 
Conjugate-based therapeutics for siRNA have become increasingly popular with the 
emergence of GalNAc-siRNA conjugates that efficiently mediate targeted knockdown 
in hepatocytes.44 This conjugate uses a trivalent N-acetylgalactosamine (GalNAc) 
ligand to target the asialoglycoprotein receptor (ASGPR) on the surface of 
hepatocytes. This conjugate is unique in that there is no obvious component or 
mechanism for translocation into the cytosol following endocytosis. It is believed 
however that this specific conjugate depends on the high expression (~106 /cell) and 
fast recycling (10-15 mins) of ASGPR.33 Under these conditions, if only 0.01% of 
cargo escaped any endosome through natural leakage, this receptor pathway would 
 22 
reach the threshold of 5,000 cytosolic siRNAs in less than 24 hours. However, most 
target receptors have much lower surface expression levels (104-105 /cell) and slower 
recycling rates (~90 mins), that reaching this critical threshold within a doubling time 
of a cell is not possible. Thus, for extra-hepatic delivery, efficiently translocating the 
endosomal membrane is a barrier that still must be overcome.45-48 
 
Endosomal Escape 
Lipid bilayers have evolved over billions of years to allow small (< 1kD), somewhat 
hydrophobic molecules to diffuse through, while preventing large, highly charged 
molecules, like nucleic acids, from passing through.33,49 To circumvent a lack of 
passive uptake, nucleic acids can be encapsulated in a particle or conjugated with a 
targeting ligand so they can be endocytosed into a target cell. However, unless the 
oligo can escape the endosome that cargo is rapidly degraded by nucleases present in 
the endolysosomal compartment, rendering the cargo ineffective. 
There are several mechanisms that researchers use to facilitate endosomal escape;50 
most commonly of which are pore formation, pH-buffering and osmotic disruption 
(i.e. proton sponge effect),51-53 or membrane fusion54-56 with the lipid bilayer. Pore 
formation occurs commonly with amphiphilic, helical peptides, that form a hole in the 
endosomal membrane that allows content to leak out. The “proton sponge effect” 
occurs when protonatable groups, such as ionizable amines, buffer protons in the 
endosome as they acidify, leading to an increase in osmotic pressure and subsequent 
endosomal membrane disruption and leakage.51-53 Fusion occurs when pH-inducible 
lipids of a carrier fuse with the endosomal membrane and the contents are released 
into the cell cytosol.54-56 Materials and chemicals that utilize these mechanisms have 
been identified and incorporated into drug carriers for this purpose. 
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Chloroquine (CQ) is small molecule lysosomotropic agent and anti-malarial drug 
commonly utilized for endosomal escape.57 Mechanistically, CQ and its derivatives58 
are believed to facilitate cytosolic delivery of nucleic acids by inhibiting acidification 
and interacting with the nucleic acids for increased activity.58 At high doses, it has 
been shown to increase endosomal disruption and therapeutic effect of the delivered 
cargo.59,60 However, CQ isn’t naturally targeted to a cell and has major toxicity at the 
high concentrations at which it is effective. Thus, researchers have incorporated 
buffering functional groups into polymers for delivery,52 or resorted to other 
mechanisms for endosomal disruption, like through pore forming agents. 
 
Pore forming agents derived from bacterial or viral infectious agents have been 
utilized for targeted disruption of the endosomal membrane. A common pore-forming 
agent utilized in delivery systems is Melittin, which is a 26-amino acid peptide and the 
primary toxic component of bee venom.61,62 Melittin forms a tetrameric structure in 
solution,63 and upon binding to a target cell membrane, forms an amphipathic helical 
structure and pore perpendicular to the cell membrane.64,65 Melittin and analogs have 
been incorporated into various delivery systems including polyplex66,67 and notably 
dynamic polyconjugate (DPC) systems.68-70 In DPCs, a Melittin derivative was 
masked with a maleic anhydride derived polymer and a GalNAc targeting ligand. The 
masking step is critical to prevent Melittin from non-specific membrane disruption. 
This conjugate was co-delivered with a cholesterol-conjugated siRNA cargo for 
specific delivery to hepatocytes. Following co-localization in the early endosome, the 
Melittin derivative is unmasked in the acidic environment of the endosome, which 
enabled Melittin to induce pore formation and subsequent escape of the cargo siRNA 
into the cytosol. Arrowhead pharmaceuticals pioneered this technology, but later 
placed a hold on clinical trials, likely due to the toxicity of Melittin.33 
 24 
 
In addition to amphiphilic, lytic peptides, bacterial toxins have also emerged as 
another class of pore-forming agents for endosomal escape. Notable in this class are 
the family of cholesterol-dependent cytolysins,71 which are soluble in aqueous 
solution, but readily form large pores (~300A) in lipid membranes with cholesterol. 
These toxins are secreted by several gram-positive bacteria and are important in their 
pathogenicity.72 Two examples of these pore forming toxins are Perfringolysin O 
(PFO) and Listeriolysin O (LLO) from Clostridium perfringens and Listeria 
monocyotogenes, respectively. These toxins are both ~52kD in size and have a similar 
tetrameric structure.73,74 They have a high affinity (KD ~10-9 M) for cholesterol, and 
oligomerize to form 20-30nm ring-shaped pores.71 Uniquely, LLO is utilized for 
endosomal escape of Listeria following uptake into a host cell. The toxin is secreted 
from the endocytosed bacterium to form a pore in the endosome so the bacteria can 
replicate in the cytosol of the host. However, following endosomal escape, the toxin 
becomes inactive at the neutral pH of the cytosol as to not kill the host, making it a 
unique target for endosomal escape in biologics delivery.  
 
LLO and PFO have been utilized for targeted intracellular delivery of immunotoxins75-
77 and siRNA.78 In these studies, conducted in the Wittrup Lab, they generated a 
bispecific antibody that both neutralized the bacterial toxin and targeted EGFR for 
specific endocytosis. When co-delivered with the immunotoxin, gelonin, or an siRNA, 
the two conjugates co-localized and the bacterial toxin facilitated release of the cargo 
into the cytosolic space. They found this was an effective method for targeted delivery 
and endosomal escape in vitro. However, this study likely did not move in vivo 
because of the immune response that would be generated from the bacterial toxin. 
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These studies emphasize the importance of incorporating a well-protected endosomal 
escape agent into a conjugate delivery system. 
 
Despite the promise of RNA therapeutics, the translation of these therapeutic entities 
continues to be limited by delivery. Because of their natural cell impermeability, 
endosomal escape remains the major hindrance to the translational potential of 
therapeutic nucleic acids. Until a method for safely incorporating endosomolytic 
agents becomes clear, disease targets are still limited to hepatocytes. Antibody 
conjugates are an effective means to target tissues beyond the liver specifically but 
incorporating siRNA and endosomal escape agents into antibody conjugates 
effectively remains difficult. In this dissertation, we will discuss methods for 
expressing, purifying, and conjugating antibodies with therapeutic cargo. We hope to 
use this work to inform the design of antibody conjugates carrying both siRNA and 
protected, potent endosomal escape agents for targeted delivery and endosomal 
escape. 
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CHAPTER 2 – ANTIBODY EXPRESSION AND CONJUGATION METHODS 
 
Background 
Antibodies have emerged over the last ~25 years as an important new class of drugs to 
treat cancer, infectious diseases, chronic inflammatory diseases, and several other 
classes of disease.1 Antibodies are an intriguing class of therapeutics because they are 
target specific, well-tolerated in humans, modular, and can work through a variety of 
mechanisms. The first monoclonal antibody was approved in 1986 (Muromonab), and 
since then, more than 50 antibody-based drugs have been FDA approved for various 
applications.79 The design and production of antibodies is constantly evolving as the 
utility of this class of drugs continues to grow. 
 
Hybridoma technology was the first method for generating monoclonal antibodies 
(mAbs). With this method, B cells from mice immunized with a particular antigen are 
fused with an immortalized myeloma cell line to produce stable antibody-expressing 
cells.3 These hybridoma cells generate mouse monoclonal antibodies, which have had 
huge success in research applications, but a minimal success rate (3%) in drug 
development80 due to the immunogenicity of mouse antibodies in humans. This has 
been largely solved though through chimeric or humanized antibodies.82-85 Generating 
these humanized antibodies can be done through phage-,81-83 ribosome-,84-88 and yeast-
display libraries,89,90 human hybridomas, or transgenic mice.91,92 Following their 
discovery and affinity maturation, antibodies can be genetically manipulated for better 
effector function with glycoengineering,93-95 constant region amino acid 
manipulation,96 and isotype modulation.97 The engineered antibodies can then be 
expressed in HEK293T, and the suspension HEK293F cells for lab scale testing.98,99 
Nearly all late-stage clinical antibodies are then produced recombinantly in Chinese 
 27 
hamster ovary (CHO) or NS0 mouse myeloma cells because of their high antibody 
titres.1  
 
mAbs are most commonly utilized for their effector function and generating a 
secondary immune response to a target cell. The Fc region of the antibody can trigger 
effector cells like NK cells, monocytes, granulocytes, or macrophages to kill the target 
cell.100-103 However, over the last 10 years researchers have also developed antibody 
drug conjugates (ADCs) in which a chemotherapeutic drug is linked through a 
chemical linker.9,104 With the specificity of the antibody and the potent activity of the 
small molecule drug, these conjugates can target specific cancer cells with 
chemotherapeutic drugs without the broad toxicity of delivering the drug systemically. 
To generate these conjugates, biorthogonal chemistry is used to covalently attach 
various molecules to proteins.16,105 Here, we utilize “click chemistry” groups with fast 
kinetics and aqueous stability for protein conjugation. 
 
“Click chemistry” is a term coined in 2001 to define reactions that have high yields, 
form stable products in physiological solutions, are wide in scope, and form only 
“inoffensive byproducts”.106 The main reactions that fall under this scope are the 
Huisgen107 and Diels-Alder108 cycloaddition reactions between azide and alkyne 
groups, and tetrazine and diverse dienophiles, respectively. These pairs are bio-
orthogonal, stable in aqueous solutions, have fast kinetics, and are commercially and 
synthetically accessible. In this chapter, we utilize all of these functional groups for 
antibody bioconjugation. 
 
Antibodies, like other proteins, can be conjugated in two major ways: non-specifically 
to accessible and abundant surface residues, or to a specific region or residue. 
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Commonly, researchers take advantage of surface primary amine groups on lysine 
residues in the protein and utilize N-hydroxysuccinimide functionalized crosslinkers to 
attach cargo. In contrast, methods for site-specific conjugation9 on antibodies include 
maleimide conjugation to native cysteines in the hinge region of IgG1’s, and 
engineering additional cysteines14,109-111 or other reactive non-natural amino 
acids18,112,113 into the constant region domains. Chemoenzymatic ligation involves the 
ligation of a chemical substrate via an enzyme to a specific amino acid sequence tag. 
These tags can vary in length and can be incorporated internally or terminally to the 
protein, depending on the tag.15 Post-translational site-specific enzymatic conjugation 
strategies include microbial transglutaminase (mTG)13,23,94,95 and lipoic acid ligase 
(LplA).114 Here, and throughout this dissertation, we utilize both non-specific and site-
specific methods for conjugating various therapeutic cargo to antibodies.  
 
Microbial transglutaminase (mTG) is a bacterial derived enzyme that can crosslink 
glutamine and lysine residues of proteins. This enzyme has also been shown to 
specifically crosslink Q295 on the Fc region of humanized antibodies with amino-
containing substrates for site-specific conjugation.23 This enzyme is commercially 
accessible and very cheap, as it is also used as “meat glue” for binding together meat 
products. It also has promiscuous substrate specificity including a variety of click 
chemistry, fluorescent, or even small molecule drug substrates.115-117 Thus, a variety of 
conjugates can be easily developed without genetic manipulation.  
 
An alternative method for site-specific conjugation involves incorporating an amino 
acid tag to the genetic antibody sequence. The LplA Acceptor Peptide (LAP) sequence 
(GFEIDKVWYDLDA) is a short, 13aa tag that can be incorporated anywhere into a 
target protein. The LplA enzyme can couple a valeric acid substrate specifically to the 
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lysine residue in the LAP tag sequence. This chemoenzymatic ligation has fast 
kinetics, variety of compatible substrates, and flexibility in sequence location.22,114,118-
122 However, to our knowledge it has not yet been incorporated into an antibody 
conjugate. In this chapter, we manipulate and express mouse and humanized 
antibodies targeting CD63 and Her2. We then use non-specific and specific 
conjugation strategies to generate antibody conjugates with functional cargo for 
targeted delivery to cells. 
 
Hybridoma Antibody Expression and Purification 
Antibodies can commonly be expressed and purified from hybridoma cells, which are 
a cross between antibody-expressing B-cells recovered from a mouse challenged with 
a specific antigen, and immortal B cancer cells called myelomas. These hybridomas 
are convenient in that they secrete monoclonal antibodies into the media they are 
cultured in, and the cells can be cultured indefinitely. Generating hybridomas can be a 
very lengthy process, but they can be acquired through shared networks such as the 
Developmental Studies Hybridoma Bank (DSHB) through the University of Iowa. 
Here, we purchased the H5C6 hybridoma cell line123 to produce an antibody targeting 
the ubiquitous tetraspanin CD63, which is known to traffic to the late 
endosome/lysosome. 
 
Hybridoma cell culture and antibody purification is a slow expansion process in full 
serum media, followed by a reduced serum production phase, antibody precipitation 
and column purification (Figure 2.1). Cells are cultured in a way such that they begin 
in a 24-well plate and are expanded continuously until they reach a desired density to 
purify antibody from. When the cells move from the well plate to a larger vessel, the 
wells of the 24-well plate are replenished with fresh media, and the remaining cells 
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that were not transferred from the well expand in the new media so the process can 
begin again. In growth phase, the hybridomas are cultured in high serum (20%) media 
to maintain viability. Following the growth phase when the cell density is high 
enough, the media can be exchanged to low serum (5%) media for the antibody 
production phase. This is done in order to reduce the amount of residual protein in the 
media that the antibody is purified from. 
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 Figure 2.1 Hybridoma Antibody Culture, Expression and Purification (CD63Ab) 
– (a)Schematic of cell culture and expansion of CD63 antibody-expressing hybridoma 
cells from 24-well plate to large culture flask. Upon proper cell density and viability, 
antibody is precipitated with saturated ammonium sulfate, pelleted, and re-suspended 
in buffer and purified on a protein A/G affinity column. (b) Analysis via SDS-PAGE 
showed no antibody remaining in the supernatant, but some remaining in the flow-
through (FT) over the protein A/G column. Following PBS washed and elutions, the 
pure antibody was detected in its full length and reduced to the proper heavy and light 
chain fragments. 
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When the hybridoma cells have died from the reduced serum, the antibody must be 
purified from the media. Because of the large volume of media recovered from these 
cells, the protein is first precipitated from the media using ammonium sulfate. Once 
the protein has precipitated and pelleted, the recovered pellet can be re-suspended in a 
smaller volume for affinity purification. That volume can be flowed over a protein 
A/G resin, which binds specifically to the Fc region of antibodies, and can be eluted at 
low pH’s. Following precipitation and purification, we see no antibody remains in the 
precipitate, and only pure antibody leaves in the eluate (Figure 2.1B). Some antibody 
was detected in the affinity column flow-through, which could be further optimized 
with more resin and a longer incubation time to load on the resin. The entire 
purification process takes 2-3 days and generates yields of ~3.3mg/L.  
 
HEK293F Cloning, Expression, and Purification of Trastuzumab 
Though hybridoma technology is an efficient means for antibody production, 
manipulation of the antibody at the genetic level in a hybridoma cell line can be 
difficult. The emergence of CRISPR technologies has made manipulation possible, but 
the design of CRISPR RNAs is non-trivial, and hybridoma cells can be slow to 
expand. Therefore, we moved to a platform where we could genetically manipulate the 
antibody in E. coli and produce the antibody in an alternative cell line. 
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Figure 2.2 Trastuzumab Antibody Cloning, Expression, and Purification from 
HEK 293F Suspension Cells – (a) Schematic of cloning and expression of 
Trastuzumab antibodies (with and without LAP Tag) in 293F Expression Cells. (b) 
SDS-PAGE of full length Trastuzumab antibody (left) and reduced to heavy and light 
chain fragments (right). 
 
Dodev and colleagues at King’s College London developed a platform for genetic 
manipulation of an antibody sequence in E. coli and expression in an Freestyle-293F 
suspension cell platform.98 Ilieva took this platform and generated a plasmid for 
expressing the FDA-approved Her2-targeting antibody, Trastuzumab99. With this 
plasmid, we were able to generate a stable, Freestyle-293F suspension cell line to 
produce full-length Trastuzumab antibody for use in our targeted delivery studies 
(Figure 2.2). This platform uses PIPE or Gibson style cloning techniques to swap 
variable and constant antibody regions in E. coli. Then, the purified plasmid can be 
easily transfected, and is stably incorporated into HEK293F cells using a commercial 
transfection reagent. These cells can have a range of expression levels and yields, as 
the level of integration into the cell genome is random. With this platform we were 
able to generate antibodies targeting Her2 and poly-Sialic acid (ch735) 124 to make 
conjugates with. Additionally, we were able to incorporate a LAP tag at the variable 
heavy or light chain region of the antibody. Having genetic manipulation capabilities 
on this antibody allowed us to use site-specific conjugation techniques rather than 
random labeling techniques as was done with the commercial and hybridoma 
expressing antibodies.  
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CD63Ab and Her2Ab Internalization into Target Cell Lines 
In order for the target antibodies to be useful in internalizing cargo, we verified their 
uptake into cells with immunofluorescence and flow cytometry. SKOV3 cells were 
incubated with CD63 and Her2 targeted antibodies for 1 hour, then permeabilized and 
labeled with a corresponding secondary antibody to determine cellular localization 
(Figure 2.3). Both antibodies were detected in the intracellular space, with Her2 
antibody also detected significantly at the cell surface, which is consistent with 
literature.125 CD63 was primarily present as punctate intracellular spots, which is 
expected as a late endosomal marker.126  
 
Relative uptake of the CD63 and Her2 targeted antibodies was analyzed in MCF7, 
HeLa, and SKOV-3 cells via flow cytometry. Each antibody was labeled with a green, 
Alexa Fluor 488 NHS-ester, and added to varying cell types to examine relative 
expression levels. CD63 expression levels were approximately equal across all three 
cell lines (Figure 2.3 B,C,D). CD63 is a ubiquitous tetraspanin that internalizes via a 
lysosomal pathway.126 Targeting this receptor with antibody conjugates would allow 
us to analyze the same pathway across a variety of cell lines to determine cell type 
dependence. Her2 expression levels varied across cell lines, with significantly higher 
expression levels in SKOV3 cells over the other two lines (Figure 2.3 B,C,D). 
Her2/ErbB2 has varying expression levels and is a primarily recycling receptor.125 
Targeting this receptor would allow us to examine expression level dependence and 
look at a fast recycling pathway which has been shown to be effective in hepatocytes. 
These two antibodies gave us a variety of pathways and expression levels to examine 
antibody conjugate efficacy. 
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Figure 2.3 Uptake of Purified Antibodies in Target Cells – (a) Immunofluorescence 
of Her2 antibody (top) and CD63 antibody (bottom) internalization into SKOV3 cells. 
Phase contrast images (left), Hoechst-stained nuclei (blue), Her2 antibody (yellow), 
CD63 antibody (orange), and merged images (right). (b-d) Flow cytometry uptake of 
AlexaFluor 488 (AF488) labeled antibodies into MCF7 (b), HeLa (c), and SKOV3 (d) 
cells. Antibodies showed similar affinities across cell lines, but varying uptake levels 
relative to expression levels. 
 
PEGylation of Antibodies with Click Chemistry 
Protein drugs often suffer from a short half-life within the body, as they are rapidly 
excreted or degraded by serum proteases. This then leads to more frequent dosing, and 
an increased immune response among treated patients. One major way that these 
issues can be alleviated is through surface PEGylation, in which a PEG (polyethylene 
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glycol) molecule is added to the protein, increasing its hydrodynamic radius and 
“shielding” the protein from the body.127 With a variety of conjugation techniques at 
hand, we used both non-specific and site-specific methods to PEGylate the surface of 
antibodies. We utilized two-step click chemistry methods for conjugation, so we could 
expand the PEGylation technique to other functional cargo like nucleic acids and 
proteins. 
 
 
 
Figure 2.4 Schematic of conjugation reactions. (A) N-hydroxy succinimidyl ester 
(NHS ester) reaction with primary amine. (B) Copper-free click reaction between 
azide with dibenzyl cyclooctyne (DBCO) (C) Inverse electron demand Diels-Alder 
reaction between methyltetrazine (MeTzine) and trans cyclooctene (TCO) 
 
We began with the statistical surface labeling via N-hydroxy succinimidyl (NHS)-
ester functionalized PEGs. These NHS-ester PEGs react with the primary amine 
present on solvent exposed lysine residues on the surface of the antibody (Figure 
2.4A). The number of available residues is dependent on the antibody sequence, 
making this method polydisperse and highly variable. However, this is a single-step 
conjugation, in which the cargo is connected directly to the antibody and is not reliant 
on a second reaction step. This method is ideal over a two-step if the NHS-ester 
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functionalized cargo exists. However, the NHS-ester readily undergoes hydrolysis in 
aqueous solution, therefore, synthesizing the NHS-ester form of a reagent isn’t always 
feasible. The NHS-ester PEG is commercially available, and thus we examined the 
resulting DOL from this reaction.  As seen in Figure 2.5D, a degree of labeling range 
from 0-3 was detected via SDS-PAGE for this particular reaction condition, but this 
can be variable dependent on the equivalencies of NHS-ester substrate, concentration, 
and reaction time for a given conjugate. Additionally, even with a similar degree of 
labeling, the location of the sites is highly variable, leading to a very heterogeneous 
mixture of conjugates. Though generating homogeneous antibody conjugates is ideal, 
these antibodies are still functional and can be made quickly and easily. 
 
Following the statistical conjugation, we optimized mTG-based PEGylation of 
antibodies with an Azide-DBCO click chemistry pair (Figure 2.4B). This method 
specifically conjugates a single PEG chain to Q295 residue in each symmetric Fc 
region of the antibody. 23 With this method, we saw a near-quantitative PEGylation of 
Trastuzumab specific to the heavy chain of the antibody as visualized with SDS-
PAGE (Figure 2.5E). However, this method requires a near stoichiometric amount of 
enzyme, long reaction time (6-24 hours), and a rigorous enzyme removal step. 
Additionally, this method requires removal of the single glycan present on the Fc 
region of the antibody, which is very important for complement immunity. Therefore, 
ADCs synthesized in this way cannot elicit a targeted complement immune response. 
Nevertheless, this method does not require genetic manipulation and can be used on 
any humanized antibody. 
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Figure 2.5 Non-specific and Site-Specific PEGylation of Purified Antibodies – (a-
c) Schematic of non-specific (a), mTG site-specific (b), and LplA site-specific (light-
chain) (c) modified antibodies with PEG. (d-g) SDS-PAGE analysis of extent of 
PEGylation of antibodies, stained with Coomassie blue. Random surface PEGylation 
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(d) showed a distribution of labeling on both heavy (HC) and light chain (LC) 
fragments. mTG labeling (e) showed quantitative labeling specifically to the heavy 
chain fragment. LplA labeling showed quantitative labeling at the light chain (f) and 
approximately 50% labeling at the heavy chain (g). 
 
Finally, we optimized the LplA-based PEGylation of antibodies at the heavy or light 
chain constant region domains. The LAP-tag (GFEIDKVWYDLDA)114 along with a 
GGGS flexible spacer was cloned into the heavy chain (HC) and light chain (LC) C-
termini of Trastuzumab. The C-termini of each constant region chain was chosen for 
ease of swapping variable regions to generate LAP-tagged antibody conjugates against 
a new antigen, and for minimal inhibition of protein folding and antigen binding. 
Addition of the LAP-tag was verified with Sanger sequencing. Using the TCO-
functionalized substrate,121 we could PEGylate the antibody at the light or heavy chain 
C-terminal specifically with a tetrazine-functionalized PEG (Figure 2.5C). With this 
conjugation, we saw near-quantitative conjugation of the light chain, and only ~50% 
conjugation of the heavy chain (Figure 2.5F&G). Further optimization or different 
substrates could help promote the quantitative conversion at the heavy chain site. This 
method requires a low enzyme concentration (10mol%) and short reaction time (1-2 
hours) relative to the mTG reaction. Also, since the LAP tag is genetically 
incorporated, it can be moved to theoretically anywhere throughout the protein. 
However, the reaction conversion site-dependent and required time-consuming genetic 
manipulation to be incorporated into the antibody. This ligation is also orthogonal to 
the mTG reaction and thus can be in combination with LplA for dual conjugation, 
which will be discussed further in chapter 6. 
 
Conclusions & Discussion 
In this chapter, we examined various expression platforms and conjugation methods 
for PEGylation of antibodies. These methods are necessary in making antibody drug 
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conjugates (ADCs) or other antibody conjugates carrying various cargo to a specific 
cell of interest. Though commercial antibodies are available, they can be very 
expensive (~$400/100µg Ab) to generate conjugates from and deliver to cells. 
Therefore, for antibody conjugation labs it is necessary to explore platforms for 
making and purifying antibodies. 
 
We analyzed two expression platforms: Hybridoma and Freestyle-293F cells. These 
cell lines are both cultured in suspension, which is necessary to achieve cell densities 
high enough to generate enough antibody without a large surface area. Hybridoma cell 
lines can be difficult to generate however, as they are dependent on mouse 
immunization and fusion with myeloma cells and several selection steps. Nonetheless, 
this method can generate antibodies without knowing the protein sequence, so can be 
used in discovering and expressing new antibodies. The alternative requires first 
acquiring the sequence of the antibody but can then be genetically incorporated easily 
into HEK293F cells using commercial transfection reagents and without the design of 
CRISPR RNAs or viral transduction. These cells are easy to grow and produce 
antibody in serum-free media and are simple to purify. Both strategies suffer from low 
yields (~2-3mg/L Ab), thus, future studies should consider ExpiCHO-S® (Life 
Technologies) cells. Though generation of a stable line of these cells is less trivial, 
transient transfection generates yields of up to 3 g/L, well beyond those of Freestyle-
293F cells that stable incorporation may not be necessary. 
 
Finally, we examined random and site-specific conjugation methods for labeling 
antibodies. We utilized TCO-tetrazine and DBCO-azide cycloaddition pairs for their 
bio-orthogonality and fast kinetics to tag a large variety of cargo to antibodies. As a 
first, easy conjugation cargo, we examined simple PEGylation and analyzed the pros 
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and cons of each conjugation method. Random NHS-ester conjugation methods are 
very simple and easy, can achieve high DOL, and use a one-step conjugation, which 
does not require intermediate purification steps, whereas a two-step conjugation 
method would. This method requires no enzyme, therefore simple size-based 
separations should be sufficient to remove the added substrate. However, this method 
yields heterogeneous conjugates that can have varying antigen affinities, efficacies, 
and pharmacokinetic/pharmacodynamic properties in vivo. Also, synthesizing NHS-
ester functionalized cargo is not always feasible, since the ester is easily hydrolyzed. 
 
The site-specific conjugation strategies using mTG and LplA generate homogeneous 
conjugates. These homogeneous conjugates should have a better affinity for their 
antigen, since the conjugation should not block the binding site. The mTG conjugation 
showed a near-quantitative conversion clicking a DBCO-functionalized PEG onto an 
azide-functionalized antibody. This was more efficient than the LplA reaction 
attaching a TCO substrate to the heavy chain C-terminal and clicking on a Tzine-
functionalized PEG. It appears that when labeling the heavy chain, the mTG reaction 
is more efficient. However, given a different set of substrates, it may be possible to get 
conversion of the HC LplA reaction equal to that of the mTG. Also, moving the LAP-
tag to a different place within the heavy chain may also improve reaction conversion. 
Light chain labeling, however, was quantitative using LplA and the TCO substrate. 
This illustrates that the “click” reaction is quantitative, and the difference in labeling is 
due to substrate incorporation into the antibody. LC labeling currently cannot be 
achieved with the mTG, thus the LplA reaction is vital for labeling the light chain 
specifically. Labeling the LC allows for the Fc to remain untouched, and therefore can 
still trigger effector response. Additionally, when comparing ADCs labeled at the LC 
vs the HC, the LC-labeled ADCs were more stable.  
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These site-specific modification methods, though generate more consistent, 
homogeneous conjugates, can be more difficult to implement. Both the mTG and 
LplA coupling reactions require more stringent purification to remove the enzyme. 
Additionally, the LplA requires additional genetic manipulation by incorporating the 
LAP tag into the antibody sequence, which is not always possible unless the antibody 
is in a genetically tractable plasmid. This is necessary though, if the cargo needs to be 
at a specific site on the antibody. Depending on the application, one strategy may be 
more beneficial than the other and it is on the researcher to decide which method is 
necessary for a given application. For preliminary characterization, it is best to begin 
with non-specific conjugation methods. However, following proof of concept studies, 
researchers should take advantage of site-specific methods whenever possible for 
optimization, especially in vivo.  
 
Materials & Methods 
Cell Culture and Reagents: Hybridoma cells were cultured in Iscove’s Modified 
Dulbecco’s Media (IMDM) and RPMI Media purchased from Life Technologies with 
20% heat-inactivated fetal bovine serum (FBS; Atlanta Biologics) and 100 U/mL 
Penicillin and Streptomycin (Pen/Strep; Life Technologies). SKOV3 and HeLa cells 
were cultured in Dulbecco’s Modified Eagle Media (DMEM; Life Technologies) with 
10% FBS. MCF7 cells were cultured in DMEM + 10% FBS with 10µg/mL insulin. 
Freestyle-293F cells were maintained in Freestyle 293 Expression medium with 
100U/mL Pen/Strep.  
All chemicals and solvents were purchased from Millipore-Sigma and VWR unless 
stated otherwise. Chemical crosslinkers were purchased from BroadPharm (Az-PEG3-
NH2, Cat#BP20580; TCO-NHS ester, BP-22417; NHS-PEG4-TCO, Cat# BP-22418; 
MeTzine-PEG5-NHS, BP-22945; DBCO-PEG4-NHS, BP-22288). DNA Primers were 
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purchased from Integrated DNA Technologies (IDT). Materials for PCR and cloning 
were purchased from New England BioLabs. Gel electrophoresis materials were 
purchased from Bio-Rad. Plasmid for Trastuzumab antibody generation was 
purchased from Addgene (Plasmid# 61883). All sequencing was done by the Cornell 
Genomics Facility using the Applied Biosystems Automated 3730xl DNA Analyzer 
using Big Dye Terminator chemistry and ApliTaq-FS DNA Polymerase. 
 
Hybridoma Culture and CD63Ab Purification: H5C6 Hybridoma cells 
(Developmental Studies Hybridoma Bank) expressing a CD63/LAMP-1 Antibody 
were quickly thawed from frozen into IMDM Media + 20% FBS + Pen/Strep, 
centrifuged at 500xg for 5 mins, then transferred to 4 wells of a 24 well plate (Costar). 
Cells were incubated overnight at 37°C with 5% CO2, then split into 8 wells of the 24 
well plate. Upon confluency, cells were transferred to a T75 (Thermo Fisher), 
followed by a T175 (Thermo Fisher). The emptied wells were refilled with IMDM 
media to recover and expand remaining cells. During growth phase, cells were fed 
with IMDM Media + 20% FBS + Pen/Strep. During antibody production phase, cells 
were fed RPMI Media + 5% FBS + Pen/Strep. Production is complete when cells are 
50% viable by Trypan Blue. 
 
200mL of media and cells from the T175’s were collected and centrifuged at 3750xg 
at 4°C to pellet cells. The supernatant was carefully decanted and mixed 1:1 with a 
saturated ammonium sulfate (SAS) solution to precipitate the proteins. The mixture 
was stirred overnight at 4°C, then pelleted at 12,000xg (JA-12 rotor) for 30mins at 
4°C. The pelleted precipitate was resuspended in 10mL PBS, then purified on a 
protein A/G column. The eluted fractions were pooled and concentrated using Amicon 
30kDa spin filters and concentration was measured via absorbance at 280 nm.  
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Cloning of LAP-tagged Antibodies. The “LAP Tag” and spacer (GGGS-
GFEIDKVWYDLDA) was incorporated into the heavy and light chain C-terminal of 
the pVITRO-ch735-IgG1 vector 124 using 4 sequential PCR steps. The tag was added 
through the reverse primer, adding ~17-20 bases at a time. The following primers were 
used: 
 
Heavy Chain LAP Tag: 
FWD (ch735): ccgccacaggcgcgcactcccagattcagctgcagcaatc 
REV1: aagccagatcctccgccTTTACCCGGAGACAGGGAGAGGC 
REV2: accacaccttgtcgatctcgaagccagatcctccgccTTT 
REV3: ACATCAggcgtccaggtcgtaccacaccttgtcgatctcg 
REV4: ATGTCTGGCCAGCTAGCTGTACATCAggcgtccaggtcgt 
 
Light Chain LAP Tag: 
FWD (ch735): gggttccagctagccgcggtgatgtagtcatgacgcagac 
REV1: aagccagatcctccgccACACTCTCCCCTGTTGAAGCTCT 
REV2: accacaccttgtcgatctcgaagccagatcctccgccACA 
REV3: TCCCTAggcgtccaggtcgtaccacaccttgtcgatctcg 
REV4: CTGCTCCTAGGCGTACGGGATCCCTAggcgtccaggtcgt 
 
PCR amplification was done with the Flash-Phusion enzyme master mix with an 
initial denaturation step for 30 sec at 98°C, followed by 30 cycles with denaturation 
for 10 sec at 98°C, and extension for 15 sec/kb at 72°C. The product was gel purified, 
and reamplified with 10ng of template for the 4 sequential amplifications. 
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To assemble the final vector, the following primers were used: 
FWDvector: TCCCGTACGCCTAGGAGCAGGTTTCCCCAATGACACAAAA 
REVvector: accgcggctagctggaacccagagcagcagaaacccaatg 
FWDch735VL: gggttccagctagccgcggtgatgtagtcatgacgcagac 
REV4VL: CTGCTCCTAGGCGTACGGGATCCCTAggcgtccaggtcgt 
 
PCR amplification was done with the Flash-Phusion enzyme master mix with an 
initial denaturation step for 30 sec at 98°C, followed by 5 cycles with denaturation for 
10 sec at 98°C, annealing for 15 sec starting at 55°C and decreasing 1°C per cycle, and 
extension time at 90% of the recommended 15 sec/kb which was 107 sec for the 
vector piece (FWDvector and REVvector) and 10 seconds for the light chain piece 
(FWDch735VL and REV4VL) at 72°C. The product was gel purified, and reamplified 
with 10ng of template for the 4 sequential amplifications. Following the touchdown 
protocol, 30 cycles of PCR were performed with denaturation for 1 sec at 98°C, 
annealing for 5 sec at 55°C and extension for 107 sec or 10 sec at 72°C respectively. 
Resulting PCR products were DpnI digested for 1 hour at 37°C. Then the digests were 
combined 1:1 to a total volume of 100 uL and incubated at RT for 1 hour. The 
reactions were cleaned up with the Qiagen PCR clean up protocol and eluted in 30 uL 
of water. The volume was brought to 100 uL with water and 2 uL of this reaction was 
used to transform NEB 10-beta chemically competent cells according to the 
manufacturer’s protocol. After recovery, the cells were plated onto 300 µg/mL HyroB 
LB plates. Colonies were picked and grown in LB + 300µg/mL HygroB, mini-
prepped, and verified with sanger sequencing. 
 
To swap the variable regions from ch735 to Trastuzumab, the following primers were 
used: 
 46 
TrasVHFwd: ccgccacaggcgcgcactccGAGGTGCAGCTGGTGGAGTC 
TrasVHRev: GATGGGCCCTTGGTGCTAGCTGAGGAGACGGTGACAAGAG 
TrasVLFwd: gggttccagctagccgcggtGACATCCAGATGACCCAGTC 
TrasVLRev: GATGGCGCCGCCACCGTACgtttgatCTCCAGCTTGGTAC 
CHFwd: GCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCT 
CHRev: accgcggctagctggaacccagagcagcagaaacccaatg 
CLFwd: cgtacggtggcggcgccatctgtcttcatcttcccgccat 
CLRev: ggagtgcgcgcctgtggcggccgccaccaagaagaggatc 
 
Variable region pieces were amplified from pVitro1-Trastuzumab-IgG1 (Plasmid# 
61883), and constant region pieces were amplified from the LAP-tag incorporated 
ch735 vector. PCR amplification was done with the Flash-Phusion enzyme master mix 
with an initial denaturation step for 30 sec 98°C, followed by 30 cycles with 
denaturation for 10 sec at 98°C, annealing for 15 sec at 60°C, and extension for 6 and 
60 sec at 72°C for variable and constant region pieces, respectively. Resulting PCR 
products were DpnI digested for 2 hours, cleaned-up, and quantified via 260/280nm 
absorbance on a Tecan Nanoquant Plate. The purified pieces were mixed at a 1:1:1:1 
molar ratio, ligated via Gibson, and transformed into NEB 10-beta chemically 
competent cells and plated onto 300µg/mL HygroB LB plates. Colonies were picked 
and grown in LB + 300µg/mL HygroB, mini-prepped, and verified with sanger 
sequencing.  
Recovered pVITRO-Trastuzumab-IgG1-LAP vectors were re-transformed, midi-
prepped, and transfected into HEK 293F suspension cells. 
 
Stable Transfection of 293F Cells and Her2Ab Purification: Methods for genetic 
incorporation of the LAP tag to the Trastuzumab plasmid are discussed in chapter 6. 
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For stable transfection of the Trastuzumab plasmid (with and without LAP Tag), 293F 
cells were cultured in suspension in Freestyle 293 Expression Media (Life 
Technologies) for at least 3 passages maintained at 1M cells/mL prior to transfection. 
30M cells in 30mL of Freestyle Media were transferred to a new flask in fresh media 
and transfected using Freestyle MAX Transfection reagent with 37.5µg of ethanol 
precipitated DNA using the standard transfection protocol.  After 24 hours, cells were 
replaced with selection media (50µg/mL Hygromycin B; Life Technologies) and 
passaged every two days maintaining at 1M cells/mL for two weeks and/or until 
control cells were no longer viable. Media was tested for antibody using a dot blot, 
and cells were maintained at 1M cells/mL passaging every 3 days with selection media 
(25µg/mL). Approximately 0.5-1L of media was purified on 1mL of protein A/G 
column. Media was flowed continuously over the resin, washed with ~50mL of PBS, 
then eluted with 5mL of 0.1M Glycine (pH 2) into 1mL of 1M Tris (pH 8). The 
antibody was concentrated and buffer exchanged to PBS with 3 centrifuge steps at 
14K x g for 8 mins using 500 µL Amicon 30 kDa MWCO (Millipore Sigma) spin 
columns.  
Sanger sequencing of constant heavy and light chain domains with LAP tag 
sequences. 
BLACK & UPPERCASE – constant region DNA sequence 
red & lowercase – LAP tag DNA sequence 
 
CH Region:  
GCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC
ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCA
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CACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGT
GGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGT
GAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAA
TCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTG
GGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA
AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATA
ATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGT
GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGT
ACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACC
ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCC
CCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGG
CTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA
GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA
CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAggcggaggatctggcttcgagatcga
caaggtgtggtacgacctggacgcc 
 
CL Region: 
GTACGGTGGCGGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGT
TGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCA
GAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAAC
TCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCT
CAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCT
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ACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGC
TTCAACAGGGGAGAGTGTggcggaggatctggcttcgagatcgacaaggtgtggtacgacctggacgcc 
 
Immunofluorescence of Antibody Internalization to SKOV3 Cells: SKOV3 cells 
were cultured via standard cell culture methods and plated 75K cells to each quadrant 
of a segmented 35mm dish, 24 hours prior to incubation. Cells were incubated with 
100nM of antibody, or Tf-AF488 positive control, for 1 hour at 37°C. Cells were 
washed with PBS then fixed with 4% paraformaldehyde for 15 mins at RT. The cells 
were then blocked overnight with blocking buffer (5% Normal Goat Serum + 0.3% 
Triton-X in PBS) at 4°C, followed by an incubation with a 1:200 dilution of Alexa 
Fluor 568-labeled anti-mouse 2° Ab (for CD63Ab) or AlexaFluor 488-labeled anti-
human 2° Ab (for Her2Ab) for 1 hour at RT. Nuclei were stained with 2µM Hoechst 
33342 for 15 mins at RT. The slide was then imaged on a Zeiss LSM880 
Confocal/Multiphoton Inverted Microscope. 
 
Antibody Functionalization: Non-specific conjugation: For random surface 
conjugations, 25µM of antibody was incubated with 250µM of either NHS-PEG4-
TCO or NHS-PEG4-MeTzine (Broadpharm) in PBS overnight at 37°C. The reaction 
mixture was purified via 30 kDa amicon spin columns (500 µL) 3 times, and 
quantified via absorbance using a quartz NanoQuant (Tecan) plate using beers law for 
the TCO conjugates (no detectable absorbance of TCO) and the following formula for 
Tzine DOL: 
cAb = (A278*eTz294-A294*eTz278)/[(eAb278*eTz294-eAb294*eTz278)*L] 
cTz = (A278*eAb294-A294*eAb278)/[(eTz278*eAb294-eTz294*eAb278)*L] 
Where: eTz294 = 29,578 M-1cm-1, eTz278 = 21,672 M-1cm-1, eAb294 = 93,710 M-
1cm-1, eAb278 = 217,900 M-1cm-1, L=0.05cm (on the Tecan Quartz Nanoquant). 
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Antibodies were sought to have an approximate degree of labeling (DOL) of 5 Tzines 
per antibody. 
mTG Site-specific Conjugation: 500µg of LplA-reacted antibody was incubated at 
12.5 µM with 200 wt% Moo Gloo (10U/g Ab; Modern Pantry), 160 molar 
equivalencies of NH2-PEG3-Az, and 0.6µL of PNGase F for 7 hours at 37°C. The 
reaction mixture was purified via Amicon 30kDa MWCO centrifugal columns and 
quantified via 280nm absorbance using a quartz NanoQuant plate (ext. coeff280nm = 
210,000 M-1 cm-1).  
LplA Site-specific Conjugation: 500µg of antibody was incubated at 20µM with 
10mol% LplA, 200µM pAz or TCO-LAP, 1mM ATP, and 5mM Mg(OAc)2 in PBS 
for 1.5 hours at 37°C. The reaction mixture was quenched with EDTA at a final 
concentration of 30mM. 
 
Antibody PEGylation: Following antibody functionalization with a click chemistry 
substrate, the antibody was examined for extent of reaction with a gel shift assay 
following conjugation of a large PEG. Recovered antibodies following substrate 
addition with mTG or LplA were incubated with a large excess (25 molar 
equivalencies) of 5,000 MW DBCO-PEG or MeTzine-PEG reagents overnight at 
37°C. Reaction mixtures were then reduced, boiled, and run on a 4-20% Mini-Protean 
TGX pre-cast protein gels (Bio-Rad) at 120V for 60 mins. Gels were stained with Bio-
Safe® Coomassie, de-stained with water, and analyzed for a gel shift indicating a 
successful click reaction. 
 
Antibody-Fluorophore Labeling: 25µM of antibody was incubated with 250µM of 
either NHS-AlexaFluor488 (AF488) (Life Technologies) in PBS overnight at 37°C. 
The reaction mixture was purified via 30 kDa amicon spin columns (500 µL) 3 times 
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and quantified via absorbance using a quartz NanoQuant (Tecan) plate (ext. coeff280 = 
210,000 M-1 cm-1; ext. coeff488 = 71,000 M-1 cm-1; CF = 0.11). 
 
Antibody Uptake via Flow Cytometry: 50,000 cells of a designated cell type (HeLa, 
SKOV3, and MCF-7) cells were plated to 24-well plates 24 hours prior to the assay. 
Green, fluorescently-labeled antibodies were incubated at varying concentrations on 
cells for 1 hour at 37°C and 5% CO2. Cells were washed with PBS, trypsinized, 
quenched with media, and pelleted at 1,000 x g for 5 mins. Trypsin and media were 
removed via aspiration and resuspended in 500µL PBS. Samples were then analyzed 
for green fluorescence intensity on each individual cell using flow cytometry. 
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CHAPTER 3 – ANTIBODY-siRNA CONJUGATES 
Background 
RNA interference (RNAi) has emerged over the last 15 years as a specific and potent 
means of targeted gene silencing at the mRNA level. Since its initial discovery in C. 
elegans, researchers have sought to harness this mechanism, by way of short 
interfering RNAs (siRNA), as an efficient route to silencing disease-causing 
genes.37,128 Because of their large size and charge, siRNAs cannot passively diffuse 
through cell membranes. However, siRNAs are small enough to be filtered by the 
kidney and are rapidly excreted following IV injection. Additionally, unmodified 
siRNAs are rapidly degraded by nucleases in serum. Consequently, siRNAs need to be 
encapsulated or conjugated to a large macromolecule to avoid kidney filtration and 
induce active cellular uptake. 
 
The most widely used delivery strategy currently involves synthetic materials to 
encapsulate the siRNA cargo into a particle, deliver it to the cell, and facilitate 
endosomal release to the cytoplasm. Among these materials are cyclodextrin polymer 
particles,129-135 lipid and lipid-like nanocarriers,136-146 and cationic polymers.147-152 
Although optimization of these delivery vehicles has been slow and limited to the 
liver, few successes have emerged. The first FDA-approved RNAi drug, Patisiran, was 
just recently approved in August 2018 to treat transthyretin (TTR) amyloidosis, a liver 
disease which leads to nerve damage and impaired heart function. Expansion to 
diseases beyond the liver has been even slower.153 This is because particle-based 
formulations can be difficult to target away from the liver.154 Preferential deposition in 
the liver is due to protein adsorption to the particle surface, followed by rapid 
clearance by phagocytic cells abundant in the liver and spleen. 155 Other types of 
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delivery modalities, such as bioconjugates,156 are now being explored to treat extra-
hepatic targets. 
 
The most successful bioconjugate thus far is the GalNAc-siRNA conjugates. 
Developed by Alnylam, this conjugate includes a trivalent N-acetylgalactosamine 
(GalNAc) and showed specific targeting and robust knockdown efficiency in cells 
containing the asialoglycoprotein receptor (ASGPR).44,157 This conjugate is unique in 
that endosomal escape is proposed to be solely dependent on endosomal leakage, but 
has a higher escape rate than other pathways because of the high expression levels, 
rapid uptake, and fast recycling rate of the ASGPR pathway.33   Unfortunately, this 
receptor is solely present on hepatocytes. To go beyond the liver, several conjugates 
are being explored with RNA-aptamer158-160 and antibody targeting ligands.161-167 
These conjugates can target a variety of cell types and surface antigens and carry the 
siRNA cargo into a cell. 
 
Antibody (Ab) and antibody fragment bioconjugates have garnered particular interest 
due to their specificity, range of receptor targets, and clinical success in antibody-drug 
conjugates (ADC’s).104 Several antibody-based bioconjugates have successfully 
delivered siRNA to epithelial tumors162,164,168 and specific leukocytes161,167,169 while 
utilizing nucleic acid binding proteins like polyarginine and protamine for siRNA 
complexation and endosomal escape. Song et al. were the first to demonstrate cell-
type specific targeted siRNA delivery via an antibody-protamine fusion, and saw 
targeted knockdown of reporter and endogenous gene targets in HIV-infected T cells 
and Her2 expressing breast cancer cells.161 These protamine fusions however, were 
difficult to express and never proceeded to the clinic. Later, researchers at Genentech 
generated directly conjugated (i.e. no protamine/arginine) antibody-siRNA conjugates 
 54 
targeting various cell surface antigens and internalization pathways and systematically 
evaluated their knockdown efficiency. Only a limited number were able to deliver 
functional amounts of siRNA to the cytosol, with unclear dependence on endocytosis 
pathway.165 This systematic evaluation illustrates that there is a significant lack of 
understanding in the critical components of siRNA conjugates, and more must be done 
to understand the impact of endocytic pathway, conjugation method, and membrane 
disrupting agents on efficient delivery. Understanding the individual component 
contributions for efficient cytosolic trafficking will help inform the design of 
bioconjugates to meet the therapeutic potential of RNAi. 
 
In this chapter, we develop antibody-siRNA conjugates for a modular dual-delivery 
strategy that decouples cellular internalization from endosomal escape through the use 
of antibody (Ab) conjugates. Cellular internalization of these conjugates is dictated 
solely by the antibody, while endosomal escape is attained with an endosomal escape 
agent (EAA), which will be explored in chapter 4. First, we generated luciferase-
expressing cells as a reporter gene in knockdown experiments. Then, we stabilized the 
siRNA to serum proteins with chemical backbone and base modifications. Next, we 
generated and characterize protein-siRNA conjugates using the native Transferrin 
protein, and antibodies against Transferrin, CD63, and Her2 receptors. These surface 
ligands are present across a variety of cell lines and cover both fast recycling and 
lysosomal endocytosis pathways. These conjugates covalently bind the siRNA and 
protein using various click chemistries and incorporate cleavable sites for siRNA 
release by endosomal enzymes including gamma-interferon-inducible lysosomal thiol 
reductase (GILT) and cathepsin B (CatB). These conjugates effectively internalize 
siRNA to target cells as measured by flow cytometry and confocal microscopy. Later, 
these can be co-delivered with Ab-EEA conjugates for targeted knockdown. 
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Results 
Generating Luciferase-Expressing Cell Lines: For preliminary studies, we examined 
knockdown of a reporter gene before moving to an endogenous gene target due to its 
higher throughput. Firefly luciferase is a widely-used reporter gene. It can be read 
easily in a well-plate format, the substrate is commercially available, and has a low 
background signal. To generate cell lines with luciferase expression, we cloned the 
Luc2 gene (replacing the GFP gene previously in the vector) into a lentiviral pCDH 
vector under a CMV promoter, then used a second-generation lentiviral transfection to 
generate stably Luc2-expressing HeLa, SKOV3, HEK293T, and MCF7 cell lines 
(Figure 3.1A). Second generation lentiviral transfection methods, for safety reasons, 
split the viral genome into three vectors: a packaging vector (psPAX2), an envelope 
plasmid (pMD2.G), and the transfer plasmid carrying the gene of interest (pCDH-
Luc2) (Figure 3.1). HEK293T cells were transfected with lentiviral components via a 
calcium phosphate transfection,170 then the virus generated from the 293T’s were used 
to infect HeLa, SKOV3, MCF-7, and fresh HEK293T cells. Following infection, cell 
lines were selected with Blasticidin and expanded. We then examined their luciferase 
expression levels with the ONE-GLO/Tox Luciferase Assay kit. We saw that these 
cells had a signal increase of 5 orders of magnitude over the wild-type cells (Figure 
3.1B&C). To verify that our siRNA was compatible, we treated cells with our 
luciferase-targeting siRNA via Lipofectamine and saw a 90% knockdown, and no 
detectable knockdown with the dummy siRNA targeting a different strain of luciferase 
(Figure 3.1D&E). These cells were used for knockdown studies with our conjugates.  
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Figure 3.1 Luciferase Expression via Viral Transduction – (a) Schematic of viral 
transduction of select cell lines with Luc2. Luc2 was cloned into a pCDH vector (from 
Paszek Lab), then transduced into HEK293T cells via a 3rd generation method with 
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three plasmids: Transfer plasmid, packaging plasmid, and envelope plasmid. Virus 
generated from HEK293T cells were used to infect HeLa, SKOV3, MCF7, and 
HEK293T cells. (b-c) Luciferase expression levels as measured by Promega ONE-
GLO reagent in Luc2 expressing SKOV3 (teal) and MCF7 (purple) cells over wild-
type. (d-e) Cell Viability (left; gray) and luciferase expression (right; teal – SKOV3, 
purple – MCF7) of treated cells with Luc2-targeting siRNA. Efficient knockdown 
with target siRNA indicated successful transduction with proper Luc2 vector. 
 
Stabilization of siRNA through base and backbone chemical modifications: Unlike 
more common delivery vehicles like polyplexes or nanoparticles, siRNAs conjugated 
to antibodies are not encapsulated and are thus more easily susceptible to serum 
nucleases. Researchers at Alnylam® Pharmaceuticals Inc. found chemical 
modification to be critical to the success of their GalNAc-siRNA conjugates for 
targeting hepatocytes and screened a large number of siRNAs with various 
modifications.171 We utilized 2’methyoxy (MeO) modifications to the 2’ hydroxyl 
(OH) group, and phosophorothioate backbone linkages at the 3’ overhangs to stabilize 
the siRNA in the presence of mouse serum (Figure 3.2). The location and number of 
modifications present on the siRNA determine the stability, but also have an impact on 
knockdown efficiency. Therefore, we made a variety of sense and anti-sense RNA 
strands with modifications at various locations, duplexed them, and looked at their 
subsequent knockdown efficiency and serum stability. 
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Figure 3.2 RNA Chemical Stability Modification – (a) Schematic of available RNA 
sense strand (top) and antisense strand (bottom) sequences and locations of 
modifications to RNA bases (large circles; blue and green) or DNA bases (large 
circles; pink) and backbone linkages (small circles; blank and orange). Sense strand 
sequences are labeled 1-3, and antisense strand sequences are labeled 4 & 5. (b) Time 
course serum stability PAGE gels stained with SYBR gold of sense strand sequences 
1-3 duplexed with antisense strand 4. Asterisk (*) indicates the most stable duplex. (c) 
Time course serum stability PAGE gels stained with SYBR gold of sense strand 
sequences 1-3 duplexed with antisense strand 5. (d) Luciferase expression normalized 
to cell viability of SKOV3 cells treated with 6 available duplexes, scramble sequence, 
and untreated control. Asterisk (*) indicates luciferase expression of cells treated with 
most stable duplex 3-4. 
 
In this study, we included 3 sense strands variations with either no modifications (1), 
2’OMe modifications to G and U bases (2) or C and U bases (3). For the anti-sense 
strand, we had two variations with either no modifications (4), or with 2’OMe 
modifications to positions 5 and 14 (5) (Figure 3.2A). We chose these modifications to 
examine the effect of antisense vs. sense strand modifications, pyrimidine vs. purine 
base modification, and location dependence on stability and knockdown efficiency. 
All strands had DNA base (dTdT) overhangs with a phosphorothioate linkage at the 3’ 
end, as is a common modification for siRNAs.39 This yielded 6 possible combinations 
of double-stranded siRNAs. Each combination was incubated in mouse serum for 24 
hours and analyzed via SDS-PAGE for stability. After 24 hours, only the (3-4) and (3-
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5) combinations could be significantly detected after 24 hours (Figure 3.2B&C). From 
this we deduced that modifications to the sense strand had the greatest impact on 
serum stability, and modifications to the pyrimidine bases was more effective than 
modifying the purine bases, which is consistent with literature.172 We then examined 
the knockdown efficiency of these duplexes against a target luciferase gene via 
lipoplexing with LipofectamineTM, a commercial transfection reagent to deliver 
siRNA. At a concentration of 50 nM, we observed a range of efficiencies from 40-
80% knockdown across the duplexes (Figure 3.2D). As expected, the unmodified 
sense and anti-sense pair had the greatest knockdown, but the lowest stability. The 
next best knockdown efficiency was observed with the 3-4 duplex, which also had the 
greatest stability. This 3-4 duplex was used for all future siRNA conjugates. We 
purchased the modified siRNA with a 3’ terminal protected thiol or terminal primary 
amine on the sense strand for conjugation to protein carriers. 
 
Transferrin Protein-Nucleic Acid Conjugates: Transferrin (Tf) is a ubiquitous iron-
chelating protein responsible for iron transport into cells. Transferrin binds to its 
receptor, Transferrin Receptor (TfR), and is internalized into a cell via clathrin-
dependent endocytosis. Following internalization, the acidic pH of the endosome 
induces the chelated iron to be released from the protein. The endosomes containing 
the protein are then recycled back to the cell surface quickly (15-30 mins), where the 
Tf then detaches from its receptor and is released back to the extracellular space to 
chelate more iron. The TfR is expressed on a variety of mammalian cell lines and has 
been shown to have elevated expression in cancerous cells. Therefore, the Tf-TfR pair 
was an ideal system to begin building conjugates. 
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Figure 3.3 Transferrin-Nucleic Acid Conjugation and Purification – (a) Schematic 
of conjugation scheme for Transferrin (Tf) protein-nucleic-acid conjugates. Tf is first 
modified with an NHS-PEG-OPSS crosslinker. The purified, mono-conjugated Tf-
OPSS is then mixed with a thiolated single stranded sense DNA/RNA, purified, then 
duplexed with the antisense strand for the final conjugate. (b) Hydrophobic interaction 
chromatography (HIC) trace of Tf reacted at increasing concentrations with NHS-
PEG-OPSS crosslinker. Red box indicates mono-conjugated product. (c) HIC trace of 
Tf-OPSS before (green) and after thiolated DNA (blue) or RNA (red) addition. A 
hydrophilic shift (i.e. earlier time) is indicative of conjugation. (d) Native PAGE of 
single-stranded (ss) and double-stranded (ds) Tf-RNA and Tf-DNA conjugates, 
stained with SYBR Gold for nucleic acids. A small, quantitative, gel shift down from 
the single-stranded conjugate is indicative of hybridization, and excess, non-
hybridized antisense strand runs at the bottom of the gel. (e) Flow cytometry analysis 
of Transferrin with varying iron-loading levels. Commercial holo-transferrin 
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(triangle), apo-transferrin (circle), and iron-loaded apo-transferrin (square). (f) Flow 
cytometry analysis of Tf protein (circle) and Tf-dsDNA-AF488 conjugates (square). 
Uptake of DNA conjugates was significantly less than that of the protein.  
 
To conjugate siRNA to Tf, we utilized an ortho-pyridyl disulfide (OPSS) linker that 
reacts with thiol groups via thiol-disulfide exchange (Figure 3.3A). The resulting 
disulfide bond can be cleaved in the reducing environment in the endosome to release 
the siRNA. To functionalize the protein, we used an N-hydroxysuccinimide (NHS) 
ester and OPSS heterobifunctional crosslinker to add OPSS groups to the solvent-
accessible surface lysine residues of Tf, of which there are 7. We optimized our 
reaction conditions for the mono-conjugated product and purified it via hydrophobic 
interaction chromatography (HIC) (Figure 3.3B). The mono-conjugated Tf-OPSS 
eluted at ~35 mins on a gradient of 100-25% 1M ammonium in phosphate buffer over 
45 mins. We then added single stranded DNA or RNA with a 3’ thiol to the mono-
conjugated Tf-OPSS and saw a characteristic hydrophilic shift via HIC (Figure 3.3C). 
After purification of the Tf-nucleic acid conjugate, positive staining for nucleic acid 
was seen via native PAGE with no free nucleic acid detected (Figure 3.3D). This 
indicated that the conjugates were made and purified successfully.  
 
Because iron is also released from Tf in high salt conditions of the HIC purification, 
the Tf conjugate was iron-loaded with iron citrate solution173 and screened for uptake 
in TfR-expressing cells (HeLa cells) (Figure 3.3E). Efficiency of iron loading was 
measured by the absorbance ratio at 465nm and 280nm and normalized to commercial 
holo-transferrin. The iron-loaded Tf (IL Tf; 212 +/- 26nM kD) showed greater uptake 
than the apo Tf but showed approximately 5-fold lower affinity than the native holo-Tf 
(47 +/- 16nM kD). Furthermore, following the DNA conjugation, the uptake of these 
conjugates was very low relative to the control Tf (Figure 3.3F). We concluded that 
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the combination of inefficient iron-loading and steric hindrance by the presence of the 
nucleic acid had a negative impact on uptake efficiency. 
 
Figure 3.4 Functionalized Nucleic Acids with Heterobifunctional Crosslinkers – 
(a-c) Chemical structures of heterobifunctional crosslinker used in antibody-nucleic 
acid conjugates. (a) TCO-functionalized linkers with and without a CatB-cleavable 
site (Valine Citrulline – VCit; Phenylalanine – FCit). Reactive with amine-
functionalized nucleic acids (b) Tetrazine-functionalized versions of the stable and 
VCit linkers in (a). (c) Stable and reducible, TCO-functionalized linkers that are 
reactive with thiolated nucleic acids. (d-f) RP-HPLC traces of nucleic acids. Parent 
DNA traces (gray) reacted with stable linkers (blue) and cleavable linkers (purple). 
Green traces show trace of intermediate product formed during CatB-cleavable oligo 
synthesis. Minor peak in purple trace in (f) is likely partially reduced biproduct. 
 
Functionalized Nucleic Acids for Antibody Conjugation: Antibody conjugates are an 
appealing modality for siRNA delivery because of the wide range of receptor targets 
and their high binding specificity. However, commercial antibodies are very expensive 
(~$400/100µg), so we sought to make conjugates at a small scale, low concentrations, 
and near 1:1 molar equivalency. We chose the trans-cyclooctene (TCO) and 
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methyltetrazine (MeTzine) reaction pair that undergo Inverse Electron Demand Diels-
Alder (IEDDA) reaction. This pair has the fastest reported reaction kinetics of any 
“click chemistry” pair (2,000 M-1 s-1),108 is bio-orthogonal, stable in aqueous solution, 
and commercially and synthetically accessible. We synthesized and purified a variety 
of heterobifunctional crosslinkers with TCO or MeTzine groups to crosslink 
antibodies and nucleic acids (Figure 3.4). These crosslinkers contained (1) a reactive 
group for amines or thiol and (2) a stable PEG linkage or a protease-cleavable or 
reducible site. These crosslinkers were reacted with 3’ functionalized nucleic acids 
and purified via RP-HPLC. 
 
 Parent Antibody Antibody-DNA Conjugate 
Transferrin Receptor (TfR) 13.3 +/- 2.0 nM 39.2 +/- 11.0 nM 
CD63/LAMP-3 7.6 +/- 1.5 nM 12.2 +/- 0.4 nM 
Her2/ErbB2 1.74 +/- 0.5 nM 1.54 +/- 0.5 nM 
 
Table 3.1 Dissociation Constants of Parent Antibodies and Antibody-DNA 
Conjugates 
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Figure 3.5 Conjugation and Uptake of Antibody-nucleic acid conjugates – (a) 
Non-specific antibody-siRNA conjugation. (top) Schematic of conjugation protocol 
with surface tetrazine functionalization, followed by a click reaction with a TCO-
functionalized oligo. The single stranded conjugate is purified, quantified, then 
hybridized with the corresponding antisense strand. (bottom) Native PAGE gel stained 
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with Coomassie (left) for protein and SYBR gold (right) for nucleic acid. Downward 
shifts and positive nucleic acid staining are indicative of conjugation and 
hybridization. Protein band shifts are near quantitative indicative of complete 
conjugation. (b) Site-specific antibody-siRNA conjugation. (top) Schematic of 
conjugation protocol to LC-LAP tagged antibody with a TCO-substrate, followed by a 
click reaction with a Tzine-functionalized oligo. (bottom) SDS-PAGE gel stained with 
Coomassie (left) for protein and SYBR gold (right) for nucleic acid. Gel shifts upward 
and positive nucleic acid staining are indicative of conjugation. Faint bands at ~37kD 
and ~60kD that stain positively for protein and nucleic acid are conjugate, however 
conversion is low. (c-e) Confocal microscopy for uptake of antibody-oligo conjugates. 
Antibody-DNA conjugates with the TfRAb (c; HeLa), CD63Ab (d; SKOV3), and 
Her2Ab (e; SKOV3). Blue = Hoechst (nuclei stain). Green = Alexa Fluor 488 
(Antibody-oligo conjugates, fluorophore on oligo). (f-h) Flow cytometry uptake of 
labeled antibodies and nucleic-acid conjugate counterparts. Antibody-DNA conjugates 
with the TfRAb (f; HeLa), CD63Ab (g; SKOV3), and Her2Ab (h; SKOV3). Blue 
traces = labeled antibody. Green traces = Antibody-oligo conjugates. 
 
Antibody-Nucleic Acid Conjugation and Cellular Uptake: After purifying the DNAs 
and RNAs, these nucleic acids could then be conjugated to a targeting antibody. To 
analyze the effect of pathway dependence on efficient siRNA delivery, we looked at  
antibodies against three different surface antigens: for the Transferrin receptor (TfR), 
CD63/LAMP-3, and the Her2 receptor. These encompass recycling and late 
endosomal pathways and have varying receptor surface densities on the cell lines 
present in the Alabi Lab. We generated Ab-nucleic acid conjugates on these antibodies 
via either a site-specific (Figure 3.5B) or random conjugation (Figure 3.5A). Unlike 
the Transferrin conjugates, these are randomly conjugated but have a DOL greater 
than 1 as measured via absorbance of the methyltetrazine group. Thus, there could be 
several DNAs conjugated to the antibody. This was verified via SDS-PAGE to see a 
gel shift on native PAGE and positive staining for nucleic acids (Figure 3.5A). We 
also tried conjugating via site-specific methods utilizing a TCO LAP tag substrate on 
the antibody heavy or light chain (Figure 3.5B). These also showed a gel shift via 
SDS-PAGE and positive staining for nucleic acids, but the extent of reaction was 
much lower, presumably because of the lower TCO DOL of the antibody. Therefore, 
we proceeded with the non-specifically conjugated antibodies. We analyzed their 
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uptake in cells expressing the given antibody receptor. For the TfRAb, CD63Ab, and 
Her2Ab, we saw that these antibodies internalized DNA into the cell via confocal 
microscopy (Figure 3.5C-E) and flow cytometry (Figure 3.5F-H). As expected though, 
these conjugates had comparable dissociation constants (KD) values (Table 3.1) 
relative to the parent antibody, but lower overall uptake. However, the decreased 
uptake is likely due to a combination of the lower relative DOL and steric hindrance 
by attaching the double-stranded nucleic acid. Nevertheless, the conjugates were 
effectively internalized and could be used in future co-delivery studies. 
 
Conclusions & Discussion 
In this chapter, we examined methods for conjugating nucleic acids to targeting 
proteins and antibodies via various chemistries and examined their uptake in receptor-
expressing cells. This is important for targeted delivery of nucleic acids to specific cell 
types as the protein-receptor pair both dictates the cell type being targeted and 
mediates internalization of nucleic acids into cells. We used both endogenous proteins 
(Transferrin protein, Tf), as well as antibodies targeting a variety of surface receptors, 
including TfR, CD63, and Her2. This range of targets would then allow us to examine 
the effect of receptor density, cell type, and endocytic pathway on nucleic acid 
delivery efficiency. 
 
First, we stabilized the siRNA via chemical modifications to the backbone and bases, 
and optimized degree of stabilization with knockdown efficiency. This has been 
shown to be vital in siRNA conjugate success, particularly with non-encapsulated 
siRNAs. While the base sequence dictates the gene target, oligonucleotide chemical 
structure dictates delivery and potency.174 In this chapter, we performed a small screen 
of chemically-modified siRNAs (6 total duplexes) with a single targeting sequence for 
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the luc2 gene (pgL4 vector; Promega). We were able to determine a sequence that was 
stable after 24 hours incubated in serum and showed ~75% knockdown at 50nM when 
delivered with Lipofectamine. This was viable for stability in serum, but it is unclear 
as to whether these were sufficient for protection from endolysosomal enzymes and 
could be a contributing factor later as to why the protein-siRNA conjugates were not 
viable in eliciting knockdown even in the presence of chloroquine, a known 
lysosomotropic agent (see Chapter 5). Given more resources, it would be useful to 
further optimize the sequence and location and number of chemical modifications to 
the siRNA to be sure this not a contributing factor. 
 
Following stability modifications of the siRNA, we moved to making conjugates with 
the endogenous Transferrin protein. Tf protein has been utilized in conjugates and on 
the surface of nanoparticles as a cancer-cell targeting protein, particularly for targeting 
the brain. It served as a simple protein for proof-of-concept studies in building the 
conjugates. However, because Tf is an iron-chelating protein and the purification of 
the conjugates with a high salt buffer caused the iron to dissociate, it was difficult to 
generate high-affinity conjugates that undergo endocytosis via the TfR. We did 
generate a protocol for iron-loading Tf, however, we still observed low uptake of the 
Tf-nucleic acid conjugates. This was likely due to a combination of inefficient iron-
loading of Tf and steric hindrance by attaching the nucleic acid non-specifically to the 
surface of the protein. Future studies could perhaps be performed with a mutant Tf 
with slower iron-release kinetics,175 or with other well-characterized internalizing 
proteins such as low density lipoprotein (LDL). 
 
To circumvent the difficulties encountered with iron-loading, we generated similar 
conjugates with antibodies. We chose TfR, CD63, and Her2-targeting antibodies. We 
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began with commercial TfR-targeted antibodies as an easy transition from the 
endogenous Tf protein. We then moved to CD63 where we were able to purchase a 
hybridoma cell line for expression and purification. Finally, we generated the Her2-
targeted antibody, Trastuzumab, because of its high expression levels on SKOV3 cells 
and ability to genetically manipulate the protein. We were able to generate Ab-siRNA 
conjugates via the efficient TCO-tetrazine click chemistry ligations. These conjugates 
internalized into receptor-expressing cell lines with lower efficiency than their parent 
antibody, as anticipated. This was likely due to a discrepancy in labeling efficiency of 
the parent antibody with the conjugate as well obstruction of the binding site due to 
the presence of a large double-stranded nucleic acid. Labeling efficiency could be 
improved with higher concentrations of both components, which is dependent on 
having greater amounts of antibody and DNA. Site-specific conjugations may also be 
able to circumvent this and make sure the DNA does not block the antigen binding site 
of the antibody. It might be necessary to include 4 conjugation sites rather than 2 as 
well, to obtain a higher DOL and better uptake. Also, the location of these sites would 
also perhaps need to be optimized to minimize interference with the antigen binding 
site on the antibody. 
 
In conclusion, we have determined that these chemical conjugation methods are viable 
for attaching nucleic acids to antibodies for internalization into mammalian cells. 
These conjugates though, have no explicit mechanism for endosomal escape and as is 
are not sufficient for cytosolic delivery of siRNA. Endosomal escape conjugates will 
be discussed in Chapter 4.  
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Materials & Methods 
Cell culture and reagents: HeLa, SKOV3, and HEK293T cells were maintained in 
Dulbecco’s modified eagle media (DMEM; Life Technologies) supplemented with 
10% Fetal bovine serum (FBS; Atlanta Biologics). MCF-7 cells were maintained in 
DMEM + 10% FBS with 10µg/mL insulin. All DNA and RNA oligos were purchased 
from IDT with any base and backbone modifications noted. All cloning materials were 
purchased from New England Biolabs (NEB). Alexa Fluor NHS-ester reagents were 
purchased from ThermoFisher Scientific. 
 
Cloning and DNA preparation: The luciferase gene (Luc2) was stably incorporated 
into SKOV3, HeLa, MCF-7, and HEK293T cells via viral transfection using a pCDH 
vector under a CMV promoter. Plasmid containing Luc2 (Addgene Plasmid #62170) 
was mini-prepped from DH5alpha cells. Luc2 and pCDH vectors were digested at 
EcoRI and NotI sites, run on an agarose gel, and the insert and backbone were 
extracted and ligated overnight at 37°C. Ligated plasmid (pCDH-Luc2) was 
transformed into Mix-and-go competent cells and plated to LB-agar plates with 
ampicillin. Plasmid DNA was mini-prepped from colonies for viral transfection. 
 
Lentiviral Transfection: 800K HEK293T cells were plated in 1.6mL media in a 6-
well plate the evening before transfection. 800µL of media from each well was 
replaced with fresh media the following morning. 3.25µg of pCDH-Luc2, 2.43µg 
psPAX2 (packaging vector), and 0.97µg pMD2.G (VSVG vector) were mixed in 
HBSS buffer with 58mM CaCl2 and added dropwise to the 6-well plate and incubated 
overnight. Media was changed the following morning to 1.6mL fresh media to collect 
virus for 36 hours. Cells to be infected were also plated at this time such that they 
reach 50% confluency by time of infection (36 hours later). After 36 hours, 1.5mL 
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media with virus was mixed with 1.2µL polybrene, then centrifuged at 2K RPM for 5 
mins to pellet any cells. 1mL of this was diluted 1:6 with fresh media and added to 
infection cells. Media was changed following an overnight incubation and incubated 
for another 36 hours. Following this, selection media (Blasticidin) was added to cells 
and following death of control cells, selected cells were expanded and frozen stocks 
were prepared. 
 
Luciferase Expression Test: To examine Luciferase expression levels in transfected 
cells, 10K cells were plated in FluoroBriteTM to a white, 96-well plate 24 hours prior 
to reading. 20µL of CellTiter-FluorTM was added to wells, then incubated for 30 mins 
at 37°C. Fluorescence intensity was measured at 400/505nm Ex/Em and normalized to 
an untreated control for cell viability/count. Luciferase activity was measured by 
adding 20µL ONE-GLOTM reagent to wells, incubating for 5 mins at RT, then 
measuring on for luminescence with a 100ms integration time. Luciferase signal was 
normalized to an untreated control. 
 
siRNA Stability Analysis: For stability analysis, 10µM stocks of each RNA strand 
were mixed 1:1 to anneal in Milli-Q H2O for 30 mins at RT. RNA duplexes were then 
mixed 1:1 with non-heat inactivated mouse serum at 37°C for 0.5, 1, 2, 6, or 24 hours. 
Untreated controls and treated samples were then loaded onto native 4-20% PAGE 
gels, run at 100V for 60 mins, stained with SYBR Gold, and imaged on a ChemiDoc 
MP Imaging system (Bio-Rad). Gels were examined qualitatively by band intensity. 
 
siRNA Knockdown Efficiency: To examine knockdown efficiency of siRNA 
duplexes, Luc2-expressing SKOV3 cells were treated with Lipofectamine 
encapsulated siRNA and analyzed for Luciferase expression levels. 15K SKOV3 cells 
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were plated in a white, 96-well plate 24 hours prior to reading. siRNA duplexes were 
mixed at a ratio of 75µL Lipofectamine per nmole of siRNA for 20 mins at RT, then 
added to cells in 100µL DMEM + 10% FBS at a final concentration of 50nM siRNA. 
The cells incubated at 37°C in 5% CO2, then were washed with PBS after 16 hours, 
replaced with fresh DMEM + 10% FBS with no phenol red for the remaining 32 
hours. Cells were analyzed with the Promega ONE-GLO/Tox Luciferase Assay Kit. 
First, 20µL of fluorescent reagent was added to wells and incubated for 30 mins at 
37°C, followed by a fluorescent measurement at 400nm/505nm Ex/Em. Then, 20µL of 
luminescent reagent was added and incubated for 5 mins at RT, followed by a 
luminescence measurement at 100ms integration time.  Luminescence signals were 
normalized by fluorescence signal (cell viability), then normalized to an untreated 
control for % luciferase expression.  
 
Cathepsin-B Labile Linker Synthesis and Purification (Appendix A.6-A.9): 
Fmoc-FCit-OH: 200mg of the Fmoc-protected phenylalanine pentafluorophenyl ester 
(Fmoc-F-OPfp) was solubilized in 2.5mL THF. 1.05 equivalents of Citrulline (H-Cit-
OH) and sodium bicarbonate were solubilized in 1mL DI water. The Fmoc-F-OPfp 
solution was added to the H-Cit-OH and NaHCO3 and stirred at 40°C overnight.  THF 
was then dried via rotary evaporation, and the remaining water layer was diluted to 
5mL with DI water and 0.5mL IPA and acidified to pH~1 with HCl. The product was 
extracted with (9:1) Ethyl Acetate:IPA 5 times, rinsed with brine, dried with sodium 
sulfate, and dried via rotary evaporation. The product was triturated with Diethyl Ether 
and the final product was recovered and verified with LCMS. 
Fmoc-FCit-PABA: 35mg of Fmoc-FCit-OH was mixed with 2 equivalents each of 4-
aminobenzyl alcohol (PABA) and N-Ethyoxycarbonyl-2-ethyoxy-1,2-
dihydroquinoline (EEDQ) in 3:1 DCM:MeOH and stirred at RT overnight. The DCM 
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and MeOH were dried via rotary evaporation, followed by trituration with diethyl 
ether. The product was verified with LCMS (data not shown). 
TCO-PEG4-FCit-PABA: 14.5mg of Fmoc-FCit-PABA was incubated with 8 
equivalents triethylamine (TEA) and 1.25 equivalents NHS-PEG4-TCO in DMSO at 
50mM at RT overnight. The TCO-PEG4-FCit-PABA was purified via semi-
preparative RP-HPLC with a gradient of water and acetonitrile with 0.1% 
trifluoroacetic acid (TFA). The product was dried immediately with argon and verified 
with LCMS (data not shown). 
TCO-PEG4-FCit-PABC: 5.2mg of TCO-PEG4-FCit-PABA was solubilized in dioxane 
with 6 equivalents of bis-4-nitrophenyl carbonate ((PNP)2CO) and 3.6 equivalents 
N,N-diisoproylethylamine (DIEA) at 25mM overnight at 50°C. The reaction mixture 
was dried immediately with argon, purified via RP-HPLC, and verified with LCMS 
(Appendix A.9). 
The Valine-Citrulline linker followed the same protocol with the following changes: 
(1) Fmoc-Valine-OPfp ester was used instead of Fmoc-F-OPfp 
(2) EEDQ coupling was performed in 2:1 DCM:MeOH instead of 3:1 
 
Thiol-Reactive Linker Synthesis and Purification:  
Non-cleavable TCO-PEG9-MAL Linker was purchased from Broadpharm (Cat# 
BP23872) 
TCO-PEG8-OPSS: 2.5 mg (9.51 µmol) of TCO-NH2 was incubated with 6.63 µL 
(47.6 µmol) TEA and 7.35mg (9.99µmol) NHS-PEG8-OPSS in 107µL anhydrous 
DMSO overnight at RT. The reaction mixture was purified on a semi-preparative RP-
HPLC on a gradient of 5-95% AcN in water over 30 mins. The product eluted at 17.3 
mins and was verified via LC-MS (Appendix A.22). 
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Nucleic-Acid Functionalization with heterobifunctional crosslinkers: All 
functionalized DNAs were purified on an analytical C18 RP-HPLC column on a 
gradient of 5-65% 0.1M triethylammonium acetate (TEAA) buffer (pH 7.0) in 
acetonitrile over 30 minutes. Product peaks were recovered and dried in a speed-vac 
and re-suspended in PBS buffer for conjugation. The recovered DNA was quantified 
via absorbance at 260nm on a quartz NanoquantTM plate. 
DNA-PEG4-TCO Synthesis: 100µg of single strand (ss)DNA-NH2 (14.5 nmol) was 
incubated with 373µg of TCO-PEG4-NHS (725 nmol) in 280mM HEPES buffer in 
53µL of 50% DMSO overnight at 37°C and purified via RP-HPLC.  
DNA-PEG4-Tzine Synthesis: 150µg of ssDNA-NH2 (21.7 nmol) was incubated with 
580µg of MeTzine-PEG5-NHS (1.09 µmol) in 200mM HEPES buffer in 72µL of 60% 
DMSO overnight at 37°C and purified via RP-HPLC. 
DNA-VCit-PEG4-TCO/Tzine Synthesis: 100µg of ssDNA-NH2 (14.5 nmol) was 
incubated with 274µg of Fmoc-VCit-PABC (Broadpharm; 290 nmol) in 110 mM 
HEPES buffer in 71µL of 75% DMSO overnight at 37°C. The mixture turned a bright 
yellow color following reaction. The mixture was then passed through a Zeba 7kD 
MWCO 500µL spin column one time at 1,500 x g for 2 mins. The recovered DNA 
was then mixed with 314µg (610 nmol) of TCO-PEG4-NHS or 310 µg (610 nmol) 
MeTzine-PEG5-NHS in 100mM HEPES buffer in 79% DMSO overnight at 37°C and 
purified via RP-HPLC. 
DNA-MAL-TCO Synthesis: 100µg of DNA (14.4 nmol) with a protected thiol 
(ssDNA-SSOH) was mixed 1:1 with 100mM DTT in PBS at a final concentration of 5 
mg/mL DNA for 1 hour at RT. The mixture was washed three times with 100µL ethyl 
acetate (EtOAc) to remove excess DTT, then the remaining aqueous layer was 
incubated with 220µg (289 nmol) MAL-PEG9-TCO in 84mM HEPES in 60µL of 75% 
DMSO overnight at 37°C and purified via RP-HPLC. 
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DNA-SS-TCO Synthesis: 100µg of DNA (14.4 nmol) with a protected thiol (ssDNA-
SSOH) was mixed 1:1 with 100mM DTT in PBS at a final concentration of 5 mg/mL 
DNA for 1 hour at RT. The mixture was washed three times with 100µL ethyl acetate 
(EtOAc) to remove excess DTT, then the remaining aqueous layer was incubated with 
244µg (289 nmol) OPSS-PEG8-TCO in 250mM HEPES in 20µL of 25% DMSO 
overnight at 37°C and purified via RP-HPLC. 
 
Antibody Functionalization:  
Non-specific conjugation: Antibodies were functionalized non-specifically with 
methyltetrazine groups by incubating 100µg of antibody at 25µM with 250µM NHS-
PEG4-methyltetrazine in PBS overnight at 37°C. Excess linker was removed by 
washing three times with PBS in Amicon 30kDa spin columns. Recovery was 
quantified via absorbance at 280nm using a quartz NanoQuant plate (ext. coeff280nm = 
210,000 M-1 cm-1). Degree of labeling of the tetrazine was quantified via absorbance at 
294nm (ext. coeff294nm = 93,710 M-1 cm-1) and calculated using the formula under 
“degree of labeling calculation”.  
mTG Site-specific Conjugation: 200µg of LplA-reacted antibody was incubated at 
12.5µM with 200 wt% Moo Gloo (10U/g Ab), 160 molar equivalencies of NH2-PEG3-
Az, and 0.6µL of PNGase F for overnight at 37°C. Excess linker was removed by 
washing three times with PBS in Amicon 30kDa MWCO centrifugal columns. 
Recovered antibody was quantified via 280nm absorbance using a quartz NanoQuant 
plate (ext. coeff280nm = 210,000 M-1 cm-1).  
LplA Site-specific Conjugation: 200µg of LC or HC LAP-tagged antibody was 
incubated at 20µM with 10mol% LplA, 200µM pAz, 1mM ATP, and 5mM Mg(OAc)2 
in PBS for 1.5 hours at 37°C. The excess linker was either removed by washing three 
times with PBS in Amicon 30kDa MWCO centrifugal columns. Recovered antibody 
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was quantified via 280nm absorbance using a quartz NanoQuant plate (ext. coeff280nm 
= 210,000 M-1 cm-1). 
 
Ab-siRNA Conjugation: Three molar equivalencies of RNA-TCO or RNA-DBCO, 
with or without a cleavable site, was added to the methyltetrazine- or azide-
functionalized antibody, respectively, overnight at 37°C. Conjugates were run on 4-
20% Tris-Glycine polyacrylamide gels under native conditions for non-specific 
conjugates, and denatured and reducing conditions for site-specific conjugates. Native 
gels were stained with 1:10,000 diluted SYBR gold in Tris-Glycine buffer for 15 
mins, then imaged on a ChemiDoc MP Imaging system (Bio-Rad). These gels were 
then stained with Bio-SafeTM Coomassie Stain, de-stained with water, and imaged on a 
ChemiDoc MP Imaging system (Bio-Rad). For denatured gels, gels were rinsed two 
times with 5% Triton-X in Tris-Glycine buffer for 30 mins before SYBR Gold and 
Bio-Safe staining, de-staining, and imaging. 
 
Degree of Labeling Calculation: Degree of labeling measurements were taken on a 
TECAN M1000pro plate reader using a quartz NanoquantTM plate and calculated 
using the formula below. This formula was adapted for protein, antibody, DNA, and 
linkers with an absorbance.    
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Equations for Degree of Labeling calculations (above). 
 
Purification of Ab-RNA Conjugates: Ab-RNA conjugates were purified using 
Millipore NanoSep® 100kDa columns via the following protocol.  Columns were 
soaked in 500µL Milli-Q H2O for 1 hour prior to purification. Water was then 
removed and 50µL of Ab-RNA reaction mixture was added to each column. Columns 
were centrifuged at the 2,500 x g for 5 minutes. Sample was recovered using two 
washes of 20µL of PBS over the membrane surface. Conjugates were run on 4-20% 
Tris-Glycine polyacrylamide native gels and stained with SYBR GOLD to assess 
purity. Following purification, Ab-RNA conjugates were quantified via absorbance at 
260nm and 280nm for protein and nucleic acid concentrations, respectively. 
 
Confocal Microscopy Uptake Analysis of Ab-dsDNA-AF488 Conjugates: HeLa 
(TfRAb conjugates) or SKOV3 (CD63Ab or Her2Ab conjugates) cells were plated to 
~75% confluency on 35mm MatTek glass bottom dishes 24 hours prior to antibody 
incubation. The cells were then treated with 100nM antibody-dsDNA-AF488 
conjugates for 1 hour in DMEM + 10% FBS at 37°C in 5% CO2. Cells were washed 
cmAb = (A280 Tzine294 A294 Tzine280 ) / [( mAb280 Tzine294 mAb294 Tzine280 )l]
cTzine = (A280 mAb294 A294 mAb280 ) / [( Tzine280 mAb294 Tzine294 mAb280 )l]
DNA
260=190,900
DNA
280=100,855
DNA
294= 23,480
mAb
260=102,346
mAb
280= 217,900
mAb
294= 93,710
Tzine
260= 7,102
Tzine
280= 21,672
Tzine
294= 29,578
 DOL = cTzine / cmAb
 max (Tzine) = 294nm
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with PBS, fixed with 4% paraformaldehyde for 15 mins at RT, followed by staining 
with 2µM Hoechst for 10 mins at RT, then stored at 4°C in PBS prior to imaging. 
Dishes were imaged on a Zeiss LSM880 inverted confocal microscope with 405nm 
and 488nm lasers at 40X magnification. 
 
Flow Cytometry Uptake Analysis of Ab-dsDNA-AF488 Conjugates: 25K HeLa 
(TfRAb conjugates) or SKOV3 (CD63Ab or Her2Ab conjugates) cells were plated to 
a 24-well plate 1 day prior to antibody incubation. Cells were incubated at the varying 
concentrations in 200µL DMEM + 10% FBS media for 1 hour at 37°C in 5% CO2. 
The cells were then washed with PBS, trypsinized, quenched with media, and 
resuspended in 500µL PBS for flow cytometry analysis on a BD FACSCalibur flow 
cytometer. Data was analyzed with FlowJo software and plotted in PRISM. All 
measurements were blanked with an untreated cell control. 
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CHAPTER 4 - MEMBRANE DISRUPTING AGENTS FOR ENDOSOMAL 
ESCAPE 
 
Background 
Biologics have emerged as a growing class of therapeutics in the drug market, 
encompassing 40% of the total market and growing at a rapid pace. This field 
encompasses protein- and nucleic acid-based drugs that often bind to a specific target 
on, or in, a cell to mediate a cellular function.176 However, delivery of biologics is 
difficult, particularly for intracellular targets. Short-interfering RNA (siRNA), in 
particular, must enter the cytosolic space of a target mammalian cell in order to 
function.153,177 Because most delivery vehicles utilize endocytosis for cellular uptake, 
the delivery cargo often resides in the endosome, where, in the absence of a 
membrane-permeating reagent, it will remain in the endosome until the cargo is 
degraded by proteases/nucleases as the endosome matures to a lysosome. Thus, 
facilitating escape from the endosomal compartment remains the major barrier to 
nucleic acids delivery. 
 
There are several mechanisms and reagents used to translocate across the endosomal 
membrane.50 Some pathways rely on natural leakage events that occur during fusion 
and fission of endosomes during endocytosis.47 Others depend on reagents that disrupt 
the membrane via direct pore-formation, pH-buffering and osmotic disruption (proton 
sponge effect),51-53 or carrier membrane fusion54-56 with the endosome bilayer. 
Materials and chemicals derived from pathogens, as well as biomimetics, that utilize 
these mechanisms have been identified and incorporated into drug carriers to facilitate 
this process. In this study, we sought to incorporate a variety of endosomal escape 
agents into a non-viral delivery system, namely an antibody bioconjugate, for co-
delivery with siRNA to facilitate targeted endosomal escape. To begin this study, we 
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examined agents that mechanistically lead to escape via pore formation in the 
endosomal membrane. 
 
A common pore-forming agent utilized in delivery systems is Melittin, which is a 26-
amino acid peptide and the primary toxic component of bee venom.61,62 Melittin forms 
a tetrameric structure in solution,63 and upon binding to a target cell membrane, forms 
an amphipathic helical structure and pore perpendicular to the cell membrane.64,65 
Melittin and several analogs have been incorporated into liposomes, polyplexes,67,178-
181 and conjugates,66,182 most notably the dynamic polyconjugate (DPC) system.68-70 In 
DPCs, Melittin was decorated with an acid-labile, maleic anhydride-derived polymer, 
and a targeting ligand for specific delivery to hepatocytes. When co-delivered with a 
cholesterol-siRNA conjugate, the endosomally unmasked Melittin induced pore 
formation and subsequent escape of the co-localized siRNA cargo into the cytosol. 
Taking inspiration from this system, we conjugated Melittin and analogues to an 
antibody for targeted extra-hepatic delivery. 
 
In addition to amphipathic helical peptides such as Melittin, arginine-rich cell-
penetrating peptides183 have also been successful in delivering functionally active 
macromolecular cargos such as proteins,184 oligonucleotides,185 and plasmid DNA. It 
is believed that the positively-charged guanidine groups in these arginine rich peptides 
enhances cellular uptake and endocytosis, and possibly also facilitate endosomal 
escape. Recently, Najjar and colleagues showed that that polyarginines were in fact 
endosomolytic and facilitate the release of cargo into the cytosolic space with pulse-
chase microscopy.186 They also showed that these affects were strongly affected by the 
number of charges and the nature of the charged group. By covalently incorporating 
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arginine-rich peptides onto antibody conjugates, we can study the efficiency of 
endosomal escape decoupled from uptake and stability. 
 
Bacterial-derived toxins are another class of pore-forming agents for endosomal 
escape. Cholesterol-dependent cytolysins71 (CDCs) are a family of toxins which are 
soluble in aqueous solution, but readily oligomerize to form large pores (~300A) in 
lipid membranes with cholesterol. These toxins are secreted by gram-positive bacteria 
and are important in their pathogenicity.72 Two examples of these pore forming toxins 
are Perfringolysin O (PFO) and Listeriolysin O (LLO) from Clostridium perfringens 
and Listeria monocyotogenes, respectively. Both toxins are tetrameric proteins, 
approximately ~52kD in size,73,74 with a conserved 4th domain undecapeptide 
responsible for its high affinity (KD ~10-9 M) for cholesterol. Approximately 30-40 
toxin molecules then come together on the membrane surface and oligomerize to form 
a pore to allow the cargo to translocate the membrane. These toxins have been used 
for cytosolic delivery of both cytotoxic proteins75,77,187 and nucleic acids.78,188 
 
In this chapter, we examine pore-forming activity and cytotoxicity of both peptide- 
and bacterial toxin-based endosomal escape agents (EEAs). We analyzed their pore-
forming ability through hemolysis assays, in which we exposed these agents to red 
blood cells, and measured hemoglobin release as a function of agent concentration. 
We then explored various conjugation strategies, taking advantage of 
heterobifunctional linkers to specifically link EEAs to antibodies. Finally, we 
examined masking strategies to prevent outer membrane disruption and target these 
agents to the endosomal membrane. Though we were not able to effectively target 
these agents specifically to the endosome, we describe the steps taken to conjugate 
these agents and insights for how to utilize other escape agents in a similar system. 
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Results 
Melittin and Melittin Analog Characterization: We began our investigation of EEAs 
with the known lytic peptide, Melittin, and two analog structures. We characterized 
these structures for membrane pore formation, followed by conjugation to targeting 
ligands. Our crosslinkers (Figure 4.4A and B) take advantage of primary amine or 
thiol conjugation handles, therefore, we modified the peptides to be amenable to that 
chemistry. 
 
In order to utilize amine-reactive chemical crosslinkers, we needed to address the 
multiple lysine residues present on the native Melittin peptide (Figure 4.1A; top), as 
this would lead to heterogeneous crosslinking. We proposed two Melittin analogues, 
MK7R and MS18R (Figure 4.1A; center & bottom), each with a truncated C-terminal 
to remove the two lysine and two arginine residues present there. Previous work has 
demonstrated that though N-terminal truncation obviates Melittin activity, C-terminal 
truncation was well-tolerated.67,189 The remaining amine at the 7th position was 
substituted with an arginine residue to preserve charge. In the MS18R analog, the 18th 
position serine was substituted with an arginine residue for additional charge. Both 
analogs left a single primary amine at the N-terminal for conjugation. The removal of 
charged residues from the peptides caused a rather dramatic shift in hydrophobicity, as 
indicated by RP-HPLC (Figure 4.11B). The second analog, MS18R, was more 
hydrophilic though as was expected with the additional charge.  
 
These peptides were then analyzed via hemolysis assay at varying pH (physiological 
and endosomal) to test their pore-forming activity and pH-selectivity. MS18R and 
MK7R peptides showed similar hemolytic activity relative to the parent Melittin with 
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HC50 values around 1-2.5µM at physiological pH (Figure 4.1C) and 2-5µM at 
endosomal pH (Figure 4.1D). However, these peptides had a slight increase in activity 
ratio toward endosomal pH, i.e. the differential in HC50 between endosomal and 
physiological pH was smaller (Figure 4.1E). This data indicated that these peptide 
analogs would behave similarly to the parent peptide in terms of endosomal 
disruption, but with the ease of a single conjugation handle at the N-terminal. 
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Figure 4.1 Peptide Endosomal Escape Agents with Amine Chemistry – Melittin 
and melittin analogs (MK7R and MS18R) with amine functionality for conjugation to 
antibodies. (A) Chemical structures of parent melittin peptide (top), MK7R (middle), 
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and MS18R (bottom). (B) RP-HPLC trace of peptides [Melittin (teal); MS18R 
(green); MK7R (maroon)] on a C18 column. (C) Hemolytic activity of Melittin 
[circle], MK7R [square], MS18R [triangle] at physiological pH (PBS buffer; pH 7.4). 
(D) Hemolytic activity of Melittin [circle], MK7R [square], MS18R [triangle] at 
endosomal pH (CBS buffer; pH 5.5). 
 
We also utilized peptides with a thiol handle for conjugation, as the intracellular 
reducing environment can serve as a cleavage cue for conjugates. We received a 
potent melittin analog, C6M3, and parent Melittin, both with a C-terminal cysteine 
residue (Figure 4.2A) from a collaborator in the Pun Lab at the University of 
Washington. The C-terminal cysteine residue allowed us to use orthogonal chemistry 
to amine-reactive functional groups, therefore did not require any peptide truncation. 
The C6M3 peptide was more hydrophilic than the parent Melittin peptide via HPLC 
(Figure 4.2B) and had previously been shown by our collaborator to be active only at 
pH < 6.5. Additionally, this peptide showed a decrease in activity when conjugated to 
polymers in the Pun Lab, therefore would need to be cleaved off of its carrier in order 
to be active. With the four lytic peptides available, we proceeded to conjugate them to 
proteins and antibodies. 
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Figure 4.2 Peptide Endosomal Escape Agents with Thiol Chemistry – Melittin and 
“venom” peptide from Pun Lab with thiol functionality for conjugation to antibodies 
(A) Chemical structures of C6M3 with C-terminal cysteine (top) and Melittin with C-
terminal cysteine (bottom). (B) RP-HPLC trace of peptides [C6M3 (purple); Melittin 
(orange)] on a C18 column. 
 
Melittin Conjugation to Transferrin Protein: To make Transferrin conjugates we 
used the mono-conjugated, OPSS-functionalized Transferrin generated in chapter 3, 
and reacted it with Melittin-SH (Figure 4.3A). We took the Tf-OPSS and added 
increasing amounts of Melittin-SH and saw a shift via SDS-PAGE indicating an 
increase in molecular weight indicative of successful conjugation (Figure 4.3B). This 
conjugate was purified with dialysis to remove excess Melittin-SH and to be used for 
co-delivery with the Tf-siRNA conjugates made in chapter 3. 
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Figure 4.3 Melittin Conjugation to Transferrin (Tf) Protein – (left) Schematic of 
Tf functionalized with a single ortho-pyridyl disulfide (OPSS) crosslinker, followed 
by thiol-disulfide exchange with a thiolated Melittin peptide. (right) Native page of Tf-
Melittin conjugation. Left panel shows native Tf protein. In the next panel, there is a 
shift upward indicative of OPSS crosslinker addition. With varying amounts of 
thiolated Melittin addition, there is a concentration dependent gel shift upward 
indicative of successful Melittin conjugation. 
 
Peptide functionalization with heterobifunctional crosslinkers: Similar to the siRNA 
conjugation used in chapter 3, we used heterobifunctional crosslinkers with click 
chemistry groups for conjugation to antibodies. First, we functionalized the peptides 
with a reactive group, then clicked them onto antibodies with the opposite 
functionality. For the melittin analogs, we utilized amine-reactive crosslinkers (Figure 
4.4A), and for the C-terminal cysteine peptides, we utilized thiol-reactive crosslinkers 
(Figure 4.4B). As expected, the parent melittin became heavily crosslinked and 
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precipitated with the addition of amine-reactive crosslinkers and could not be used. 
The MK7R proved to be too hydrophobic after addition of the crosslinker that it 
crashed out onto the HPLC column. Therefore, we purified the MS18R analog with a 
stable linker (MS18R-PEG4-TCO), and with two cleavable linkers with a Cathepsin-B 
labile Valine-Citrulline (VCit) or Phenylalanine-Citrulline (FCit) site within the linker 
(Appendix A.6-A.9). These peptides were still quite hydrophobic though, eluting near 
~95% acetonitrile on a C4 RP-HPLC column for all three variations (Figure 4.4C). 
The thiol-reactive peptides were much more hydrophilic after addition of a stable 
maleimide-peg4-DBCO crosslinker, eluting near 60% acetonitrile on a C18 RP-HPLC 
column (Figure 4.4D). All peptide masses were verified with LCMS (Appendix A.1-
A.5, A.10-A.16). Some oxidation of the W19 residue was observed on the purified 
peptide MS18R peptide conjugate, however we proceeded with conjugation anyway. 
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Figure 4.4 Peptide Conjugations with Chemical Linkers – Lytic peptides and 
chemical linker structures for conjugation to antibodies via “click chemistry” groups. 
(A) Chemical structures of stable (top) and Cathepsin B labile (middle & bottom) 
linkers functionalized with trans-cyclooctene (TCO) groups for reaction with tetrazine 
and para-nitrophenyl ester groups for reaction with amines. (B) Chemical structure of 
chemical linker with DBCO group for reaction with azides and maleimide groups for 
reactions with thiols. (C) RP-HPLC trace of MS18R peptide reacted with linkers in 
(A). (D) RP-HPLC trace of C6M3 (purple) and Melittin (orange) reacted with linker in 
(B). 
 
Following successful crosslinker addition with the lytic peptides, we followed a 
similar methodology with a non-lytic peptide, R9K (Figure 4.5A).Though this peptide 
did not display any hemolytic activity at either pH (Figure 4.5C), it has been shown 
previously by us190 and others183,186 that guanidine-rich oligomers are efficient at cell 
membrane translocation. Therefore, we used a similar conjugation approach and a 
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DBCO crosslinker (Figure 4.4B) via an NHS-ester conjugation to the lysine group on 
the c-terminal end of R9K. This peptide mass was purified via RP-HPLC (Figure 
4.5D) and verified with LCMS (Appendix A.17-A.19). This R9K-DBCO could then 
be used with the other lytic peptides and conjugated to antibodies. 
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Figure 4.5 Characterization and Conjugation of R9K – Arginine reach peptide 
with amine functionality (R9K) characterization on red blood cells and conjugation 
with a chemical linker. (A) Chemical structure of R9K peptide. (B) Chemical structure 
of amine-reactive NHS-PEG4-DBCO group for reaction with azides. (C) Hemolytic 
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activity of R9K at physiological pH (blue) and endosomal pH (maroon). (D) RP-
HPLC trace on a C18 column of R9K reacted with the linker in (B). 
 
Lytic Peptide Conjugation Methods to Cell Receptor Targeting Antibodies: In order 
to deliver these peptides in a targeted manner, we conjugated them to cell-surface 
targeting antibodies via several conjugation methods; non-specific, Fc-region specific, 
and light-chain specific (Figure 4.6A). 
To non-specifically conjugate the MS18R peptide to an antibody, we took the TCO-
functionalized MS18R peptide and added increasing molar ratios to a randomly 
tetrazine-functionalized antibody. This resulted in a gel shift and band intensity 
increase on both the heavy and light chains of the antibody, indicating that the peptide 
was successfully conjugated (Figure 4.6B). It also however, indicated that the peptide 
was conjugating indiscriminately all over the antibody, with little control over 
stoichiometry. Additionally, because the MS18R peptide was so hydrophobic, the 
resulting conjugated antibody precipitated out of solution.  
With this result, we performed site-specific conjugation with azide-functionalized 
antibodies specifically on the Fc domain on the heavy chain, or the constant light 
chain (LC) domain with mTG and LplA enzymes, respectively. For this we used the 
two, more hydrophilic peptides, C6M3 and R9K and analyzed via SDS-PAGE. In this 
case, when the peptide was conjugated via mTG or LplA there was a very small 
specific shift in just one domain of the antibody (HC for the mTG conjugation, LC for 
the LplA conjugation), and no observable difference in band intensity (Figure 4.6C 
and D). This difference is very small and should be further verified with MALDI-
TOF, but was encouraging enough to proceed. These antibody conjugates did not 
precipitate out of solution and could potentially be functional for delivery.  
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Figure 4.6 Conjugation of Peptides to Antibodies – SDS-PAGE analysis of 
antibodies conjugated to antibodies via random and site-specific conjugation methods. 
(A) Gradient conjugation of MS18R, functionalized with TCO, to a randomly 
tetrazine-labeled antibody. (B) Gradient conjugation of C6M3 peptide, functionalized 
with DBCO, to a Fc-region azide-labeled antibody. (C) Gradient conjugation of R9K 
peptide, functionalized with DBCO, to a LC-region azide-labeled antibody. 
 
Bacterial Toxins in Endosomal Escape – Perfringolysin O (PFO): In addition to 
membrane-disrupting peptides, we investigated bacterial toxins for endosomal escape 
agents, specifically the cholesterol-dependent cytolysin (CDC) family of toxins. These 
toxins are unique in that they are aqueous soluble yet still have a strong membrane-
affinity for pore formation. First, we considered Perfringolysin O (PFO), a secreted 
toxin from Clostridium perfringens, to characterize and investigate.  
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Figure 4.7 Perfringolysin O (PFO) Characterization – Characterization of 
commercial PFO hemolytic activity and PEGylation. (A) Crystal structure of full-
length PFO191 and zoom on domain four. Red box highlights single cysteine residue, 
shown in orange. (B) PEGylation reagents used for non-reducible (i) and reducible (ii) 
PEGylation of LLO on fourth domain cysteine. (C) Hemolytic activity of PFO and 
PEGylated counterparts with reducible (OPSS) and non-reducible (MAL) PEGs. (D) 
SDS-PAGE of control and PEGylated (reversible and stable) with and without bME. 
Expected mass of PFO+Tag = 66.2 kD 
 
PFO, like other CDCs contains a characteristic, single, cysteine residue in the fourth 
domain of the protein (Figure 4.7A191). This domain and the undecapeptide within it 
has been shown to be responsible for cholesterol binding and membrane incorporation 
into a target cell membrane.192 This cysteine residue thus served as a convenient 
reversible handle for both activity attenuation and conjugation. To demonstrate the 
activity attenuation, we incubated PFO with non-reducible (MAL)(Figure 4.7Bi) and 
reducible (OPSS)(Figure 4.7Bii) PEGylating agents and examined subsequent changes 
in hemolytic activity. As expected, the PEG addition significantly reduced the toxin 
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hemolytic activity up to 2.5 nM, with a small amount of detectable activity at 5 nM 
with the reducible linker  (Figure 4.7C). When analyzed via SDS-PAGE, we observed 
a gel shift corresponding to the addition of the PEG chain (Figure 4.7D). When treated 
with a reducing agent, beta-mercaptoethanol (bME), the band corresponding to the 
toxin with the reducible PEG returned to the position of the parent toxin, while the 
non-reducible linkage was not affected. This is expected because the thiosuccinimide 
linkage is stable to reducing agents. After demonstrating that the toxin could be 
reversibly attenuated, we moved to a similar bacterial toxin that is known to be more 
active at endosomal pH, Listeriolysin O (LLO). 
 
Bacterial Toxins in Endosomal Escape – Listeriolysin O (LLO): LLO is a member of 
the same family of CDCs as PFO, however; LLO is derived from the intracellular 
pathogen, Listeria monocytogenes. LLO is unique among CDCs in that it is used for 
endosomal escape of the Listeria and is more active in the endosomal compartment 
than the cytosolic or extracellular space. Using a plasmid generously donated by Dr. 
Daniel Portnoy’s Lab at UC Berkeley, we were able to express and purify His-tagged 
WT LLO from BL21 E. coli cells. We characterized LLO for hemolytic activity and 
determined an HC50 value of 30 pM at endosomal pH. We also observed a pH 
differential in lytic activity of about 3.3X between physiological and endosomal pH 
(Figure 4.8A). This was consistent with literature and an indicator that LLO would be 
more active on the endosomal membrane than the outer cell membrane. Additionally, 
LLO also has the single, conserved cysteine residue at the fourth domain of CDCs that 
attenuates activity. We conjugated LLO with a reducible PEGylating agent (Figure 
4.8Gii) and saw efficient PEGylation of the toxin via SDS-PAGE that was reversible 
with bME (Figure 4.8B). This PEGylation corresponded to a reduction in hemolytic 
activity by an order of magnitude at both physiological (Figure 4.8C) and endosomal 
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pH (Figure 4.8D) that was reversible with the addition of dithiothreitol (DTT). We 
saw a similar activity modulation with the toxin was conjugated with a reducible, 
heterobifunctional crosslinker for antibody conjugation (Figure 4.8E&F). This 
attenuation via the D4 cysteine was effective, but only attenuated the active range of 
the toxin to between 1-10nM. Unfortunately, the potency is higher than the dosing 
concentration of the antibody conjugates. Therefore, we needed to further attenuate the 
toxin. 
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Figure 4.8 Listeriolysin O (LLO) Characterization – Characterization of LLO 
hemolytic activity, pH differential, and PEGylation. (A) Hemolytic activity of LLO at 
physiological [PBS buffer (pH 7.4)] and endosomal [CBS buffer (pH 5.5)] pH. Has a 
differential of 3.3-fold between endosomal and physiological pH. (B) SDS-PAGE of 
LLO with and without reducible PEGylation reagent (G-ii) and before and after 
treatment with bME. (C&D) Hemolytic activity of LLO with reducible PEG (G-ii) at 
physiological [blue; PBS buffer (pH 7.4)] and endosomal [red; CBS buffer (pH 5.5)] 
pH and reduced with DTT. (E&F) Hemolytic activity of LLO with reducible bi-
functional PEG linker (G-iii) at physiological [blue; PBS buffer (pH 7.4)] and 
endosomal [red; CBS buffer (pH 5.5)] pH and reduced with DTT. (G) Schematic of 
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PEGylation of LLO with two PEG structures used in this figure. G-ii; PEG-OPSS. G-
iii; MeTzine-PEG8-OPSS 
 
Surface PEGylation of LLO for Reduced Outer Membrane Affinity: Surface 
PEGylation has been shown previously to decrease adherence of several materials, 
including proteins, by adding an extra “water” layer around the given material117,127. 
Therefore, to decrease the affinity of the toxin for the target membrane, we first 
examined PEG length and PEG degree of labeling (DOL) on hemolytic activity. We 
screened mono- and poly-disperse NHS-PEGs with 1,200, 2,000, and 5,000 molecular 
weights (MW) (Figure 4.9B; top) at a range of molar equivalencies (3-10 fold) for 
attenuation of the toxin via surface PEGylation. Via SDS-PAGE, we saw a band shift 
to higher molecular weights with both increasing molar equivalencies of PEG (Figure 
4.9A; left) and increasing PEG length (Figure 4.9A; right), as anticipated. This surface 
PEGylation correlated with decreasing amounts of hemolytic activity along the same 
trend (Figure 4.9C and D). The greatest decrease in activity was observed with the 
longest PEG chain length and highest equivalencies (10-fold molar excess). With this 
information, we generated an amine-reactive, para-nitrophenol functionalized PEG 
that is self-immolative following reduction of the internal disulfide (Figure 4.9B; 
bottom). We then showed via SDS-PAGE (Figure 4.9G) and hemolysis assay (Figure 
4.9F) that this linker could PEGylate the surface of the toxin and is reversible with 
bME and DTT (Figure 4.9E and F).  
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Figure 4.9 LLO Surface PEGylation- Studies on surface PEGylating LLO for 
reduced interaction with the outer cell membrane. (A) SDS-PAGE of LLO reacted 
with NHS-PEGs (B; top) with varying molar equivalencies (left) and varying 
molecular weights (right). (B) Chemical structures of non-reducible (top) and 
reducible (bottom) surface PEGylation reagents. (C&D) Hemolytic activity of LLO 
with non-reducible surface PEGylation with varying molar excess (C) and varied PEG 
length (D). (E) SDS-PAGE of LLO reacted with reducible surface PEGylation reagent 
(B; bottom) before and after treatment with bME. (F) Hemolytic activity of LLO 
reacted with reducible surface PEGylation reagent (B; bottom) before and after 
treatment with DTT. (G) Hemolytic activity of LLO WT (closed circle) and 
W491AW492A mutant (open circle) at physiological (blue) and endosomal (red) pH. 
(H) MTS assay for cytotoxicity on mammalian cells of WT LLO (closed circle) and 
mutant (open circle). 
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Site Directed Mutagenesis to 4th Domain Undecapeptide for Toxin Attenuation: To 
further reduce LLO’s potency above the dosing concentration (~100 nM), we 
performed site-directed mutagenesis to mitigate overall toxicity to mammalian cells. 
In a similar targeted dual-delivery system in which a CDC was used for endosomal 
escape of a protein therapeutic, Gelonin, and later for siRNA, Yang and colleagues 
found that when PFO was mutagenized at T490A and L491V positions, the toxin had 
drastically reduced toxicity toward the mammalian cell target, but comparable activity 
to the WT in the targeted delivery system.77,78 Taking inspiration from this system, we 
mutagenized W491A and W492A on LLO via Quik-change® mutagenesis and 
observed the change in lytic activity. After mutagenesis, the toxin showed a decrease 
in hemolytic activity at physiological pH by 4-orders of magnitude, and a decrease at 
endosomal pH by 2,000-fold (Figure 4.9G). This yielded a mutant toxin that had an 
activity range of 10-100nM at endosomal pH, and greater than 1µM for physiological 
pH, which increased the pH differential from 3.3- to 20-fold compared to the wild 
type, and in the ideal concentration range for our delivery system. Additionally, this 
mutant showed no detectable toxicity via MTS assay on SKOV3 cells on 
concentrations up to 1µM (Figure 4.9H). Next, we combined the mutagenesis and 
PEGylation and examined uptake of the toxin into mammalian cells. 
 
Outer Membrane Binding of Attenuated and PEGylated LLO: CDCs have a very 
high affinity for cholesterol,192 which is what makes them very potent membrane 
disruptors. However, the cholesterol binding by LLO to the cell surface competes with 
antibody binding and endocytosis of the entire conjugate. Therefore, we examined the 
impact of the mutagenesis and PEGylation of the toxin on the outer membrane 
binding. To do this, we labeled the toxin on the fourth domain cysteine with a 
maleimide AlexaFluor 488 (AF488) and PEGylated the surface, which corresponded 
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to an increase in MW and positive fluorescent signal (Figure 4.10A and B). We took 
these fluorescently-labeled toxins and examined their interaction with SKOV3 cells 
via flow cytometry. Following the trend in hemolytic activity, we observed a decrease 
in cellular uptake with increased PEG length and DOL. This uptake however, was still 
detectable above the BSA control even at the most extreme PEGylation condition 
(Figure 4.10C and D). Additionally, when we took the mutagenized toxin and 
conjugated it to Her2-targeted antibody via non-specific conjugation (Figure 4.10E), 
we saw uptake into mammalian cells that was receptor-independent (Figure  
4.10F&G). In a final attempt to reduce surface interaction, we PEGylated the toxin 
and specifically conjugated it to the LC of Her2-targeted antibodies (Figure 4.10H) 
and examined uptake into SKOV3 cells. Unfortunately, the overall uptake of the 
conjugate was low and on-order with the PEGylated toxin alone (Figure 4.10J). This 
was indicative that the cholesterol affinity was greater than the antibody affinity, or 
the addition of the toxin was blocking the binding site of the antibody. With this 
information, we concluded that although the toxin was no longer toxic, it was too 
“sticky” to deliver via this antibody conjugation system. 
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Figure 4.10 LLO-Antibody (Ab) Conjugation and Uptake into Mammalian Cells 
(SKOV3 Cells) – Studies examining the effect of surface PEGylation and conjugation 
to a targeting antibody on uptake into mammalian cells. (A) Schematic of 
simultaneous labeling of LLO with fluorescent AlexaFluor 488 (AF488) on the D4 
cysteine and PEGylation via surface lysine residues. (B) SDS PAGE of fluorescently-
labeled LLO with varying molar excess of PEG and varying PEG length under 
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Coomassie and fluorescence imaging. (C&D) Flow cytometry analysis of 
fluorescently-labeled and PEGylated LLOmut as a function of PEG length (C) and 
extent of surface labeling (D). Labeled BSA and Her2-targeted Ab are negative and 
positive controls for uptake in SKOV3 cells, respectively. (E) SDS-PAGE stained with 
Coomassie of non-specific conjugation of LLO to Her2-targeted antibodies as a 
function of increasing LLO excess. Mass LLO – 52kD; Mass Ab – 150kD; Mass 
conjugate – 200+ kD. (F) Surface Her2 receptor expression as depicted by flow 
cytometry measured Her2Ab uptake in SKOV3 cells (black) and HeLa cells (gray). 
(G) Uptake of Her2Ab-LLO conjugates in SKOV3 cells (black) and HeLa cells (gray) 
as a function of concentration. (H) SDS-PAGE stained with Coomassie of site-specific 
conjugation of PEGylated LLO (with varying PEG lengths) to light-chain tagged 
antibodies. (J) Uptake of PEGylated LLO and PEGylated LLO-Antibody conjugates in 
SKOV3 cells as measured by flow cytometry. Uptake of antibody conjugate and free 
LLO are comparable and well below antibody control, therefore uptake is not driven 
by antibody, only by LLO. 
 
Conclusions & Discussion 
In this chapter, we characterized both peptide and bacterial toxin endosomal escape 
agents (EEAs) with different potencies and conjugated both to antibodies for later use 
in an antibody conjugate delivery system. Lytic peptides included Melittin, a bee-
venom derived peptide, and analogs, whereas bacterial toxins were cholesterol-
dependent cytolysins (CDCs) derived from Clostridium perfringens and Listeria 
monocytogenes. To characterize these agents, we examined their hydrophobicity, 
hemolytic activity, and mammalian cellular uptake, and were able to conjugate them 
to antibodies using amine-reactive or thiol-reactive heterobifunctional crosslinkers. 
The hemolytic activity spanned picomolar to micromolar range, allowing us to screen 
agents with a range of membrane potencies and how efficiently they can induce 
endosomal escape. However, despite the hope that this conjugate system could de-
couple uptake and stability from endosomal escape, the two were still indeed coupled. 
 
We found that when the Melittin and Melittin-like peptides were too hydrophobic and 
non-specifically conjugated, the conjugates precipitated out of solution and could not 
be effectively delivered. However, when we took more hydrophilic peptides and 
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conjugated them specifically, the conjugates were much more stable in solution. Due 
to the chronology of this study, the site-specific antibody-peptide conjugates were 
never tested for uptake and endosomal escape. It is very likely that these conjugates 
would not have the same “sticky” fate as the antibody-LLO conjugates, as the potency 
of these lytic peptides was much lower than that of the bacterial toxins. However, 
these peptides may not be potent enough in the endosome, as these peptides had HC50 
values in the low µM range, and it may be necessary to have a high peptide:antibody 
ratio to reach critical endosomal concentration for efficient lysis This could be 
achieved, through multifunctional crosslinkers like those developed in our lab, which 
would allow for a high DOL while still maintaining site-specificity on the antibody. 
 
Out of concern of a lack of lytic potency, we transitioned from lytic peptides to water-
soluble, highly potent, cholesterol-dependent cytolysins. The high affinity for 
cholesterol and potency was to our detriment though, as these toxins still showed 
receptor-independent uptake into mammalian cells despite significant attenuation 
attempts. Structural evidence74,192 suggests this may be due to the toxin forming a pre-
pore complex on the surface of the cell, but not converting to a final pore. This would 
make the toxic non-toxic, but still “sticky”. The most effective means of attenuation is 
still held by the Wittrup lab77,78,193 where an evolved fibronectin (Fn3) domain 
reversibly attenuates the toxin and releases it in the endosome. To extend this system 
to other EEAs would be difficult though as new Fn3 evolution would be required for 
each toxin. Chemical means of attenuating these toxins, or synthetic alternatives, 
could be an approach for future work. 
 
From this study, we have learned that it is difficult to engineer conjugates to target 
lytic agents specifically to the endosomal membrane. This field is on-going, as there 
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currently is no antibody-conjugate based delivery system in the literature that 
effectively screens endosomal escape agents. Future studies should utilize a 
previously-validated receptor target, escape agent, and a highly stabilized cargo to 
more efficiently address this problem. This can then be expanded to new surface 
receptors, escape agents, and therapeutic cargos. 
 
Materials & Methods 
Reduction Sensitive Linker Synthesis and Purification (Appendix A.20-A.27):  
TCO-PEG4-OPSS: 2.1 mg (7.99 µmol) of TCO-NH2 was incubated with 5.57µL (40.0 
µmol) TEA and 4.7mg (8.39 µmol) NHS-PEG4-OPSS in 90µL anhydrous DMSO 
overnight at RT. The reaction mixture was purified on a semi-preparative RP-HPLC 
on a gradient of 5-95% AcN in water over 30 mins. The product eluted at 18.5 mins 
and was verified via LC-MS. (Appendix A.21) 
TCO-PEG8-OPSS: 2.5 mg (9.51 µmol) of TCO-NH2 was incubated with 6.63 µL 
(47.6 µmol) TEA and 7.35mg (9.99µmol) NHS-PEG8-OPSS in 107µL anhydrous 
DMSO overnight at RT. The reaction mixture was purified on a semi-preparative RP-
HPLC on a gradient of 5-95% AcN in water over 30 mins. The product eluted at 17.3 
mins and was verified via LC-MS (Appendix A.22). 
TCO-PEG24-OPSS: 1.2 mg (4.57 µmol) of TCO-NH2 was incubated with 3.18µL 
(22.8 µmol) TEA and 6.9mg (4.79 µmol) NHS-PEG24-OPSS in 51µL anhydrous 
DMSO overnight at RT. The reaction mixture was purified on a semi-preparative RP-
HPLC on a gradient of 5-95% AcN in water over 30 mins. The product eluted at 18.4 
mins and was verified via LC-MS (Appendix A.23). 
MeTzine-PEG8-OPSS: 6.5 mg (17.9 µmol) of methyltetrazine-PEG4-NH2 was 
incubated with 12.5µL (89.4 µmol) TEA and 10.5mg (18.8 µmol) of NHS-PEG4-
OPSS in 248µL anhydrous DMSO overnight at RT. The reaction mixture was purified 
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on a semi-preparative RP-HPLC on a gradient of 5-95% AcN in water over 30 mins. 
The product eluted at 18.0 mins and was verified via LC-MS (Appendix A.25). 
MeTzine-PEG28-OPSS: 2.5mg (6.88 µmol) of methyltetrazine-PEG4-NH2 was 
incubated with 4.8µL (34.4 µmol) TEA and 10.4mg (7.22 µmol) NHS-PEG24-OPSS in 
159µL anhydrous DMSO overnight at RT. The reaction mixture was purified on a 
semi-preparative RP-HPLC on a gradient of 5-95% AcN in water over 30 mins. The 
product eluted at 18.3 mins and was verified via LC-MS (Appendix A.26). 
PNP-SS-PEG5K: 4mg (800 nmol) of PEG5K-NH2 was incubated with 1.12µL (8 
µmol) TEA and 3.88 mg (8µmol) bis-SS-PNP in 121µL anhydrous DMSO for 3 hours 
at RT. The reaction mixture was purified on a semi-preparative RP-HPLC on a 5-95% 
gradient of AcN (0.1% TFA) in water (0.1% TFA) over 72 mins. The product eluted at 
47 mins (Appendix A.27). 
 
Truncated Melittin Linker Conjugation: 200µg of the truncated Melittin peptide 
(MS18R) was incubated with 2 equivalencies CatB cleavable linkers in DMSO with 
20 equivalencies triethylamine (TEA) overnight at 37°C. The reaction mixture was 
purified on an analytical C4 HPLC column with a gradient of acetonitrile in water 
with 0.1% trifluoroacetic acid (TFA). Product was verified with LCMS. (Appendix 
A.10-A.11) 
 
Non-specific Ab Functionalization: Purified anti-CD63 antibody (CD63Ab) or mouse 
isotype control (mAb) was functionalized at 25µM with 10 equivalencies NHS-PEG4-
MeTzine in PBS overnight at 37°C. The reaction mixture was purified via 30kD 
amicon spin columns 3 times, and quantified via absorbance at 280nm and 294nm for 
concentration and DOL, respectively. 
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Site-Specific Ab Functionalization:  
LplA Conjugation: 500µg of antibody was incubated at 20µM with 10mol% LplA, 
200µM pAz or TCO-LAP, 1mM ATP, and 5mM Mg(OAc)2 in PBS for 1.5 hours at 
37°C. The reaction mixture was purified via Amicon 30kDa MWCO centrifugal 
columns and quantified via 280nm absorbance using a quartz NanoQuant plate (ext. 
coeff280nm = 210,000 M-1 cm-1). 
Transglutaminase (mTG) Conjugation: 500µg of antibody was incubated at 12.5µM 
with 200 wt% Moo Gloo (10U/g Ab), 160 molar equivalencies of NH2-PEG3-Az or 
NH2-PEG5-MeTzine, and 0.6µL of PNGase F for overnight at 37°C. The reaction 
mixture was purified via Amicon 30kDa MWCO centrifugal columns and quantified 
via 280nm absorbance using a quartz NanoQuant plate (ext. coeff280nm = 210,000 M-1 
cm-1).  
 
PFO PEGylation with OPSS-PEG2000: 5µg of recombinant PFO (MyBioSource.com) 
in PBS and 10% glycerol was incubated at 5µM with 10 equivalents of OPSS-PEG2000 
for ~3 hours at RT. Conjugation was verified with gel electrophoresis and stained for 
protein with SYPRO Ruby. Activity changes due to conjugation were analyzed with 
red blood cell assays. 
 
Red Blood Cell Assay: Single-donor human red blood cells were washed two times 
with PBS, then diluted to 4% v/v in PBS or CBS buffers at pH 7.4 and 5.5, 
respectively. Samples were serial diluted 1:1 in buffer, then 50µL was mixed 1:1 with 
RBC’s in a v-bottom 96-well plate and incubated at 37°C for 1 hour shaking. The 
plate was then centrifuged at 500xg for 5 mins at 4°C, and 75µL of supernatant was 
transferred to a fresh plate and measured on a plate reader at 414nm. 
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His-tagged LLO Toxin Purification: Listeriolysin O (LLO) was expressed and 
purified from BL21 E. coli cells as previously described. Briefly, LLO-expressing 
BL21 cells were cultured in LB + Kan overnight, then subcultured into 300mL LB + 
Kan to mid-exponential phase (~ OD600=0.5). At that point, cells were induced for 
LLO expression with 1mM IPTG for 6 hours. Cells were pelleted, re-suspended in 
lysis buffer (50mM phosphate (pH 8.0), 1M NaCl, 20mM imidazole, 10mM bME), 
homogenized, and the insoluble material was pelleted at 12Kxg for 30 mins. The 
soluble portion was purified over a Ni-NTA column and eluted with elution buffer 
(lysis buffer, pH 6.0) with varying amounts of imidazole (25mM, 50mM, 100mM, 
250mM, and 500mM). Fractions verified for purity with gel electrophoresis were 
dialyzed into storage buffer (elution buffer – imidazole + 1mM EDTA). LLO was 
quantified via absorbance at 280nm (ext. coeff = 77,407). 
 
LLO “Quik-Change” Site-Directed Mutagenesis: Mutants of LLO with a small 
number of amino acid changes can be done via “Quik-change” mutagenesis. Primers 
were designed to target the undecapeptide region of LLO, specifically Tryptophan 
residues at positions 491 and 492. These residues were changed to Alanine with the 
following primers: 
FWD: GGTTTAGCTTGGGAAGCGGCGAGAACGGTAATTGATGACCGGAAC 
REV: GTTCCGGTCATCAATTACCGTTCTCGCCGCTTCCCAAGCTAAACC 
25ng of template LLO DNA was used for two PCR’s, one with forward primer and 
one with reverse primer at a 50µL reaction volume. These strands were amplified with 
Phusion HF polymerase with standard Phusion thermocycle conditions for 10 cycles. 
25µL of each PCR product was mixed together with an additional 0.5µL of 
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polymerase and run again through the thermocycler for 18 cycles. The PCR product 
was digested with 1µL DpnI to remove methylated template DNA at 37C for 1 hour. 
This mixture was cleaned up with Qiagen mini-prep columns and quantified via 
absorbance at 260/280nm. Final DNA was electroporated into DH5a cells and plated 
to Kan agar plates. DNA from a single colony was mini-prepped and the product was 
confirmed with sequencing. LLOmut DNA was then chemically transformed into 
BL21 cells for protein expression and purification. 
 
Surface PEGylation of LLO: 100µg of LLO was incubated with varying equiv. and 
lengths of NHS-mPEG at 40µM overnight at RT. Degree of labeling of the unpurified 
reaction mixture was analyzed via SDS-PAGE. In the cases where LLO is conjugated 
to a thiol-reactive linker or fluorophore, the LLO was incubated with 20 or 10 equiv. 
linker or fluorophore, respectively, overnight at RT at 40µM the day after or day 
before the LLO PEGylation, respectively. 
 
Linker Conjugation to Listeriolysin O (LLO): 100µg of LLO (WT or mut) was 
incubated at 40µM with 20 equiv. of OPSS-PEG-TCO or OPSS-PEG-MeTzine in 
phosphate buffer pH 6.0 overnight at RT. The mixture was purified of excess linker 
via three washes in Amicon 30kD spin columns. The recovered protein was quantified 
via absorbance at 280nm (and 294nm for MeTzine Linker) for subsequent reaction 
with antibody. 
 
Flow Cytometry Analysis of Cellular Uptake: To verify uptake of the conjugates to 
mammalian cells, SKOV3 WT cells were plated at 25K cells per well 2 days prior to 
the assay. Varying concentrations of Ab-LLO-AF488 conjugates LLO were incubated 
on cells in full serum media for 1.5 hours at 37°C with 5% CO2. Cells were washed 
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with PBS, trypsinized, quenched with media, pelleted, and resuspended in 400µL PBS 
for FACS analysis. Mean fluorescence values of histograms were plotted as a function 
of concentration to determine binding affinity. 
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CHAPTER 5 – ANTIBODY CONJUGATES FOR DUAL-DELIVERY 
 
Background 
Antibody bioconjugates have emerged as an efficient modality for targeted delivery of 
siRNA. Antibodies can efficiently bind and internalize via a specific surface antigen 
on a target cell and bring with it an siRNA cargo. Following endocytosis though, the 
antibody and its cargo are either degraded by intracellular enzymes or recycled back to 
the surface before it can be utilized by RISC for gene knockdown. Inefficient cytosolic 
localization of delivered siRNA continues to be a key challenge in RNAi therapeutic 
development50. Some antibody conjugates fused to protamine or other nucleic-acid 
binding peptides have shown efficacy in eliciting knockdown in target cells,161-163,168 
but were difficult to manufacture into drugs.153 Other covalently conjugated antibody-
siRNA conjugates also showed very limited knockdown and no obvious dependence 
on endocytosis pathway.165 Thus, the correlation between internalization pathway and 
endosomal escape agent efficacy still remains largely unknown. 
 
One unique strategy to incorporate and evaluate endosomal escape agents in 
bioconjugate vehicles is through a dual-delivery strategy, in which the endosomal 
escape agent and the siRNA are conjugated to two carriers and co-delivered. Both 
vehicles internalize into a target cell, co-localize, and the escape agent facilitates the 
release of the cargo into the cytosolic space. This method decouples the escape agent 
and the therapeutic cargo, thus enabling manipulation of the delivery ratio and 
avoiding the chemical complexity of combining both cargo into a single conjugate. 
There are two prime examples of this method in the literature, the first of which are 
Dynamic Polyconjugates (DPCs). 
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DPCs were introduced by Rozema et. al68,69,194 and consists of multiple components 
for targeted delivery. The backbone of the DPC is a butyl and amino vinyl ether 
(PBAVE) endosomolytic polymer to facilitate the endosomal release of the siRNA 
cargo. This polymer is masked using an acid-labile carboxy dimethyl maleic 
anhydride (CDM)195 functionalized PEG and N-acetylgalactosamine (GalNAc) ligand, 
which targets the asialoglycoprotein receptor (ASGPR) on hepatocytes. In later 
iterations, the masked polymer was co-delivered with a cholesterol-conjugated siRNA 
for efficient knockdown of apolipoprotein-B (apoB) in non-human primates.70 The co-
delivery method was 500-fold more efficacious than the cholesterol-siRNA alone and 
proved the co-delivery system as a viable strategy. 
 
A similar co-delivery strategy was evaluated by the Wittrup group with two 
conjugates targeting carcinoembryonic antigen (CEA) and epidermal growth factor 
receptor (EGFR) for delivery of a protein toxin71-73 and siRNA78. They developed a 
bispecific, neutralizing antibody directed to EGFR and Perfringolysin O and co-
delivered a CEA-targeted gelonin toxin. They saw an increase in efficacy in the co-
delivery system over the CEA-targeted gelonin alone. In later studies, they co-
delivered an siRNA-binding protein targeted to a different epitope of EGFR for 
maximum co-localization and saw subsequent siRNA-mediated knockdown. With 
inspiration from these works, we sought to develop a similar co-delivery strategy to 
screen agents that facilitate endosomal escape across a range of cellular targets. 
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Figure 5.1 Schematic of Proposed Antibody Dual-Conjugate Delivery System – 
Antibodies carrying siRNA and an endosomal escape agent (EEA) are co-delivered to 
a target cell for intracellular co-localization and endosomal escape. (1) Antibody 
conjugates bind to their corresponding receptor on the surface of a target cell (2) 
Antibody conjugates are internalized via endocytosis (3) Early endosomes fuse, co-
localizing both conjugates to the same intracellular compartment (4) siRNA and EEA 
cargo are cleaved from their antibody carrier via an endosomal cue (5) EEA induces 
pore formation and facilitates release of siRNA into the cytosol (6) siRNA binding to 
RISC complex, triggering target gene knockdown. 
 
We began developing a modular dual-delivery strategy using antibody (Ab) 
conjugates (Figure 5.1). Cellular internalization of these conjugates is dictated solely 
by the antibody, while endosomal escape is attained with an endosomal escape agent 
(EAA). Two bioconjugates, an antibody-siRNA and antibody-EEA, were prepared 
using the same antibody to ensure compartmental co-localization196,197 within the cell, 
then co-delivered to initiate RNAi. Decoupling internalization from escape enables us 
to screen EEAs that disrupt membranes for cytosolic translocation of siRNA 
independently of its endocytic pathway. The modularity of this system then allows us 
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to then explore the effect of entry pathway on gene silencing by substituting the 
targeting antibody. This approach could then be used as a platform to elucidate 
structure-activity relationships of potent EEAs and effects of entry pathway on the 
efficient delivery of siRNAs. In this chapter, we discuss the effort of testing the 
efficacy the antibody-siRNA and antibody-EEA conjugates developed in chapters 3 
and 4 in a co-delivery system. 
 
Results 
Homotypic Fusion and Co-localization of Antibody Conjugates: Antibody conjugate 
co-delivery system hinges on the co-compartmentalization of the both conjugates in a 
single endosome following endocytosis. To verify that homotypic fusion occurs with 
the same type of antibodies carrying two different cargos, we examined co-
localization of a green fluorescently labeled TfRAb-dsDNA-AF488 conjugate with a 
red fluorescently labeled TfRAb-AF647 conjugate (Figure 5.2A). We proposed that 
because the antibodies target the same receptor, their endosomes should fuse in the 
early endosomal pathway. To observe the fusion of endosomes, we looked for co-
localization of the green signal (from the DNA conjugate) and the red signal (from the 
AF647 conjugate) to give a yellow, overlaid spot (Figure 5.2B). The overlay of these 
in punctate spots and quantification via Fiji Coloc2 plug-in showed that the two 
conjugates co-localized with 59% efficiency and verified that the dual-delivery 
method is viable. 
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Figure 5.2 Early Endosomal Fusion and Co-localization of TfR Antibody 
Conjugates – Antibodies carrying two different cargo and targeting the same surface 
receptor co-localized to the same endosomal compartment. (a) Schematic of 
homotypic fusion of endosomes carrying green-labeled TfRAb-dsDNA conjugates and 
red-labeled TfRAb conjugates. (b) Confocal microscopy images of TfRAb co-
localization into HeLa cells. From left to right: nuclei (blue), TfRAb-dsDNA-AF488 
conjugates (green), TfRAb-AF647 (red), and merged images. Yellow spots are 
indicative of co-localized endosomes. 
 
Melittin-siRNA Conjugate Delivery: We began our studies with an untargeted system 
in which we complexed Melittin directly with siRNA and delivered it to cells. Melittin 
has previously been shown to penetrate cell membranes and localize siRNA to the 
cytosol, and therefore is a good positive control for our experiments. The siRNA and 
Melittin were complexed at different concentrations and ratios, added to Luc2-
expressing SKOV3 cells, and examined for knockdown efficiency of luciferase 
(Figure 5.3). We found that the amount of Melittin in the complex had a greater 
impact than the amount of siRNA, as samples with 2 µM Melittin had the same level 
of knockdown with either 50 nM or 100 nM siRNA. Similarly, complexes with 500 
nM Melittin had the same level of knockdown with either 50 nM or 100 nM siRNA, 
and less knockdown than the 2 µM Melittin counterpart. With this data, we knew that 
Nucleus (Hoechst) TfRAb-dsDNA-AF488
TfRAb-AF647 Merge
AF647
AF488
AF647
AF488
A B
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Melittin was an effective agent for membrane translocation and could move forward in 
making protein conjugates to decouple the action of cellular uptake and endosomal 
escape. 
 
Figure 5.3 Melittin-siRNA complexation for Luciferase Knockdown – Melittin and 
Luc2-targeted siRNA were complexed and delivered to SKOV3-Luc2 cells and 
analyzed for knockdown. (a) Melittin and siRNA components (b) Cell viability of 
treated cells (c) Luciferase expression of treated cells (d) Luciferase Expression 
normalized to cell viability.  
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Figure 5.4 Transferrin (Tf)-siRNA and Tf-Melittin Conjugate Co-Delivery – 
Transferrin conjugates carrying siRNA and Melittin co-delivered to SKOV3-Luc2 
cells. Black bars are controls and orange bars are Transferrin conjugate treated cases. 
(a) Schematic of Tf conjugates carrying siRNA and Melittin, each with a reducible 
disulfide linker. (b) Cell viability of treated cells (c) Luciferase expression of treated 
cells (d) Luciferase Expression normalized to cell viability. 
 
Transferrin Conjugate Delivery: In chapter 3 and 4, we generated Transferrin 
conjugates carrying either siRNA or Melittin and co-delivered them to SKOV3-Luc2 
cells (Figure 5.4). We co-delivered the two conjugates carrying 200ng of siRNA per 
well with 1:1 and 5:1 molar ratios of Melittin:siRNA to see if the Melittin conjugate 
was able to facilitate endosomal escape of the siRNA conjugate. As anticipated, the 
siRNA conjugate alone elicited no knockdown, but neither did the co-delivery with the 
Lip
ofe
ct 
(50
ng
)
Lip
ofe
ct 
(10
0n
g) 
Lip
ofe
ct 
(20
0n
g)
Lip
ofe
ct 
(du
mm
y s
iRN
A)
siR
NA
 no
 ca
rri
er
Tf-
siR
NA
 (2
00
ng
)
Tf-
Me
l: T
f-s
iRN
A (
1:1
)
Tf-
Me
l: T
f-s
iRN
A (
5:1
)
Tf-
Me
l: s
iRN
A (
5:1
)
Bla
nk
0
50
100
150
%
 C
el
l V
ia
bi
lit
y
%
 L
uc
ife
ra
se
 A
cti
vi
ty
Lip
ofe
ct 
(50
ng
)
Lip
ofe
ct 
(10
0n
g) 
Lip
ofe
ct 
(20
0n
g)
Lip
ofe
ct 
(du
mm
y s
iRN
A)
siR
NA
 no
 ca
rri
er
Tf-
siR
NA
 (2
00
ng
)
Tf-
Me
l: T
f-s
iRN
A (
1:1
)
Tf-
Me
l: T
f-s
iRN
A (
5:1
)
Tf-
Me
l: s
iRN
A (
5:1
)
Bla
nk
0
50
100
150
N
or
m
al
iz
ed
 L
uc
ife
ra
se
 A
cti
vi
ty
Lip
ofe
ct 
(50
ng
)
Lip
ofe
ct 
(10
0n
g) 
Lip
ofe
ct 
(20
0n
g)
Lip
ofe
ct 
(du
mm
y s
iRN
A)
siR
NA
 no
 ca
rri
er
Tf-
siR
NA
 (2
00
ng
)
Tf-
Me
l: T
f-s
iRN
A (
1:1
)
Tf-
Me
l: T
f-s
iRN
A (
5:1
)
Tf-
Me
l: s
iRN
A (
5:1
)
Bla
nk
0
50
100
150
Tf
S S
Tf
S S
Tf-siRNA
Tf-Mel
A B
C D
 117 
Melittin conjugate at any condition. This was either an indication that the Melittin is 
not effective in this format, or perhaps the uptake levels or endocytic pathway of these 
conjugates were not sufficient. Thus, we moved forward with the antibody-based 
bioconjugates. 
 
Antibody Conjugate Delivery with Chloroquine: After successfully generating 
antibody-siRNA conjugates on antibodies targeting TfR, CD63, Her2, and Tubulin 
(negative control), we screened their efficiency when delivered with a known 
lysosomotropic agent, chloroquine (CQ) (Figure 5.5 and 5.6). CQ is thought to induce 
endosomal escape by the “proton-sponge effect” in which the tertiary amine in the 
structure absorbs protons as the endosome acidifies, inducing an influx of protons and 
a disruption of osmotic pressure of the endosome and leakage in the membrane. We 
dosed all the Ab-siRNA conjugates at 100nM with 100 or 150µM of CQ. In all 
antibodies, there was no detectable knockdown observed with or without CQ. 
Interestingly though, we did discover in this study that knockdown could be observed 
when the Ab-siRNA was complexed with Lipofectamine. This was observed with and 
without a cleavable linker for the siRNA (data not shown), indicating that the 
lipofectamine works independently of what the siRNA is attached to, and the siRNA 
can still be effectively loaded into RISC. 
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Figure 5.5 Antibody-siRNA Conjugate Delivery with Chloroquine Treatment – 
Antibody conjugates targeting TfR, CD63, and Tubulin Control (dosed at 100nM Ab 
and ~100-200nM siRNA) for knockdown in SKOV3-Luc2 cells. Chloroquine was 
added at 100µM as a small molecule endosomal escape agent. Black bars are controls, 
blue bars are TfRAb treated, green bars are CD63Ab treated, and gray bars are 
Tubulin Ab treated. Conjugates were either treated alone, encapsulated in 
lipofectamine, or co-treated with 100µM CQ. (a) Schematic of antibodies with color 
designation (left) and chemical structure of chloroquine (CQ) endosomal escape agent. 
(b) Cell viability of treated cells (c) Luciferase expression of treated cells (d) 
Luciferase Expression normalized to cell viability. 
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Figure 5.6 Her2Ab-siRNA Conjugate Delivery with Chloroquine Treatment – 
Antibody conjugates dosed at 100nM antibody (100-200nM siRNA) targeting the 
Her2 receptor on SKOV3-Luc2 cells, co-treated with small molecule endosomal 
escape agent, chloroquine (CQ), at 150µM. Chloroquine showed some toxicity but no 
detectable increase in knockdown relative to the controls. (a) Schematic of antibodies 
with color designation (left) and chemical structure of chloroquine (CQ) endosomal 
escape agent. (b) Cell viability of treated cells (c) Luciferase expression of treated 
cells (d) Luciferase Expression normalized to cell viability. 
 
Antibody-LLO Conjugate Delivery: We attempted the co-delivery strategy again 
with a more potent endosomal escape agent, Listeriolysin O (LLO). As discussed in 
chapter 4, we discovered that the WT toxin was alone very toxic to mammalian cells, 
and had to mutate the 4th domain to be able to dose at the proper concentrations. We 
conjugated this mutant to the CD63Ab for co-delivery with the CD63Ab-siRNA 
conjugate. In this study, we looked at the effect of simultaneous addition (Figure 5.7A 
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and B) and sequential addition of conjugate (Figure 5.7C and D), as there was a 
concern that because the conjugates target the same receptor, they could be out-
competing each other for uptake. We also looked at varying dosing ratios and total 
concentrations. In all cases, though we did not observe any apparent toxicity, there 
was no observed knockdown either. As we learned in chapter 4, this could be due to 
the membrane binding of the LLOmut being greater than that of the antibody. With 
that information, we decided to tag the LLOmut directly with siRNA and deliver it to 
cells. 
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Figure 5.7 CD63Ab-siRNA and LLOmut Conjugate Co-Delivery: Simultaneous 
and Sequential Addition – Antibody conjugates targeting the CD63 receptor carrying 
siRNA and mutant LLO (non-PEGylated) delivered either simultaneously (top) or 
sequentially (bottom). (a) Schematic of simultaneous delivery of CD63Ab-siRNA and 
CD63Ab-LLOmut conjugates with varying concentration ratios. Cells were treated for 
6 hours with conjugates, washed, then analyzed for luciferase activity. (b) (left to 
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right) Cell viability of treated cells, luciferase expression of treated cells, luciferase 
Expression normalized to cell viability. Black bars are controls and green are treated 
samples. (c) Schematic of sequential delivery of CD63Ab-siRNA conjugate for 1.5 
hours, followed by CD63Ab-LLOmut conjugates with varying concentration ratios. 
Cells were treated for another 6 hours with conjugates, washed, then analyzed for 
luciferase activity. (d) (left to right) Cell viability of treated cells, luciferase expression 
of treated cells, luciferase Expression normalized to cell viability. Black bars are 
controls and green are treated samples. 
 
LLO Conjugate Delivery: After conjugating the targeting siRNA with mutant LLO 
on its 4th domain cysteine, we examined knockdown via direct translocation of the 
LLOmut across the membrane (Figure 5.8). Again, there was no observed toxicity of 
the conjugate to mammalian cells, but there was no observed knockdown either. With 
this data, we concluded that the LLOmut either is not potent enough to translocate the 
membrane with siRNA or remains stuck to the surface of the cell and does not actually 
get internalized. With this, we postulated that there were several factors beyond those 
considered that could be impacting the delivery. Therefore, we moved forward with 
dosing a single conjugate complexed with an endosomal membrane disruptor. 
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Figure 5.8 Conjugated LLOmut-siRNA Delivery – LLOmut conjugated directly 
with siRNA via 4th domain cysteine for non-targeted delivery to cells. Black bars are 
controls and yellow bars are treated samples (a) Schematic of LLOmut control and 
conjugated LLOmut-siRNA. (b) Cell viability of treated cells (c) Luciferase 
expression of treated cells (d) Luciferase Expression normalized to cell viability. 
 
Ab-R9K Conjugate Delivery: Previous studies in siRNA conjugates have shown 
efficacy with antibodies complexed with siRNA via nucleic acid-binding proteins and 
peptides like polyamines and polyarginines. In this case, we looked at Her2Ab 
conjugates complexing siRNA with R9K, a known cell-penetrating peptide (CPP). We 
looked at these conjugates in two ways, by either conjugating siRNA directly to the 
antibody and complexing R9K, or directly conjugating R9K or complexing siRNA 
(Figure 5.9). Again, we examined multiple ratios and looked at their knockdown 
efficiency. Similar to other assays, there was no observed knockdown for any case. 
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This assay showed an abnormally high luciferase signal, indicating that the R9K could 
also be interfering with the assay kit. Future studies could parse out why the luciferase 
signal was high and analyze greater ratios of R9K and siRNA to see charge effects on 
the delivery efficiency. 
 
 
Figure 5.9 Her2Ab-R9K-siRNA Non-covalent conjugate delivery – Her2Ab 
conjugates covalently conjugated with R9K or siRNA, and complexed with siRNA or 
R9K, respectively. Dark pink bars show antibody conjugates, light pink bars show 
R9K-siRNA complexes, and black bars are controls. (a) Schematic of Ab conjugates 
and siRNA-R9K complexes (b) Cell viability of treated cells (c) Luciferase expression 
of treated cells (d) Luciferase Expression normalized to cell viability. 
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Discussion 
In this chapter, we examined varying endocytic pathways, endosomal escape agents, 
and conjugation methods to co-deliver and study each components effect on 
knockdown efficiency. Unfortunately, we were not able to observe knockdown with 
any of the agents tried, but it did give us some insight into effective strategies for 
future studies.  
 
We determined early on that potency of endosomal escape agents was not the most 
important factor in effectively delivering siRNA. When siRNA was directly 
complexed with Melittin, which has HC50 values in the low µM range, efficient 
knockdown was observed with only 50-100nM siRNA. However, with the LLOmut, 
with HC50 values in the high nanomolar range, was conjugated with siRNA, no 
knockdown was observed. This could be due to the membrane interaction of each 
membrane disruption agent, as the Melittin polyplex has a strong cationic charge and 
is likely taken up by macropinocytosis followed by endosomal escape, whereas the 
LLOmut conjugate binds cholesterol on the cell surface and forms a membrane bound 
pore. Additionally, more potent agents like LLO run into issues with outer membrane 
disruption because the agent is more potent than the dosing concentration of the 
antibody conjugate. More effective strategies for reversibly blocking the membrane 
interactions of the pore-forming toxins for those to be effectively incorporated into 
antibody conjugates. 
 
I believe there is promise in the final complexation method that used the cationic R9K 
peptide with siRNA on an antibody conjugate. Putting both components on a single 
conjugate ensures that they are in the same intracellular compartment, and the ratio 
can be controlled with the complexation ratios. In future studies, this strategy could be 
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used with other cationic peptides and polymers with varying net charge to look at their 
endosomal escape efficacies. These conjugates could then be generated against 
different antibodies to look at their efficacy across different endocytic pathways. 
Later, dual-labeled conjugates with non-complexed endosomal escape agents could be 
developed using dual-labeling strategies to be discussed in chapter 6. 
 
Materials & Methods 
Homotypic Fusion Confocal Microscopy: To observe intracellular co-localization of 
co-delivered conjugates, SKOV3 cells were plated to ~75% confluency on MatTek 
35mm glass-bottom dishes 24 hours prior to incubation. The cells were incubated with 
green-fluorescent TfRAb-dsDNA-AF488 and red-fluorescent TfRAb-AF647 
conjugates at 50nM for 1 hour at 37°C in 5% CO2. Following incubation, cells were 
washed with PBS, fixed with 4% paraformaldehyde, stained with Hoechst nuclear 
stain, and stored in PBS at 4°C prior to imaging. Dishes were imaged on a Zeiss 
LSM880 inverted confocal microscope with 405nm, 488nm, and 633nm lasers. Gain 
was determined based on an untreated cell control. Degree of co-localization was 
determined from the Coloc-2 plug-in in Fiji of red and green channels.  
 
Knockdown Assay conditions: All knockdown assays used the following conditions 
unless stated otherwise. 15K SKOV3-Luc2 cells were plated in white Nunclon Delta 
coated flat bottom 96-well plates (ThermoFisher) 24 hours prior to the assay. Cells 
were treated with lipofectamine controls at a ratio of 75µL Lipofectamine per nmole 
of target siRNA (Sense strand: rGrGrA mCrGrA rGrGrA mCrGrA rGmCrA 
mCmUmU rCT*T; Antisense strand: rGrArA rGrUrG rCrUrC rGrUrC rCrUrC 
rGrUrC rCT*T) or dummy siRNA (Sense strand: rArArC rGrCrU rGrGrG rCrGrU 
rUrArA rUrCrA rAdTdT; Antisense strand: rUrUrG rArUrU rArArC rGrCrC rCrArG 
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rCrGrU rUdTdT) complexed at a 1:1 molar ratio. After 48 hours, cells were washed 
with PBS and replaced with 100µL fresh media (DMEM; high glucose, L-glutamine, 
No Phenol red, 10% FBS) and analyzed with the Promega ONE-GLO/Tox Luciferase 
Assay Kit. Fluorescence (cell viability) and luminescence (luciferase activity) signals 
were normalized to untreated controls. “Normalized Luciferase Activity” signals were 
luminescence signal normalized by cell count (i.e. fluorescence signal), then 
normalized to an untreated control.  
Melittin-siRNA Complexation: For Melittin-siRNA complex delivery, 500nM or 1µM 
of double-stranded siRNA was complexed with 5µM or 20µM Melittin-SH in OPTI-
MEM for 20 mins at RT. The solution was then diluted 1:10 into 100µL of DMEM + 
10% FBS on SKOV3-Luc2 cells and incubated for 1 hour at 37°C. Cells were then 
washed with PBS and replaced with fresh DMEM for the remaining 47 hours. 
Transferrin-Melittin Conjugates: For Transferrin (Tf) conjugate co-delivery, 200ng of 
double-stranded siRNA either conjugated to iron-loaded Tf or free in solution was 
incubated with 0, 1, or 5 molar equivalencies of Tf-Melittin conjugate in 100µL. The 
sample were incubated for 48 hours, replaced with fresh DMEM, and analyzed via 
Luc/Tox Luciferase Assay. 
Antibody Conjugates + Chloroquine: For co-delivery of CatB cleavable Ab-siRNA 
conjugates with the lysosomotropic agent, Chloroquine (CQ), 100nM of conjugate 
was incubated with either 100µM CQ (TfRAb, CD63Ab, and TubAb), or 150µM 
(Her2Ab) for 24 hours at 37°C. The samples were then replaced with fresh DMEM 
and incubated for the remaining 24 hours at 37°C before analyzing via Luc/Tox 
Luciferase Assay. 
CD63Ab-siRNA and CD63Ab-LLOmut Conjugate Dual Delivery: For co-delivery of 
CD63Ab-siRNA (CatB-cleavable) and CD63Ab-LLOmut (reducible) conjugates to 
HeLa-Luc2 cells, experimental conditions were examined with simultaneous or 
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sequential addition of the two conjugates. For simultaneous addition, either 10nM or 
25nM of CD63Ab-siRNA and 10nM or 25nM of CD63Ab-LLOmut were incubated 
simultaneously for 6 hours at 37°C, washed with PBS, and replaced with fresh media 
and incubated at 37°C for the remaining 18 hours. For the sequential addition, either 
25nM or 50nM of CD63Ab-siRNA was incubated for 1.5 hours at 37°C, followed by 
10nM or 20nM CD63Ab-LLOmut for 6 hours at 37°C. The cells were then washed 
with PBS, replaced with fresh media, and incubated at 37°C for the remaining 16.5 
hours.  
LLOmut-siRNA Conjugates: For delivery of LLOmut-siRNA conjugates with no 
antibody carrier, 50nM of siRNA, LLOmut, or the conjugate were added to HeLa-
Luc2 cells for 16 hours at 37°C, washed with PBS, replaced with fresh media, and 
incubated at 37°C for the remaining 8 hours. 
Her2Ab-R9K Conjugates: For delivery of Her2Ab conjugates with R9K complexation 
with siRNA, antibodies were either conjugated with siRNA and complexed with R9K, 
or vice versa, at ratios of 1:1 or 1:2 at RT for 1 hour prior to assay. Then, 200nM of 
conjugate (based on protein) was incubated on cells at 37°C for 16 hours. Cells were 
washed with PBS, replaced with fresh media, and incubated at 37°C for the remaining 
34 hours. 
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CHAPTER 6 – DUAL-LABELED ANTIBODY DRUG CONJUGATES FOR 
ORTHOGONAL CARGO RELEASE 
Background 
Antibody drug conjugates (ADCs) have emerged as a promising modality for the 
targeted delivery of drugs due to the powerful combination of antibody specificity and 
potency of certain chemotherapeutics and antibiotics. However, ADC aggregation due 
to non-specific conjugation and premature drug release remain key challenges in ADC 
development. Early generation ADCs therapeutic warheads were conjugated non-
specifically to lysine residues on the surface of therapeutically relevant antibodies, 
which led to heterogeneous ADCs with a high propensity for aggregation, low 
tolerability, and ultimately poor efficacy.14 This poor efficacy is further exacerbated 
by drug deconjugation in serum due to non-specific linker degradation.109 To mitigate 
these issues, there has been a push for site-specific conjugation methods9,15,17 that can 
generate homogeneous antibody bioconjugates (ABCs) with improved affinity, target 
receptor internalization, and reduced aggregation.  
Methods for site-specific antibody conjugation9 include maleimide conjugation to 
native cysteines in the hinge region of IgG1’s,198,199 C-terminal selenocysteines,200 N-
terminal serine oxidation and ligation,201 ligation to Fab nucleotide binding sites,202 
glycan remodeling and glycoconjugation,203-209 cystine re-bridging,210-212 and 
engineering additional cysteines14,109-111 or other reactive non-natural amino 
acids18,112,113 into the constant region domains. Since codon optimization for efficient 
incorporation of non-natural amino acids can be difficult, peptide tags using natural 
amino acids have also been incorporated for chemoenzymatic ligation. 
Chemoenzymatic ligation involves the conjugation of a chemical substrate via an 
enzyme to a specific amino acid tag incorporated internally or terminally to the 
protein. Site-specific enzymatic conjugation strategies include microbial 
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transglutaminase (mTG),13,14,23,115,116 butelase 1,213 sortase A,213,214 and formylglycine-
generated enzyme (FGE).25 New methods for site-specific conjugation to antibodies 
remain an active area of research. 
 
Figure 6.1 Schematic for Dual-Labeled Antibody Conjugates and Orthogonal 
Cleavage - The one-pot reaction of a dual site-specific assembly of an antibody 
bioconjugate possessing two cargo units that can be orthogonally released in response 
to specific enzyme triggers 
In light of multi-drug resistant (MDR) cancers and antibacterial drug resistance, 
combination therapies have also become increasingly necessary to improve therapeutic 
outcomes215. Several groups have created dual-labeled216 ADCs via multifunctional 
linkers or multiple conjugation sites for this purpose. For example, Seattle Genetics 
developed dual-labeled ADC’s with two complementary tubulin inhibitors, MMAE 
and MMAF,217 and showed significantly increased efficacy in a Hodgkin’s lymphoma 
model.  The single glycan in the heavy chain of antibodies has also been utilized for 
dual radiolabeling of antibodies26 as well as incorporation of a radio-label and 
chemotherapeutic drug.218 Additionally, other methods have utilized orthogonal 
enzymatic tags at multiple sites along the antibody, such as with multiple mTG-active 
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sites,219 butelase A and sortase A,213 and CLIP and SNAP tags.220 We221 and 
others222,223 have incorporated multifunctional crosslinkers at a single site on proteins 
for examining intracellular conjugate processing. However, none of the conjugates in 
these examples incorporate orthogonal enzyme-triggered temporal control, in which 
one cargo needs to be released first to achieve a cooperative effect with the second.215 
By integrating orthogonal cleavage sites into site-specific dual-labeled antibodies, we 
can generate ABCs that can achieve programmable sequential controlled release. 
In this work, we report the first example of a site-specific Lipoate-acid ligase A 
(LplA)-mediated ligation to an antibody via incorporation of a LplA acceptor peptide 
(LAP)-tag (GFEIDKVWYDLDA) into the heavy and light chain of a humanized 
antiHer2 antibody, Trastuzumab. Furthermore, we demonstrate temporal control by 
designing site-specific dual-labeled antibody conjugates with controlled release 
properties via two orthogonal enzymatic cues (Figure 6.1). To do this, we utilized the 
mTG enzyme, along with LplA in a one-pot reaction to demonstrate attachment and 
release of two cargos at to two different sites on Trastuzumab via orthogonally 
cleavable bonds. This is shown with two fluorescent linkers, one cleavable by an 
extracellular protease, Matrix Metalloproteinase-2 (MMP-2), and the other cleavable 
by an intracellular protease, Cathepsin B (CatB). Following treatment with MMP-2 
and CatB, we demonstrated orthogonal cargo release with either MMP-2 or CatB 
(Figure 6.1). This dual-labeled antibody platform will allow for sequential drug release 
from a single conjugate for cooperative drug combinations. 
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Results 
 
 
Figure 6.2 LAP-Tag incorporation into pVitro vector for simultaneous 
transfection and expression of light chain (LC) and heavy chain (HC) tagged 
Trastuzumab (A) Schematic representation of incorporation of LAP tag into pVitro 
dual-cassette vector. (B) MALDI-TOF MS of native (black), light-chain LAP-tagged 
(top, green) and heavy-chain (bottom, green) LAP-tagged antibody fragments (C) 
SDS-PAGE of (top) full-length and (bottom) reduced antibodies. 
 
The LAP-tag (GFEIDKVWYDLDA)114 along with a GGGS flexible spacer at the N-
terminal was cloned into the heavy chain (HC) and light chain (LC) C-termini of 
Trastuzumab. The pVitro dual-cassette expression vector system was used to transfect 
and express the heavy and light chains in a single vector (Figure 1A). The C-termini of 
each constant region chain was chosen for ease of swapping variable regions to 
generate LAP-tagged antibody conjugates against a new antigen, and for minimal 
inhibition of protein folding and antigen binding. Addition of the LAP-tag was 
verified with Sanger sequencing and MALDI-TOF mass spectrometry (Figure 6.2B). 
The MALDI of the reduced antibody conjugates shows the expected ~1.8 kDa mass 
shift for the addition of the 17-mer peptide (4-mer linker + 13-mer LAP-tag) as 
expected in both the light and heavy chains (Figure 6.2B). The extent of assembly and 
protein yield (~1-2 mg/L) of the LAP-tagged antibodies is comparable to that of the 
native antibody when expressed in the same cells (Figure 6.2C). 
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Figure 6.3 Efficient conjugation of antibodies with pAz and TCO substrates and 
Click-able PEGs (PEG-Tz and PEG-DBCO) via LplA - (A) Schematic 
representation of LplA two-step conjugation via TCO- and pAz-LAP tag substrates. 
(B) and (C) HIC traces of light and heavy chain modified antibodies functionalized 
with TCO and pAz-substrates via LplA. Hydrophobic shifts are indicative of 
functionalization (D) SDS-PAGE showing site-specific PEGylation of antibodies at 
light-chain (left) or heavy-chain (right) C-terminal. 
 
To verify specificity, substrate scope and extent of reaction, LAP-tag modified 
antibodies were conjugated to picolyl-azide (pAz) and trans-cyclooctene (TCO) 
substrates via the LplA enzyme (Figure 6.2A). All conjugations were performed with 
20 µM antibody, 10-fold excess substrate and 10 mol% LplA at 37°C for 90 minutes. 
Extent of conjugation was determined via hydrophobic interaction chromatography 
(HIC) (Figure 6.3B and C). Both pAz and TCO additions resulted in an increase in 
retention on the column relative to the LAP-tag modified antibody, an indication of 
greater hydrophobicity. The TCO modification resulted in a more hydrophobic 
bioconjugate relative to the pAz modified antibody. By measuring the area under the 
curve (AUC), conjugation efficiencies for the LC additions were calculated to be 86% 
for the pAz and 88% for TCO. Conjugation efficiencies for the HC additions were 82 
% for the pAz substrate and 69 % for the TCO substrate. To verify that these 
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functional groups were accessible for conjugation after addition to the antibody, pAz 
and TCO functionalized antibodies were reacted with the corresponding large (5,000 
MW) PEG-dibenzyl cyclooctyne (DBCO) or PEG-tetrazine to observe a gel shift via 
SDS-page (Figure 6.3D). Extent of reactions were calculated to be about 96% for the 
pAz substrate and 85% for the TCO substrate on the light chain LAP antibody, and 
58% and 47% for the pAz and TCO substrates, respectively, on the HC LAP antibody. 
Successful conjugation indicates that the functional groups were accessible after 
attachment to the antibody. In general, we see that conjugation to the LC is more 
efficient than conjugation to the HC.  
 
 
Figure 6.4 Dual-Labeled Antibodies via mTG and LplA – (A) Structures of 
fluorescein and rhodamine linkers with enzymatically labile sites or stable PEG 
controls. RP-HPLC traces of (B) purified fluorescein and (C) rhodamine linkers. (D) 
Schematic of a one-pot sequential labeling via LplA and mTG with TCO and pAz 
substrates, respectively, and subsequent modification with methyltetrazine and 
DBCO-functionalized fluorescent linkers. (E) Reduced SDS-PAGE of fluorescently-
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labeled antibodies with fluorescein channel (green), rhodamine channel (red), and 
Coomassie channel (grey). 
 
To demonstrate orthogonal labeling and sequential and orthogonal release from the 
ABCs, we synthesized fluorescein and rhodamine linkers, with and without cleavable 
sites, for facile detection of orthogonal cleavage from the ABCs. The valine-citrulline 
(VCit) peptide linkage has been verified previously to be cleaved by the intracellular 
enzyme, cathepsin B224 and has been widely utilized in antibody drug conjugates. The 
PVGLIG peptide linkage was discovered via a large-scale screen of MMP’s by Turk 
and colleagues225 and used in a methotrexate-dextran conjugate by Chau, Tan and 
Langer226 for enzyme-mediated drug release. This particular sequence was also chosen 
because none of the side-chains had reactive functional groups. Rhodamine linkers 
were functionalized with a DBCO group for strain-promoted copper-free “click” 
reaction with azide groups, and fluorescein linkers were functionalized with a 
methyltetrazine group for inverse electron demand Diels-Alder (IEDDA) reaction with 
TCO groups (Figure 6.4A). Detailed synthesis and characterization of the fluorescent 
linkers can be found in the Appendix (A.33-A.41). Linkers with peptide sequences 
(i.e. cleavable linkers) were slightly more hydrophobic than the non-cleavable linkers 
as determined via reverse-phase analytical HPLC (Figure 6.4B and C).  
To demonstrate the compatibility of the LAP-tag with other site-specific 
modifications, as well as demonstrate sequential and orthogonal drug release, we 
adopted the mTG chemoenzymatic ligation as an additional, site-specific, conjugation 
method that does not require genetically encoding another conjugation site. Following 
deglycosylation of Trastuzumab with PNGase F to expose glutamine 295 (Q295) on 
the HC, conjugation via mTG leads to the generation of a thioester at Q295 that 
subsequently reacts with the primary amine substrate. This method of conjugation is 
orthogonal to LplA coupling of the lysine residue in the LAP-tag with valeric acid 
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substrates. Thus, we hypothesized that both enzymatic couplings could be performed 
in a one-pot reaction via sequential addition of the enzymes with a single purification 
step of both substrates and enzymes (Figure 6.4D). Fluorescent linkers synthesized 
with and without cleavable bonds in Figure 6.4A were used to verify reaction 
orthogonality (Figure 6.4D). Using both the cleavable and non-cleavable linkers, 
modified Trastuzumab was simultaneously labeled on the LAP-tag site, as well as the 
Q295 residue in Fc region and analyzed via fluorescent SDS-PAGE (Figure 6.4E). In 
the LC LAP-tagged Trastuzumab antibodies (Figure 6.4D, [5] and [6]), the LC shows 
green fluorescein fluorescence, and the HC shows red rhodamine fluorescence. There 
was no observed cross reactivity between the sites (Figure 6.4E). Additionally, in the 
HC LAP-tagged antibodies (Figure 6.4D, [7] and [8]), the HC showed both green and 
red fluorescence, indicating the two sites on the HC could be labeled simultaneously.  
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Figure 6.5 Enzymatic Cleavage of Linkers via CatB and MMP-2 – (A) Reduced 
SDS-PAGE of LC (top) and HC (bottom) dual-labeled antibodies treated with CatB 
and MMP-2. Fluorescein channel (green), rhodamine channel (red), and Coomassie 
channel (grey). Fluorescein cleavage by CatB generates a large green spot near the HC 
band. Rhodamine cleavage by MMP-2 leads to disappearance of the red band on the 
HC. (B) Green fluorescence de-quenching of cleavable conjugates relative to stable 
controls in the presence of CatB (C) Green fluorescence de-quenching of cleavable 
conjugates relative to stable controls in the presence of MMP-2. 
To observe cleavage of the fluorescent linkers with the corresponding enzyme, 
antibodies were incubated with Cathepsin B (CatB, Sigma) and Matrix 
Metalloproteinase-2 (MMP-2, R&D Systems) and analyzed via fluorescent SDS-
PAGE. In the presence of MMP-2, the red band is cleaved from the antibody with no 
apparent change in green fluorescence. Similarly, in the presence of CatB, the green 
band is partially cleaved from the antibody, generating free fluorescein that runs near 
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the heavy chain band (proof that free fluorescein runs at this position upon cleavage 
can be seen in the control in Appendix A.42) on SDS-PAGE (Figure 6.5A). No cross-
cleavage was observed with either MMP-2 or CatB. As the fluorescein and rhodamine 
fluorophores undergo resonance energy transfer, the fluorescein is partially quenched 
when attached to the antibody and in proximity of rhodamine. Upon the addition of 
CatB, the fluorescein is cleaved from the molecule and is de-quenched. Similarly, 
upon the addition of MMP-2, the rhodamine is cleaved from the molecule, and the 
fluorescein is also de-quenched. Relative to the non-cleavable control, both the light 
chain and heavy chain LAP-tagged antibodies showed dequenching of green 
fluorescence upon addition of enzyme. With the addition of CatB, the antibodies 
showed ~ 2-fold increase in green fluorescence on the LC and HC tagged antibodies, 
respectively (Figure 6.5B). With the addition of MMP-2, the antibodies showed ~ 4-
fold increase in green fluorescence on both the LC and HC tagged antibodies 
respectively (Figure 6.5C). These results thus demonstrate temporal control of cargo 
release via two orthogonal enzymatic cues on site-specific dual-labeled antibody 
conjugates. 
 
Conclusions & Discussion 
In this study, we generated site-specifically dual-labeled Trastuzumab bioconjugates, 
at two different sites via a one-pot reaction with orthogonally releasing linkers. The 
expression system developed in this work was used to generate Trastuzumab 
antibodies for dual chemoenzymatic ligation with LplA and mTG enzymes. Here, the 
LAP-tag was placed at the heavy and light chain C-termini; however, the LAP-tag 
could be moved to other locations on the antibody or at multiple sites for higher drug-
antibody ratios. The fast kinetics of the LplA substrate addition to the antibody makes 
for rapid generation (~1-2 hours) of conjugates using click chemistry or fluorescent 
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substrates.22,118,119,122 Additionally, the variable region swap method developed by 
Dodev and colleagues98 allows for the straight-forward generation of antibodies 
against new antigens as shown in this work for Her2 and recently against polysialic 
acid124. This method, which involves simple transfection and generation of stable 
antibody-expressing 293F cells without viral components, allows the facile expression 
of antibodies for bioconjugation. The one-pot reaction demonstrated here utilizes two 
orthogonal chemistries with two orthogonal substrates. In this study, we used the TCO 
substrate with LplA, and an azido amine substrate with mTG. However, the Ting lab 
has generated several various substrates compatible with LplA variants22,118,119,122, and 
mTG has been shown to be promiscuous to many amine-containing substrates116. Both 
enzymes are accessible to labs as the plasmid for LplAW37V is available on Addgene 
with protocol227 for expression and purification, and mTG is cheap and accessible in 
meat glue formulations (Moo Glue, Modern Pantry). Quantitative labeling, though not 
achieved here, could be obtained through further optimization of reaction conditions 
with a different pair of substrates. 
The orthogonal cleavage sites used in this study involve an extracellular protease, 
MMP-2, and an intracellular protease, CatB, which could be implicated in sequential 
drug release applications. With both extracellular and intracellular release triggers, it is 
possible to deliver drugs that need sequential release, such as the release of an efflux 
pump inhibitor followed by a hydrophobic chemotherapeutic drug, as could be 
necessary in multi-drug resistant (MDR) cancers228. This dual-labeling of a single 
antibody can also be utilized in imaging applications to examine uptake, trafficking, 
and intracellular cleavage of antibody conjugates221,222. The CatB-cleavable linker has 
been used in a large number of ADCs and has been shown to work with a variety of 
dipeptide cleavage sites, the most prominent being valine-citrulline used in this work. 
 140 
The MMP-2 linker has not yet been utilized in an ADC but has been used in other 
polymer-drug conjugates for MMP2-triggered drug release. To the best of our 
knowledge, this work represents the first demonstration of antibody bioconjugates 
with two, orthogonal enzymatically cleavage sites at two different, site-specific, 
locations. By demonstrating orthogonal cleavage with extracellular and intracellular 
enzymes, this work holds great promise for the design of ADCs with sequential 
release properties and could be beneficial for disease applications that require 
cooperative drug combinations. 
 
Materials & Methods 
Materials. All chemicals and solvents were purchased from Millipore-Sigma and 
VWR unless stated otherwise. Chemical crosslinkers were purchased from 
BroadPharm (Az-PEG3-NH2, Cat#BP20580; TCO-NHS ester, BP-22417; NHS-
PEG4-TCO, Cat# BP-22418; MeTzine-PEG5-NHS, BP-22945; DBCO-PEG4-NHS, 
BP-22288). Purified Cathepsin B enzyme was purchased from Millipore Sigma (Cat# 
C0150-2UN) and recombinant Matrix Metalloproteinase-2 was purchased from R&D 
Systems (Cat# 902-MP). Peptides were purchased from Genscript. DNA Primers were 
purchased from Integrated DNA Technologies (IDT). Materials for PCR and cloning 
were purchased from New England BioLabs. Gel electrophoresis materials were 
purchased from Bio-Rad. Plasmid for Trastuzumab antibody generation was 
purchased from Addgene (Plasmid# 61883). All sequencing was done by the Cornell 
Genomics Facility using the Applied Biosystems Automated 3730xl DNA Analyzer 
using Big Dye Terminator chemistry and ApliTaq-FS DNA Polymerase.  
 
Cloning of LAP-tagged Antibodies. The “LAP Tag” and spacer (GGGS-
GFEIDKVWYDLDA) was incorporated into the heavy and light chain C-terminal of 
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the pVITRO-ch735-IgG1 vector 124 using 4 sequential PCR steps. The tag was added 
through the reverse primer, adding ~17-20 bases at a time. The following primers were 
used: 
 
Heavy Chain LAP Tag: 
FWD (ch735): ccgccacaggcgcgcactcccagattcagctgcagcaatc 
REV1: aagccagatcctccgccTTTACCCGGAGACAGGGAGAGGC 
REV2: accacaccttgtcgatctcgaagccagatcctccgccTTT 
REV3: ACATCAggcgtccaggtcgtaccacaccttgtcgatctcg 
REV4: ATGTCTGGCCAGCTAGCTGTACATCAggcgtccaggtcgt 
 
Light Chain LAP Tag: 
FWD (ch735): gggttccagctagccgcggtgatgtagtcatgacgcagac 
REV1: aagccagatcctccgccACACTCTCCCCTGTTGAAGCTCT 
REV2: accacaccttgtcgatctcgaagccagatcctccgccACA 
REV3: TCCCTAggcgtccaggtcgtaccacaccttgtcgatctcg 
REV4: CTGCTCCTAGGCGTACGGGATCCCTAggcgtccaggtcgt 
 
PCR amplification was done with the Flash-Phusion enzyme master mix with an 
initial denaturation step for 30 sec at 98°C, followed by 30 cycles with denaturation 
for 10 sec at 98°C, and extension for 15 sec/kb at 72°C. The product was gel purified, 
and reamplified with 10ng of template for the 4 sequential amplifications. 
 
To assemble the final vector, the following primers were used: 
FWDvector: TCCCGTACGCCTAGGAGCAGGTTTCCCCAATGACACAAAA 
REVvector: accgcggctagctggaacccagagcagcagaaacccaatg 
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FWDch735VL: gggttccagctagccgcggtgatgtagtcatgacgcagac 
REV4VL: CTGCTCCTAGGCGTACGGGATCCCTAggcgtccaggtcgt 
 
PCR amplification was done with the Flash-Phusion enzyme master mix with an 
initial denaturation step for 30 sec at 98°C, followed by 5 cycles with denaturation for 
10 sec at 98°C, annealing for 15 sec starting at 55°C and decreasing 1°C per cycle, and 
extension time at 90% of the recommended 15 sec/kb which was 107 sec for the 
vector piece (FWDvector and REVvector) and 10 seconds for the light chain piece 
(FWDch735VL and REV4VL) at 72°C. The product was gel purified, and reamplified 
with 10ng of template for the 4 sequential amplifications. Following the touchdown 
protocol, 30 cycles of PCR were performed with denaturation for 1 sec at 98°C, 
annealing for 5 sec at 55°C and extension for 107 sec or 10 sec at 72°C respectively. 
Resulting PCR products were DpnI digested for 1 hour at 37°C. Then the digests were 
combined 1:1 to a total volume of 100 uL and incubated at RT for 1 hour. The 
reactions were cleaned up with the Qiagen PCR clean up protocol and eluted in 30 uL 
of water. The volume was brought to 100 uL with water and 2 uL of this reaction was 
used to transform NEB 10-beta chemically competent cells according to the 
manufacturer’s protocol. After recovery, the cells were plated onto 300 µg/mL HyroB 
LB plates. Colonies were picked and grown in LB + 300µg/mL HygroB, mini-
prepped, and verified with sanger sequencing. 
 
To swap the variable regions from ch735 to Trastuzumab, the following primers were 
used: 
TrasVHFwd: ccgccacaggcgcgcactccGAGGTGCAGCTGGTGGAGTC 
TrasVHRev: GATGGGCCCTTGGTGCTAGCTGAGGAGACGGTGACAAGAG 
TrasVLFwd: gggttccagctagccgcggtGACATCCAGATGACCCAGTC 
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TrasVLRev: GATGGCGCCGCCACCGTACgtttgatCTCCAGCTTGGTAC 
CHFwd: GCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCT 
CHRev: accgcggctagctggaacccagagcagcagaaacccaatg 
CLFwd: cgtacggtggcggcgccatctgtcttcatcttcccgccat 
CLRev: ggagtgcgcgcctgtggcggccgccaccaagaagaggatc 
 
Variable region pieces were amplified from pVitro1-Trastuzumab-IgG1 (Plasmid# 
61883), and constant region pieces were amplified from the LAP-tag incorporated 
ch735 vector. PCR amplification was done with the Flash-Phusion enzyme master mix 
with an initial denaturation step for 30 sec 98°C, followed by 30 cycles with 
denaturation for 10 sec at 98°C, annealing for 15 sec at 60°C, and extension for 6 and 
60 sec at 72°C for variable and constant region pieces, respectively. Resulting PCR 
products were DpnI digested for 2 hours, cleaned-up, and quantified via 260/280nm 
absorbance on a Tecan Nanoquant Plate. The purified pieces were mixed at a 1:1:1:1 
molar ratio, ligated via Gibson, and transformed into NEB 10-beta chemically 
competent cells and plated onto 300µg/mL HygroB LB plates. Colonies were picked 
and grown in LB + 300µg/mL HygroB, mini-prepped, and verified with sanger 
sequencing.  
Recovered pVITRO-Trastuzumab-IgG1-LAP vectors were re-transformed, midi-
prepped, and transfected into HEK 293F suspension cells using Freestyle MAX 
reagent and selected with 50µg/mL HygroB for two weeks to generate a stable line. 
Stably expressing 293F cells were cultured in LAP-tagged antibody was purified from 
the 293F media using gravity column purification using protein A/G resin 
(ThermoFisher). The recovered antibody was buffer exchanged into PBS using 
Amicon 30kDa MWCO centrifugal columns and quantified via 280nm absorbance 
using a quartz NanoQuant plate (ext. coeff280nm = 210,000 M-1 cm-1).  
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Sanger sequencing of constant heavy and light chain domains with LAP tag 
sequences. 
BLACK & UPPERCASE – constant region DNA sequence 
red & lowercase – LAP tag DNA sequence 
 
CH Region: 
GCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC
ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCA
CACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGT
GGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGT
GAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAA
TCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTG
GGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA
AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATA
ATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGT
GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGT
ACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACC
ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCC
CCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGG
CTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA
GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA
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CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAggcggaggatctggcttcgagatcga
caaggtgtggtacgacctggacgcc 
 
CL Region: 
GTACGGTGGCGGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGT
TGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCA
GAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAAC
TCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCT
CAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCT
ACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGC
TTCAACAGGGGAGAGTGTggcggaggatctggcttcgagatcgacaaggtgtggtacgacctggacgcc 
 
LplA Conjugation. 500µg of antibody was incubated at 20µM with 10mol% LplA, 
200µM pAz or TCO-LAP, 1mM ATP, and 5mM Mg(OAc)2 in PBS for 1.5 hours at 
37°C. The reaction mixture was quenched with EDTA at a final concentration of 
30mM. The extent of reaction was quantified via hydrophobic interaction 
chromatography (HIC) on a Tosoh TSK Phenyl-5PW column on a gradient of 100-
40% high salt buffer (1.5M ammonium sulfate, 25mM phosphate, pH 7.0) in low salt 
buffer (18.75mM sodium phosphate, 25% v/v isopropanol, pH 7.0) over 60 mins.  
For click reactions with corresponding PEG reagents, the quenched reaction was 
washed with PBS three times at 14,000 x g for 8 minutes in 500µL Amicon 30kDa 
MWCO centrifugal columns, recovered via inversion at 1,000 x g for 1 min, and 
quantified via 280nm absorbance using a quartz NanoQuant plate (ext. coeff280nm = 
210,000 M-1 cm-1). Recovered antibodies were incubated with a large excess (25 molar 
equivalencies) of 5,000 MW DBCO-PEG or MeTzine-PEG reagents overnight at 
37°C. Reaction mixtures were then reduced, boiled, and run on a 4-20% Mini-Protean 
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TGX pre-cast protein gels (Bio-Rad) at 120V for 60 mins. Gels were stained with Bio-
Safe® Coomassie, de-stained with water, and analyzed for a gel shift indicating a 
successful click reaction. 
 
One-pot LplA and Transglutaminase Dual Conjugation. 500µg of antibody was 
incubated at 20µM with 10mol% LplA, 200µM pAz or TCO-LAP, 1mM ATP, and 
5mM Mg(OAc)2 in PBS for 1.5 hours at 37°C. After 1.5 hours, 200 wt% Moo Gloo 
(10U/g Ab), 160 molar equivalencies of NH2-PEG3-Az, and 0.6µL of PNGase F was 
added to the mixture for a final concentration of 12.5µM antibody in PBS with for 7 
hours at 37°C. The reaction was washed with PBS three times at 14,000 x g for 8 
minutes in 500µL Amicon 30kDa MWCO centrifugal columns to remove excess 
substrate and recovered via inversion at 1,000 x g for 1 min, then quantified via 
280nm absorbance using a quartz NanoQuant plate (ext. coeff280nm = 210,000 M-1 cm-
1). Recovered antibodies were incubated with 10 molar equivalencies each of 
fluorescein and rhodamine linkers overnight at 37°C. The entire mixture was purified 
on 0.2mL NAbTM Protein A/G spin columns. The reaction mixture was added to the 
spin column and incubated for 10 mins at RT. After 10 mins, the column was 
centrifugated at 5,000 x g for 1 minute. The flow-through was then passed over the 
column two additional times. The mixture was washed 3 times with PBS, then eluted 
two times with 200µL 0.1M glycine (pH 2) into neutralizing 20µL 1M Tris (pH 8) and 
one time with 100µL 0.1M glycine into 10µL 1M Tris. The three eluted fractions were 
pooled and concentrated in 500µL Amicon 30kDa MWCO centrifugal columns with 
one spin at 14,000 x g for 15 mins, then recovered by inversion at 1,000 x g for 1 
minute. The final dual-labeled conjugates were quantified on a quartz NanoQuant 
plate using 280nm, 498nm, and 565nm absorbances for antibody, fluorescein, and 
rhodamine concentrations, respectively (ext. coeff280nm = 210,000 M-1 cm-1; ext. 
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coeff498nm = 30,900  M-1 cm-1; ext. coeff565nm = 36,500 M-1 cm-1). Correction factors 
for fluorescein and rhodamine signals at 280nm were 0.154 and 0.49, respectively. 
 
Antibody Conjugate Cargo Release with Cathepsin B (CatB). Fluorescently labeled 
antibodies were incubated at 5µM with 0.025U of CatB in 10µL of in the 
recommended enzyme buffer (352mM K2PO4, 48mM Na2PO4, 4mM EDTA, 2mM 
Cysteine) for 48 hours at 37°C. Controls were incubated in buffer with an equal 
volume of enzyme storage solution (0.1% Brij 35) instead of enzyme. Samples were 
measured for fluorescence dequenching by measuring green fluorescence signal 
(494/521nm Ex/Em) normalized to red fluorescence (568/583nm Ex/Em), then 
normalized to controls without enzyme. The remainder of sample (5µL) was analyzed 
with fluorescent SDS-PAGE. 
To verify that the large spot on SDS-PAGE is indeed the cleaved fluorophore, the 
cleavable fluorescein linker was incubated at 50µM with 0.2U of CatB or Brij 35 
control in 10µL of the recommended enzyme buffer for 3 hours at 40°C. The linker 
was either run alone or mixed with 5µg of unlabeled antibody to verify that the 
cleaved fluorophore runs just below the heavy chain band (Figure S8).  
 
Antibody Conjugate Cargo Release with MMP-2. MMP-2 enzyme was first activated 
at 0.1mg/mL with 1mM 4-aminophenylmercuric acid (APMA) for 1 hour at 37°C. 
Fluorescently labeled antibodies were incubated at 5µM with 0.01mg/mL enzyme in 
MMP-2 buffer (50mM Tris, 10mM CaCl2, 150mM NaCl, 0.05% Brij 35) for 24 hours 
at 37°C. Samples were measured for fluorescence dequenching by measuring green 
fluorescence signal (494/521nm Ex/Em) normalized to red fluorescence (568/583nm 
Ex/Em), then normalized to controls without enzyme. The remainder of sample (5µL) 
was analyzed with fluorescent SDS-PAGE. 
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Fluorescent SDS-PAGE. Antibodies conjugated with fluorophores were analyzed via 
SDS-PAGE imaged for fluorescein and rhodamine fluorescence and co-stained with 
Coomassie Blue. 2.5µg of antibody was mixed 1:1 with Laemmli buffer with 5% (v/v) 
beta-mercaptoethanol (bME) and heated to 100°C for 10 mins. Samples were run on 
4-20% Mini-Protean TGX pre-cast protein gels (Bio-Rad) at 120V for 60 mins. 
Fluorescent gels were first imaged on a ChemiDoc MP Imaging system (Bio-Rad) for 
fluorescein and rhodamine, then stained with Bio-Safe® Coomassie stain, de-stained 
with water, and imaged. 
 
pAz Synthesis and Purification (Appendix A.29-A.30): The azide-functionalized LAP 
tag substrate (pAz, 7) was synthesized and purified according to Uttamapinant et. 
al.227 Briefly, 10g (51.27 mmol) of dimethyl 2,5-pyridine dicarboxylate (1) and 22.76 
g (205.4 mmol) of anhydrous calcium chloride were solubilized in 300mL of 2:1 
anhydrous THF:MeOH on ice. Then, 3.9 g (103.1 mmol) of NaBH4 was slowly added 
to the reaction mixture and allowed to stir for 2 hours at 0°C. The reaction was 
quenched with 100mL ice-cold water, concentrated via rotary evaporation, extracted 
with chloroform, washed twice with water, and dried. Next, 1.2 g (7.14 mmol) of the 
recovered product, methyl 6-(hydroxymethyl)nicotinate (2), was solubilized in 72mL 
anhydrous DCM. Then, 4 mL (28.5 mmol) triethylamine (TEA) and 2.0 g (10.7 mmol) 
p-toluenesulfonyl chloride was added to the flask and stirred at RT for 3 hours. The 
mixture containing the tosylated product (3) was dried via rotary evaporation, re-
solubilized in 72mL THF with 4.5 g (68.9 mmol) sodium azide, stirred at RT for 24 
hours. The reaction mixture was extracted 3 times with ethyl acetate and water, and 
the organic layer was dried and purified via flash chromatography (Teledyne ISCO) 
on a gradient of 0-50% ethyl acetate in hexanes over 15 mins. Next, 394 mg (2.05 
mmol) of the eluted product, methyl 6-(azidomethyl)nicotinate (4), was solubilized in 
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20.5 mL MeOH with 6.12mL of 1M LiOH and stirred at RT for 25 mins. The mixture 
was quenched with 210µL acetic acid and concentrated via rotary evaporation, then 
purified by flash chromatography on silica with isocratic ethyl acetate with 1% (v/v) 
acetic acid. Then, 300mg (1.68 mmol) of eluted product, 6-azidomethylnicotinic acid 
(5), was solubilized in 5mL anhydrous DMF with 352µL (2.5 mmol) TEA and 647 mg 
(2.5 mmol) N-N’-disuccinimidyl carbonate for 3 hours at RT. The reaction mixture 
was dried and purified via flash chromatography on silica using 1:1 isocratic 
hexanes:ethyl acetate to yield the succinimidyl ester of 6-azidomethyl nicotinic acid 
(6). Next, 100mg (0.36 mmol) of 6, 76 mg (0.65 mmol) of aminovaleric acid, and 
90µL (0.65 mmol) TEA were stirred together for 3 hours at RT in 1mL DMF. The 
final product, 5-(6-(azidomethyl)nicotinamido) pentanoic acid or pAz (7), was purified 
via flash chromatography on silica with isocratic ethyl acetate with 1% acetic acid. 
The final product was verified with H1-NMR and LCMS (Figure S1). 
 
TCO-LAP Synthesis and Purification (Appendix A.31-A.32): The TCO-
functionalized LAP tag substrate (TCO-LAP, 8) synthesis protocol was adapted from 
Liu et. al121. Briefly, 6mg (0.0227 mmol) of TCO-NHS ester was incubated with 
2.8mg (0.0239 mmol) of aminovaleric acid in 2:1 DMSO:PBS overnight at RT. The 
reaction mixture was purified via RP-HPLC on a gradient of 25-60% AcN + 0.1% 
TFA in H2O + 0.1% TFA over 14 mins on a C18 semiprep RP-HPLC column. The 
product (8) eluted at ~11 mins and mass was verified via LC-MS (Figure S2). 
 
Fluorescein Linker Synthesis. To synthesize the fluorescein cleavable and stable 
linkers, first 9.2 mg (19.5 µmol) of Fluorescein-NHS was solubilized in 194µL of 
anhydrous DMSO with 14.4 mg (97.2 µmol) bis-PEG2-NH2 and 5.4µL (38.9 µmol) 
TEA for 3 hours at RT. The resulting Fluorescein-PEG2-NH2 (9) was purified on a 
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C18 RP-HPLC semiprep column on a gradient of 5-65% AcN in H2O with 0.1% TFA 
over 20 mins, dried, and verified with LCMS. The product eluted at ~11 mins. 
For the stable linker (10), 2 mg (3.95 µmol) of Fluorescein-PEG2-NH2 (9) was 
incubated in 181µL anhydrous DMSO with 2.76µL (19.8 µmol) TEA and 2.1 mg 
(3.95 µmol) NHS-PEG4-MeTzine at RT for 3 hours. The final product was purified on 
a C18 RP-HPLC semiprep column on a 5-95% gradient of AcN + 0.1% TFA in H2O + 
0.1% TFA. The product (10) eluted at 16.25 mins and mass was verified via LC-MS 
(Figure S3). 
For the CatB-cleavable linker (13), 5.9 mg (11.63 μmol) of Fluorescein-PEG2-NH2 (9) 
was incubated with 233 μL of anhydrous DMSO with 6.48 μL (46.50 μmol) 
triethylamine and 8.9 mg (11.63 μmol) of Fmoc-Val-Cit-PAB-PNP ester at RT for 1.5 
hours to generate 11. Removal of Fmoc protecting group was performed by the 
addition of 23.90 μL of piperidine. Deprotection via piperidine was carried out at RT 
for 30 minutes. The final product (12) was purified on a C18 RP-HPLC semiprep 
column on a linear gradient of 5-35% AcN in H2O with 0.1% TFA over 40 mins, 
dried, and verified with LCMS. The product eluted at ~31.5 mins. 
Val-Cit-PAB-PEG2-Fluorescein (12) (1.60 mg, 1.76 μmol) was incubated with 70.2 
μL of anhydrous DMSO with 12.23 μL (17.56 μmol) triethylamine and NHS-PEG5-
MeTzine (0.94 mg, 1.76 μmol) at RT for 5 hours. The final product (13) was purified 
on a C18 RP-HPLC semiprep column on a linear gradient of 5-55% AcN in H2O with 
0.1% TFA over 50 mins, dried, and verified with LCMS. The product eluted at ~40.5 
mins. 
 
Rhodamine Linker Synthesis. To synthesize the rhodamine cleavable and stable 
linkers, first 5 mg (8.68 µmol) of Rhodamine sulfonyl chloride was incubated with 
(43.4 µmol) bis-PEG2-NH2 and (43.4 µmol) TEA in 113µL DMF for 16 hours at RT. 
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The resulting Rhodamine-PEG2-NH2 (14) was purified on a C18 RP-HPLC semiprep 
column on a 5-95% gradient of AcN + 0.1% TFA in H2O + 0.1% TFA. The product 
(14) eluted at ~15 mins and the mass was verified via LC-MS. 
For the stable linker (15), 1.5 mg (2.2 µmol) of Rhodamine-PEG2-NH2 (14) was 
incubated in 151µL anhydrous DMSO with 15.2µL (10.9 µmol) TEA and 2.1 mg (3.3 
µmol) NHS-PEG4-DBCO for 3 hours at RT. The final product (15) was purified on a 
C18 RP-HPLC semiprep column on a gradient of 5-65% AcN in H2O with 0.1% TFA 
over 20 mins, dried, and verified with LCMS (Figure S5). The product eluted at ~20.5 
mins and was quantified via absorbance at 565nm (ext. coeff565nm = 36,500 M-1 cm-1). 
For the MMP-2-cleavable linker (19), 0.8 mg (1.03 µmol) of Fmoc-PVGLIG-OH 
(Genscript, 16) was incubated with 2.1 µmol each DIC and N-hydroxysuccinimide in 
28.5µL anhydrous DMF for 1 hour. After 1 hour, 1.29 µmol of rhodamine-PEG2-NH2 
(14) and TEA were added to the mixture to a final volume of 62µL. The mixture was 
incubated overnight at RT to yield 17, then Fmoc-deprotected with 10% (v/v) 
piperidine. The NH2-PVGLIG-Rhodamine (18) product was purified via RP-HPLC on 
a 5-95% gradient of AcN + 0.1% TFA in H2O + 0.1% TFA. The two product isomers 
eluted at 17.2 and 18.1 mins, were quantified via absorbance at 565nm (ext. coeff565nm 
= 36,500 M-1 cm-1) and mass was verified via LC-MS. The eluted product (18) 
(0.4mg; 0.33 µmol) was then solubilized in dry DMSO, and incubated with 0.5 µL 
(3.3 µmol) TEA and 0.49 µmol NHS-PEG4-DBCO in 114µL dry DMSO for 3 hours at 
RT. The final product (19) was purified on a C18 RP-HPLC semiprep column on a 
gradient of 5-65% AcN in H2O with 0.1% TFA over 20 mins, dried, and verified with 
LCMS (Figure S6). The product eluted at ~21 mins and was quantified via 
absorbance at 565nm (ext. coeff565nm = 36,500 M-1 cm-1). 
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CHAPTER 7 – CONCLUSIONS AND FUTURE DIRECTIONS 
 
Antibody therapeutics are among the fastest growing field of biologics in the market 
currently and show no signs of slowing down. The target specificity, evolvability, and 
range of therapeutic mechanisms available with antibodies make it an unparalleled 
protein therapeutic for a huge host of disease targets. With the current display 
technologies available, antibodies can be evolved for better affinity and binding site 
variability against any extracellular target. Some argue that the accessible extracellular 
disease markers and targets have already been identified, and thus the future of 
antibodies lies optimization of antibodies against existing targets. This can be done by 
enhancing affinity, modulating the binding site, inducing a more enhanced secondary 
response, building bispecific and multi-targeting antibodies, and incorporating better 
conjugation sites onto antibodies to deliver drugs. 
 
The antibody drug conjugate (ADC) branch of antibody-based therapeutics is a 
relatively new field but has been growing very quickly. After the discovery that site-
specific, homogeneous ADCs are better tolerated in animals and humans, the field of 
site-specific antibody conjugation has seen rapid growth. However, the increased 
complexity of site-specific ADCs tends to lead to more purification steps and thus an 
increase in cost in an already expensive biologic. This can possibly be circumvented 
with reaction pairs or chemoenzymatic ligations with fast kinetics, quantitative yields, 
and strong serum stability. Currently, the most commonly used site-specific 
conjugation technique is through engineered cysteine residues. These are easy to 
incorporate into antibodies, but maleimide chemistry can lead to premature drug 
release and systemic toxicity. However, there has been a large amount of work to 
stabilize the thio-succinimide linkage.  
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Chemoenzymatic methods are an alternative means for coupling cargo to antibodies 
with stable linkages. These can form stable amide bonds or incorporate “click 
chemistry” functional groups that are aromatically stabilized after conjugation. This 
does not alleviate the purification problem though and could be even more rigorous to 
remove the added enzyme. Work like FGE ligation from the Bertozzi lab with co-
translationally modified antibodies is an effective means to minimize purification, and 
other systems that could incorporate bio-orthogonal functional groups onto antibodies 
in this way would be effective. The FGE method is great, but not optimal, because the 
corresponding substrate, the HIPS reagent, has limited stability in aqueous solution 
and difficult to work with. 
 
The purification problem is further amplified with more complicated ADCs, such as 
those with multiple cargo on a single antibody. There are a number of strategies to do 
this, including methods discussed in this dissertation. Our work is unique in 
incorporating cleavable linkers with orthogonal cleavage sites to a single antibody, but 
we still suffer from incomplete reaction conversion using the microbial 
transglutaminase (mTG) and lipoic acid ligase (LplA) enzymes. I believe this can be 
circumvented though with more antibody, which would allow us to use higher reaction 
concentrations and drive them to completion. Additionally, the instability of the trans-
cyclooctene could be an attributing factor for a lack of reaction conversion. I think 
developing these more complex ADCs will be very important in the field of biologics 
delivery, where a lack of non-toxic modalities for endosomal translocation still 
plagues the field. 
 
The emergence of N-acetylgalactosamine (GalNAc)-siRNA conjugates and their 
efficacy has really enlightened the community in the benefits of targeted conjugate 
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therapeutics over particle-based carriers in delivering certain biologics. However, 
making effective conjugates to target beyond the liver continues to be a challenge. 
Based on the theory that the GalNAc conjugates work so well because of the high 
abundance and fast recycling of the ASGPR, it’s going to be difficult to find another 
receptor ligand pair in another disease that works just as well. It is possible that higher 
affinity binding ligands could prompt different internalization pathways depending on 
the epitope, as has been seen with Transferrin-receptor targeted antibodies, but this 
would require quite a bit of screening and optimization. RNA aptamers may provide 
an alternative to this antibody screening method, as large RNA libraries are available 
and target siRNAs can be easily added to the sequence. However, instability of RNA 
conjugates is still a major variable in RNA conjugates, as the location and number of 
chemical modifications varies from sequence to sequence. Collaborations with 
companies or research groups with RNA synthesis capabilities could be helpful in 
studying these delivery methods. Either way, for ligand-receptor pairs with lower 
abundance and internalization rates, endosomal escape is still the major barrier to 
effective delivery. 
 
There are a large host of reagents available with membrane-disrupting capabilities for 
endosomal escape; but applying these reagents in a way that does not disrupt the outer 
membrane or elicit an immune response is still very difficult. Antimicrobial peptides 
and bacterial toxins are excellent pore-formers but are not specific to the endosomal 
membrane and need to be protected and later deprotected by an endosomal-specific 
reagent. Additionally, these can illicit an immune response in circulation as they are 
derived from pathogens. I feel the future lies in incorporating small, potent, 
hydrophobic, synthetic endosomal escape domains into the conjugate. These small 
hydrophobic domains must be incorporated in such a way though that they are only 
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uncovered once the conjugate reaches the endosomal compartment, likely from 
cleavage by an endosomal protease. These hydrophobic domains can then be used to 
drag the RNA across the endosomal membrane into the cytosol. They should be 
synthetic though, as to not induce an immunological response or be degraded in the 
endosomal compartment. These should also be attached in a way that keeps the siRNA 
attached to the endosomal escape domain but is released from the targeting ligand. 
This way, the siRNA is covalently attached to the escape domain and is not reliant on 
passive leakage from the endosome following pore formation in the endosomal 
membrane. Furthermore, better understanding of endosomal and lysosomal trafficking 
must be investigated to better understand the limitations in efficient intracellular 
delivery. 
With this, despite being unable to produce a functional antibody conjugate for siRNA 
delivery and endosomal escape, I remain hopeful for the future of RNA-based 
therapeutics.  Transient gene therapies don’t come with the ethical issues of permanent 
genetic manipulation in technologies like CRISPR, but still lead to gene knockdown 
long enough for disease mediation. The first RNAi-mediated therapy was FDA-
approved in 2018, and I feel the next 10 years will bring a host of new, targeted, 
RNAi-mediated carriers.  
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APPENDIX 
 
 
 
 
Appendix A.1 LCMS analysis of parent Melittin peptide. TIC trace for elution time of 
peptide (6.679 mins) and corresponding mass spectra. Expected mass 2845.74. 
Detected (M+2H)2+ 1424.000, (M+3H)3+ 949.600, (M+4H)4+ 712.500, (M+5H)5+ 
570.100, (M+6H)6+ 475.300. 
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100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z (Da)
0
50000
100000
150000
200000
250000
300000
350000 570.100
100.00%475.300
95.60%
712.500
52.78%
482.100
34.13%
578.400
14.28%
949.600
12.69%
502.300
7.10% 602.500
5.07%
477.900
4.14%
105.100
3.57%
956.900
3.15%
720.500
2.58%
260.200
2.47%
1424.000
1.67%
719.400
1.14%
186.000
0.99%
799.200
0.91%
954.900
0.54%
/Users/danatho...Lab/LCMS/DT5.D/ Injection 1 Function 1 (DT5) MS + spectrum 6.85
(M+2H)2+
(M+3H)3+
(M+4H)4+
(M+5H)5+(M+6H)6+
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Appendix A.2 LCMS analysis of parent MK7R, truncated Melittin peptide analog. 
TIC trace for elution time of peptide (8.404 mins) and corresponding mass spectra. 
Some apparent oxidation of presumably tryptophan residue was detected. Expected 
mass of parent peptide 2195.32. Expected mass of singly oxidized peptide 2227.31. 
Detected (M+2H)2+ 1099.013, (M+O+Na+2H)3+ 745.711. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
1200000
1300000
8.404
/Users/danatho...6-10-22/MK7R.D/	Injection	1	Function	1	(MK7R)	TIC
600 650 700 750 800 850 900 950 1000 1050 1100 1150 1200 1250 1300 1350 1400 1450 1500 1550 1600
m/z	(Da)
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000 1099.013
100.00%745.711
97.14%
1016.907
49.11% 1109.993
47.34%
688.954
35.42% 1090.433
32.06% 1251.701
29.03%
1117.948
19.50%
1521.897
19.41%
1252.697
18.88%740.514
14.76% 951.260
11.58%
867.205
10.68%
751.469
9.35%
1532.884
9.31%
1419.798
9.29%
1120.920
8.80%
823.626
8.50%
1253.697
7.58%
678.326
7.46%
1522.914
6.73%
710.585
5.63%
626.471
5.31%
1081.564
5.07%
1223.676
4.35%
910.554
3.68%
1017.598
3.15%
1002.729
3.08%
1167.656
2.57%
583.248
2.02%
1617.897
2.00%
1535.863
1.81%
1391.776
1.76%
1422.832
1.68%
855.344
1.27%
1321.815
1.24%
862.241
1.17%
816.284
1.16%
/Users/danatho...6-10-22/MK7R.D/	Injection	1	Function	1	(MK7R)	MS	+	spectrum	8.10..9.45
(M+2H)2+
(M+Na+H)2+
(M+O+Na+2H)3+
(M+Na+2H)3+ (M+O+Na+H)2+
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Appendix A.3 LCMS analysis of parent MS18R, truncated Melittin peptide analog. 
TIC trace for elution time of peptide (7.581 mins) and corresponding mass spectra. 
Expected mass 2188.36. Detected (M+2H)2+ 1095.600, (M+3H)3+ 730.900. 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
1200000
1300000
7.581
/Users/danatho...-10-22/MS18R.D/	Injection	1	Function	1	(MS18R)	TIC
650 700 750 800 850 900 950 1000 1050 1100 1150 1200 1250 1300 1350 1400 1450 1500 1550
m/z	(Da)
0
5000
10000
15000
20000
25000
30000
35000
40000
1095.600
100.00%
938.500
21.37%730.900
19.25%
626.500
17.81% 1010.500
15.11% 1111.200
12.75%
1051.600
11.88%
939.500
11.37%
743.400
10.36%
725.400
9.12%
657.200
8.93%
1521.800
8.15%
1139.600
8.08%
841.500
7.72%
1251.700
6.74%921.500
4.89%
612.500
4.47%
1002.100
4.01%
1053.500
3.63%
746.100
2.96%
879.500
2.58%
1017.900
2.37%
810.500
2.06%
711.400
1.73%
1217.200
1.65%
625.500
1.52%
1423.700
1.26%
1310.700
1.16%
1474.300
1.04%
1360.800
0.95%
1157.600
0.77%
1564.800
0.76%
/Users/danatho...-10-22/MS18R.D/	Injection	1	Function	1	(MS18R)	MS	+	spectrum	7.54
(M+2H)2+
(M+3H)3+
(M+2Na+H)3+
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Appendix A.4 LCMS analysis of C6M3 Parent Peptide. TIC trace for elution time of 
C6M3 (6.563 mins) and corresponding mass spectra. Expected mass 2681.57. 
Detected (M+2H)2+ 1341.400, (M+3H)3+ 895.100, (M+4H)4+ 671.800, (M+5H)5+ 
537.200, (M+6H)6+ 447.900. 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
50000
100000
150000
200000
250000 6.563
/Users/danatho.../DT-C6M3-CYS.D/	Injection	1	Function	1	(DT-C6M3-Cys)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
447.900
100.00%
509.900
88.19%
537.200
78.35%
424.900
44.69%
523.300
19.07%
636.900
18.31%
445.100
16.49%
576.200
14.94%
192.800
13.16%
895.100
12.38%156.000
8.30%
738.400
7.13%
352.100
5.92%
815.200
5.81%
450.000
5.77%
251.800
5.69%
983.800
5.46%
1341.400
5.02%
1203.500
3.68%
1273.400
3.04%
1049.500
2.07%
1474.800
1.88%
1139.000
1.67%
1410.400
1.12%
1600.700
0.96%
/Users/danatho.../DT-C6M3-CYS.D/	Injection	1	Function	1	(DT-C6M3-Cys)	MS	+	spectrum	6.58
(M+2H)2+
(M+3H)3+
(M+5H)5+
(M+6H)6+
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Appendix A.5 LCMS analysis of parent Mel-Cys peptide. TIC trace for elution time of 
peptide (6.547 mins) and corresponding mass spectra. Expected mass 2948.75. 
Detected (M+2H)2+ 1475.200, (M+3H)3+ 983.800, (M+4H)4+ 738.300 
 
 
 
 
 
 
 
Appendix A.6 Synthesis Scheme of TCO-functionalized, amine-reactive, self-
immolative, CatB-cleavable linker with Phe-Cit cleavable site. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
50000
100000
150000
200000
250000
300000
6.547
/Users/danatho...2/DT-MEL-CYS.D/	Injection	1	Function	1	(DT-Mel-Cys)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
50000
100000
150000
200000
576.000
100.00%
863.500
80.77% 983.800
74.34%
576.100
62.55%
863.900
48.93%
576.300
48.65%
814.900
39.15%
983.700
38.91%
983.900
38.27%738.300
35.17%
143.000
34.55%
432.400
26.94%
738.200
24.90%
863.700
24.82%
779.400
22.34%
143.100
21.25% 576.200
17.55%
432.500
16.37%
666.100
16.16%
432.200
15.27%
126.900
15.22%
251.900
15.05%
723.300
13.68%
983.500
12.76% 1475.200
9.58%
984.000
9.44%
926.900
8.96%
341.100
8.15%
492.300
6.09%
1106.400
5.20%
397.900
5.17%
739.000
3.56%
1314.500
3.15%
1220.000
2.38%
1543.900
1.87%
791.300
1.17%
1629.500
1.04%
1386.700
1.00%
/Users/danatho...2/DT-MEL-CYS.D/	Injection	1	Function	1	(DT-Mel-Cys)	MS	+	spectrum	5.92..8.33
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Appendix A.7 LCMS analysis of TCO-functionalized, amine-reactive, self-
immolative, CatB-cleavable linker with Val-Cit cleavable site. TIC trace for elution 
time of linker (8.436 mins) and corresponding mass spectra. Fragmentation tends to 
occur at carbamate bond, generating a fragment lacking the TCO mass (-153.09). 
Expected mass 943.45. Detected (M+H)+ 944.200. 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
8.436
/Users/danatho...VCIT_FREEZER.D/	Injection	1	Function	1	(VCIT_freezer)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
50000
100000
150000
200000
250000
300000
350000
400000
792.200
100.00%
944.200
55.66%
793.200
42.59%
945.200
27.96%
900.300
17.81% 967.200
11.75%
794.200
10.93%609.200
5.34%
504.200
3.20%
761.300
1.65%
1000.300
1.13%
808.100
0.99%
319.100
0.76%
/Users/danatho...VCIT_FREEZER.D/	Injection	1	Function	1	(VCIT_freezer)	MS	+	spectrum	8.44
(M-TCO+H)+
(M+H)+
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Appendix A.8 Synthesis Scheme of TCO-functionalized, amine-reactive, self-
immolative, CatB-cleavable linker with Phe-Cit cleavable site. 
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Appendix A.9 LCMS analysis of TCO-functionalized, amine-reactive, self-
immolative, CatB-cleavable linker with Phe-Cit cleavable site. TIC trace for elution 
time of linker (8.720 mins) and corresponding mass spectra. Fragmentation tends to 
occur at carbamate bond, generating a fragment lacking the TCO mass (-153.09). 
Expected mass 991.45. Detected (M+H)+ 992.200. 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
200000
400000
600000
800000
1000000
1200000
8.720
/Users/danatho...-19/FCIT_NEW.D/	Injection	1	Function	1	(FCIT_new)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
50000
100000
150000
200000
250000
840.200
100.00%
992.200
54.18%
841.200
47.02%
993.200
30.26%
948.200
19.06%
1015.200
17.24%842.200
13.61%
657.200
5.76%
1016.200
5.32%
552.200
3.16%
843.200
2.87%
809.300
1.84%
367.200
0.84%
/Users/danatho...-19/FCIT_NEW.D/	Injection	1	Function	1	(FCIT_new)	MS	+	spectrum	8.75
(M-TCO+H)+
(M+H)+
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Appendix A.10 LCMS analysis of MS18R, truncated Melittin peptide analog, 
conjugated with CatB cleavable, TCO-functionalized linker with Val-Cit cleavable 
site. TIC trace for elution time of peptide conjugate (9.081 mins) and corresponding 
mass spectra. Fragmentation tends to occur at carbamate bond, generating a fragment 
lacking the TCO mass (-153.09). Expected mass 2992.78. Detected (M+2H)2+ 
1497.800, (M+3H)3+ 998.800. 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
500000
1000000
1500000
9.018
/Users/danatho...MS18RVCITTCO.D/	Injection	1	Function	1	(MS18RVCITTCO)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
100000
200000
300000
400000
948.100
100.00%
1497.800
45.82%
998.800
15.39%
1117.100
5.12%
1006.100
5.02%
1508.800
3.17%
1248.600
2.95%
942.400
2.12%
1347.200
2.03%
1443.700
1.70%
711.300
0.79%
/Users/danatho...MS18RVCITTCO.D/	Injection	1	Function	1	(MS18RVCITTCO)	MS	+	spectrum	9.14
(M-TCO+3H)3+
(M+2H)2+
(M+3H)3+
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Appendix A.11 LCMS analysis of MS18R, truncated Melittin peptide analog, 
conjugated with CatB cleavable, TCO-functionalized linker with Phe-Cit cleavable 
site. TIC trace for elution time of peptide conjugate (9.060 mins) and corresponding 
mass spectra. Fragmentation tends to occur at carbamate bond, generating a fragment 
lacking the TCO mass (-153.09). Expected mass 3040.78. Detected (M+2H)2+ 
1521.800, (M+3H)3+ 1014.800. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
500000
1000000
1500000
2000000
2500000 9.050
/Users/danatho...18RFCITTCO_2.D/	Injection	1	Function	1	(MS18RFCITTCO_2)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
100000
200000
300000
400000
964.100
100.00%
1521.800
67.35%
1014.800
31.43%
1117.500
8.53%
1022.100
7.38% 1532.700
4.76%
958.500
3.85%
1467.700
3.25%
1248.600
3.20%
174.000
3.10%
230.100
0.97%
723.400
0.82%
286.100
0.55%
/Users/danatho...18RFCITTCO_2.D/	Injection	1	Function	1	(MS18RFCITTCO_2)	MS	+	spectrum	9.32
(M-TCO+3H)3+
(M+2H)2+
(M+3H)3+
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Appendix A.12 LCMS analysis of MS18R, truncated Melittin peptide analog, 
conjugated with stable, PEG, TCO-functionalized linker. TIC trace for elution time of 
peptide conjugate (9.523 mins) and corresponding mass spectra. Fragmentation tends 
to occur at carbamate bond, generating a fragment lacking the TCO mass (-153.09). 
Expected mass 2588.59. Detected (M+2H)2+ 1295.100. 
 
 
 
 
 
 
 
 
Appendix A.13 Reaction Scheme for C6M3-MAL-PEG4-DBCO Synthesis 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
9.523
/Users/danatho...18RPEG4TCO_1.D/	Injection	1	Function	1	(MS18RPEG4TCO_1)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
20000
40000
60000
80000
100000
120000
140000
160000
1295.100
100.00%
812.800
65.96%
807.100
22.71%
1240.600
7.95%
1306.100
5.69%831.300
1.86%
282.000
1.65%
774.000
1.63%
904.600
1.26%
126.900
0.96%
1066.400
0.90%
506.100
0.84%
226.000
0.75%
963.600
0.69%
1433.400
0.63%
1502.800
0.60%
623.900
0.60%
1210.200
0.60%
/Users/danatho...18RPEG4TCO_1.D/	Injection	1	Function	1	(MS18RPEG4TCO_1)	MS	+	spectrum	9.87
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Appendix A.14 LCMS analysis of C6M3-MAL-PEG4-DBCO. TIC Trace for elution 
time of product (6.940 mins) and corresponding mass spectra. Expected mass 3355.87. 
Detected (M+3H)3+ 1119.900, (M+4H)4+ 840.200, (M+5H)5+ 672.400. 
 
 
 
 
 
 
 
Appendix A.15 Reaction Scheme for Mel-MAL-PEG4-DBCO Synthesis 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
50000
100000
150000
200000
6.940
/Users/danatho..._C6M3-DBCO_3.D/	Injection	1	Function	1	(DT_C6M3-DBCO_3)	TIC
200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000 1050 1100 1150
m/z	(Da)
0
500
1000
1500
2000
2500
3000
3500
644.700
100.00%
672.400
72.72%
736.600
58.76%
617.000
45.25%
537.300
44.77% 789.000
38.69%578.800
33.66%
485.500
33.57%
206.100
31.30%
723.200
30.01%
840.200
27.67%252.000
23.87%
457.600
22.64%
411.900
21.65%
529.400
21.29%
670.700
19.38% 882.800
16.59%
1119.900
15.33%
224.900
13.99%
796.300
13.54%
957.700
12.52%
1041.700
12.49%
168.000
11.71%
470.600
10.84%
310.900
9.82%
265.300
9.67%
352.100
8.18%
995.900
7.31%
1172.700
6.11%
/Users/danatho..._C6M3-DBCO_3.D/	Injection	1	Function	1	(DT_C6M3-DBCO_3)	MS	+	spectrum	6.94
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Appendix A.16 LCMS analysis of Mel-MAL-PEG4-DBCO peptide. TIC trace for 
elution time of peptide (6.878 mins) and corresponding mass spectra. Expected mass 
3623.05. Detected (M+3H)3+ 1208.800, (M+4H)4+ 906.800, (M+5H)5+ 725.600 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
50000
100000
150000
200000
250000
300000
350000
6.878
/Users/danatho..._MEL-DBCO_F1.D/	Injection	1	Function	1	(DT_Mel-DBCO_F1)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
5000
10000
15000
20000
906.800
100.00%
725.600
54.88%
800.800
39.13%
1208.800
29.09%601.000
23.77% 864.200
17.32%732.300
13.13%
604.800
12.75% 1062.500
10.05%
601.700
9.59%
206.000
9.17%
813.000
7.20%
921.000
6.83%
143.100
5.81%
1140.200
5.81%
708.700
5.25%
277.200
4.22%
1210.600
4.11%
807.500
3.06%
481.000
2.33%
1386.800
1.79%
341.100
1.63%
398.000
1.60%
1306.200
1.47%
1558.300
1.19%
1455.700
1.05%
1628.200
0.72%
/Users/danatho..._MEL-DBCO_F1.D/	Injection	1	Function	1	(DT_Mel-DBCO_F1)	MS	+	spectrum	6.99
(M+3H)3+
(M+4H)4+
(M+5H)5+
(M+6H)6+
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Appendix A.17 LCMS analysis of Parent R9K peptide. TIC trace for elution time of 
R9K (0.738 mins) and corresponding mass spectra. Expected mass 1592.04. Detected 
(M+H)+ 1592.800, (M+2H)2+ 797.000, (M+3H)3+ 531.600, (M+4H)4+ 399.000, (M+5H)5+ 
319.400. 
 
 
 
 
 
 
 
Appendix A.18 Reaction scheme for R9K-PEG4-DBCO Synthesis.  
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/Users/danatho...08-30/DT_R9K.D/	Injection	1	Function	1	(DT_R9K)	MS	+	spectrum	0.79
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Appendix A.19 LCMS of R9K-PEG4-DBCO Reaction Mixture. TIC trace for elution 
mixture and corresponding mass spectra. Product elution time is underlined in black 
(4.516 mins). Expected Mass 2126.28. Detected (M+2H)2+ 1063.700, (M+3H)3+ 
709.700, (M+4H)4+ 532.400, (M+5H)5+ 426.600. 
 
 
 
 
 
 
 
 
 
 
Appendix A.20 Reaction Scheme for TCO-functionalized, reducible linker synthesis 
with varying PEG lengths. n = 4, 8, or 24 PEG units. 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Retention	time	(min)
20000
40000
60000
80000
100000
120000
140000
160000
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200000
4.516
/Users/danatho...-PEG4-DBCO	2.D/	Injection	1	Function	1	(DT_R9K-PEG4-DBCO)	TIC
100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000 1050 1100
m/z	(Da)
0
500
1000
1500
2000
2500
3000
251.900
100.00%
288.000
86.89%
192.800
75.67%
437.100
73.99%321.100
67.47%
206.000
55.26% 445.900
47.97%308.900
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426.600
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532.400
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460.700
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14.28%
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11.00%
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9.66%
777.800
9.15%
878.300
7.33%
920.800
6.30%
1053.800
6.17%
1097.000
4.70%
/Users/danatho...-PEG4-DBCO	2.D/	Injection	1	Function	1	(DT_R9K-PEG4-DBCO)	MS	+	spectrum	4.53
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Appendix A.21 LCMS analysis of TCO-PEG4-OPSS, reduction sensitive linker. TIC 
trace for elution time of linker (7.649 mins) and corresponding mass spectra. Expected 
mass 670.31. Detected (M+H)+ 671.200, (M+Na)+ 693.200. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
500000
1000000
1500000
2000000
2500000
7.649
/Users/danatho...EG4-OPSS_OLD.D/	Injection	1	Function	1	(DT...-PEG4-OPSS_old)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
100000
200000
300000
400000
693.200
100.00%
671.200
73.47%
694.200
36.11%
672.200
29.05%
695.200
17.14%673.200
13.13%260.200
7.57%
408.200
6.94%
519.200
5.33%
696.200
4.74%112.100
1.75%
561.200
1.15%
675.200
1.02%
196.100
0.65%
377.200
0.58%
/Users/danatho...EG4-OPSS_OLD.D/	Injection	1	Function	1	(DT...-PEG4-OPSS_old)	MS	+	spectrum	7.70
(M+H)+
(M+Na)+
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Appendix A.22 LCMS analysis of TCO-PEG8-OPSS, reduction sensitive linker. TIC 
trace for elution time of linker (7.649 mins) and corresponding mass spectra. Expected 
mass 846.41. Detected (M+H)+ 847.400, (M+Na)+ 869.400. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
500000
1000000
1500000
7.649
/Users/danatho...CO-PEG8-OPSS.D/	Injection	1	Function	1	(DT_TCO-PEG8-OPSS)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
50000
100000
150000
200000
250000
869.400
100.00%
870.400
46.40%348.200
42.64%
847.400
29.71%
871.400
22.05%
435.200
19.66% 848.400
14.20%370.200
9.76%
584.300
8.58%
885.300
7.66%
695.300
5.50%
758.300
3.37%
361.200
2.70%
112.100
2.43%
850.400
2.23%
455.200
2.06%
535.300
1.49%
276.700
0.71%
/Users/danatho...CO-PEG8-OPSS.D/	Injection	1	Function	1	(DT_TCO-PEG8-OPSS)	MS	+	spectrum	7.70
(M+H)+
(M+Na)+
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Appendix A.23 LCMS analysis of TCO-PEG24-OPSS, reduction sensitive linker. TIC 
trace for elution time of linker (7.602 mins) and corresponding mass spectra. Expected 
mass 1550.83. Detected (M+H)+ 1551.700, (M+Na)+ 1573.700, (M+2H)2+ 787.800, 
(M+2Na)2+ 798.400. 
 
 
 
 
 
 
 
 
 
Appendix A.24 Reaction Scheme for methyl tetrazine-functionalized, reducible linker 
synthesis with varying PEG lengths. n = 4 or 24 PEG units. 
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0.65%
/Users/danatho...O-PEG24-OPSS.D/	Injection	1	Function	1	(DT_TCO-PEG24-OPSS)	MS	+	spectrum	7.60
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Appendix A.25 LCMS analysis of MeTzine-PEG8-OPSS, reduction sensitive linker. 
TIC trace for elution time of linker (7.366 mins) and corresponding mass spectra. 
Expected mass 807.33. Detected (M+H)+ 808.200, (M+Na)+ 830.200, (M+2H)2+ 
404.600. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
500000
1000000
1500000
2000000
2500000
3000000 7.366
/Users/danatho...ZE-PEG8-OPSS.D/	Injection	1	Function	1	(DT...inze-PEG8-OPSS)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
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200000
300000
400000
830.200
100.00%
808.200
84.12%
831.200
44.98%
809.200
37.15%
832.200
20.99%810.200
17.68%
279.100
9.92%
404.600
7.65%
697.200
7.44%
833.200
6.25%112.100
1.64%
345.100
1.27%
628.100
0.96%
/Users/danatho...ZE-PEG8-OPSS.D/	Injection	1	Function	1	(DT...inze-PEG8-OPSS)	MS	+	spectrum	7.43
(M+H)+
(M+Na)+
(M+2H)2+
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Appendix A.26 LCMS analysis of MeTzine-PEG28-OPSS, reduction sensitive linker. 
TIC trace for elution time of linker (7.476 mins) and corresponding mass spectra. 
Expected mass 1687.85. Detected (M+2H)2+ 844.800, (M+3H)3+ 563.600. 
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/Users/danatho...ZINEPEG8OPSS.D/	Injection	1	Function	1	(DT_MTzinePEG8OPSS)	MS	+	spectrum	7.49
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Appendix A.27 HPLC Trace of Amine-reactive, reduction sensitive PEGylation 
reagent on a C18 column on a gradient of AcN in water. 
 
 
 
 
 
Appendix A.28 Size Exclusion Chromatography Traces of Antibodies purified from 
293F cells, with or without LAP tag incorporated. All antibodies elute at ~9 mins and 
show few aggregates across both antibody types, with and without the LAP tag. 
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Appendix A.29 Synthesis Scheme for pAz substrate for LplA chemoenzymatic 
ligation. 
 
 
 
 
 
 
 
 
 
Appendix A.30 LCMS analysis of pAz substrate for LplA chemoenzymatic ligation. 
TIC trace for elution time of linker (5.098 mins) and corresponding mass spectra. 
Expected mass 277.12. Detected (M+H)+ 278.100. 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Retention	time	(min)
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
5.098
/Users/danatho...AZ	CRUDE	MIX.D/	Injection	1	Function	1	(DT_pAz	crude	mix)	TIC
100 150 200 250 300 350 400 450 500 550 600 650 700 750
m/z	(Da)
0
10000
20000
30000
40000
50000
60000
70000
80000
278.100
100.00%
250.100
96.99%
279.100
16.18%
377.100
15.12%
251.100
14.18%
133.100
14.15%
528.200
6.19%
399.100
4.89%134.100
2.29%
436.100
1.70%
252.100
1.66%
232.100
1.65%
280.000
1.59%
105.100
1.56%
593.100
0.92%
172.000
0.81%
349.100
0.76%
476.000
0.67%
553.000
0.63%
701.200
0.51%
/Users/danatho...AZ	CRUDE	MIX.D/	Injection	1	Function	1	(DT_pAz	crude	mix)	MS	+	spectrum	5.13
(M+H)+
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Appendix A.31 Synthesis Scheme for TCO-LAP substrate for LplA chemoenzymatic 
ligation. 
 
 
 
 
 
Appendix A.32 LCMS analysis of TCO-LAP substrate for LplA chemoenzymatic 
ligation. TIC trace for elution time of linker (7.211 mins) and corresponding mass 
spectra. Expected mass 269.16. Detected (M-H)- 268.400. 
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Retention	time	(min)
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300000
350000
400000
7.211
/Users/danatho...OLAPSUBS_NEG.D/	Injection	1	Function	1	(DT_TCOLAPSubs_neg)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
5000
10000
15000
20000
25000
142.200
100.00%
268.400
70.13%
269.400
14.08%143.200
8.63%
255.300
6.84% 559.800
2.94%
429.600
1.74%
141.200
1.61%
325.500
1.34%
1066.900
0.88%
486.400
0.83%
793.800
0.79%
1591.100
0.70%
735.900
0.70%
1483.000
0.59%
618.800
0.52%
/Users/danatho...OLAPSUBS_NEG.D/	Injection	1	Function	1	(DT_TCOLAPSubs_neg)	MS	-	spectrum	7.23
(M-H)-
 179 
 
 
 
 
 
 
 
 
Appendix A.33 Synthesis Scheme for MeTzine-PEG4-Fluorescein, Stable, non-
cleavable Fluorescent 
 
 
 
 
Appendix A.34 LCMS analysis of MeTzine-PEG4-Fluorescein, Stable, non-cleavable 
Fluorescent Linker. TIC trace for elution time of linker (7.539 mins) and 
corresponding mass spectra. Expected mass 924.35. Detected (M+H)+ 925.100, 
(M+2H)2+ 463.100 
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Retention	time	(min)
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7.539
/Users/danatho..._FLUOR-TZINE.D/	Injection	1	Function	1	(DT_Fluor-Tzine)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
100000
200000
300000
400000
500000
600000
700000
800000
900000 925.100
100.00%
926.100
53.86%
927.100
17.06%
856.100
9.65%463.100
7.00% 948.100
4.08%579.000
1.35%
667.000
0.54%
/Users/danatho..._FLUOR-TZINE.D/	Injection	1	Function	1	(DT_Fluor-Tzine)	MS	+	spectrum	7.54
(M+H)+
(M+2H)2+
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Appendix A.35 Synthesis Scheme for MeTzine-Val-Cit-Fluorescein, CatB-cleavable 
Fluorescent Linker. 
 
 
 
 
 
Appendix A.36 LCMS analysis of MeTzine-Val-Cit-Fluorescein, CatB-cleavable 
Fluorescent Linker. TIC trace for elution time of linker (7.444 mins) and 
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Retention	time	(min)
0
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500000
600000
700000
800000
900000
1000000
1100000
7.444
/Users/danatho...E-VCIT-FLUOR.D/	Injection	1	Function	1	(DT_Tzine-VCit-Fluor)	TIC
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
m/z	(Da)
0
50000
100000
150000
200000
250000
1330.400
100.00%
1331.400
73.23%
1332.400
32.70%551.100
27.12%
665.700
10.36%
1333.400
9.78%
552.000
8.59%
780.200
7.42%
507.100
5.31% 1334.400
2.41%
814.200
1.32%
/Users/danatho...E-VCIT-FLUOR.D/	Injection	1	Function	1	(DT_Tzine-VCit-Fluor)	MS	+	spectrum	7.48
(M+H)+
(M+2H)2+
 181 
corresponding mass spectra. Expected mass 1329.56. Detected (M+H)+ 1330.400, 
(M+2H)2+ 665.700 
 
 
 
 
 
Appendix A.37 Synthesis scheme for DBCO-PEG4-Rhodamine, stable, non-cleavable 
Fluorescent Linker. 
 
 
 
 
Appendix A.38 LCMS analysis of DBCO-PEG4-Rhodamine, stable, non-cleavable 
Fluorescent Linker. TIC trace for elution time of linker (8.452 mins) and 
corresponding mass spectra. DBCO tends to fragment at the tertiary amide on the 
DBCO ring (M-187.1). Expected mass 1222.35. Detected (M+H)+ 1223.300, (M+2H)2+ 
612.200 
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/Users/danatho...DT_DBCO-RHOD.D/	Injection	1	Function	1	(DT_DBCO-Rhod)	TIC
100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000 1050 1100 1150 1200 1250 1300 1350 1400 1450 1500
m/z	(Da)
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200000
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350000 1223.300
100.00%
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74.99%
612.200
53.49%
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39.23%
936.200
19.90% 1226.300
15.95%1018.200
11.60%509.700
6.38%
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4.70%
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4.48%
689.100
2.52%
893.200
1.95%
288.100
1.77%
939.200
1.68%
743.100
1.64%
206.100
1.54%
1021.200
0.98%
372.100
0.70%
/Users/danatho...DT_DBCO-RHOD.D/	Injection	1	Function	1	(DT_DBCO-Rhod)	MS	+	spectrum	8.47
(M+H)+
(M+2H)2+
(M-DBCO+H)+
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Appendix A.39 Synthesis scheme for Rhodamine-PVGLIG-PEG4-DBCO, the MMP-2 
cleavable Fluorescent Linker. 
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Appendix A.40 LCMS analysis of Rhodamine-PVGLIG-NH2, intermediate product 
[Appendix 39(i)] for synthesis of MMP-2 cleavable Fluorescent Linker. TIC trace for 
elution time of linker (7.271 mins) and corresponding mass spectra. Expected mass 
1224.59. Detected (M+H)+ 1225.300, (M+2H)2+ 613.200. 
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3000000
3500000
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Appendix A.41 LCMS analysis of final Rhodamine-PVGLIG-PEG4-DBCO, the MMP-
2 cleavable Fluorescent Linker [Appendix 39(ii)]. TIC trace for elution time of linker 
(8.672 mins) and corresponding mass spectra. DBCO tends to fragment at the tertiary 
amide on the DBCO ring (M-187.1). Expected mass 1758.83. Detected (M+2H)2+ 
880.400, (M+3H)3+ 587.300. 
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Appendix A.42 SDS-PAGE of antibody and Tzine-Val-Cit-Fluorescein Linker 
control. (Left) Coomassie stain for protein (Right) Fluorescein channel for linker. 
Non-conjugated linker was treated with CatB and analyzed on SDS-PAGE for band 
location relative to the antibody.
75kD -
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Coomassie Fluorescein
Antibody
CatB
+- +-+- +-
+- +- +- +-
 
 
186 
 
REFERENCES 
 
1. Carter, P. J. Potent antibody therapeutics by design. Nat Rev Immunol 6, 343–
357 (2006). 
2. Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nature 
Publishing Group 15, 361–370 (2015). 
3. Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting 
antibody of predefined specificity. Nature 256, 495–497 (1975). 
4. Scott, A. M. et al. A phase I clinical trial with monoclonal antibody ch806 
targeting transitional state and mutant epidermal growth factor receptors. 
Proceedings of the National Academy of Sciences 104, 4071–4076 (2007). 
5. Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer. 1–10 
(2012). doi:10.1038/nrc3236 
6. Johnson, P. & Glennie, M. The mechanisms of action of rituximab in the 
elimination of tumor cells. Seminars in Oncology 30, 3–8 (2003). 
7. Byrd, J. C. et al. The mechanism of tumor cell clearance by rituximab in vivo 
in patients with B-cell chronic lymphocytic leukemia: evidence of caspase 
activation and apoptosis induction. Blood 99, 1038–1043 (2002). 
8. Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with 
Metastatic Melanoma. New England Journal of Medicine 363, 711–723 
(2010). 
9. Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Strategies and challenges 
for the next generation of antibody–drug conjugates. Nature Publishing 
Group 16, 315–337 (2017). 
10. LoRusso, P. M., Weiss, D., Guardino, E., Girish, S. & Sliwkowski, M. X. 
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in 
Development for Human Epidermal Growth Factor Receptor 2-Positive 
Cancer. Clinical Cancer Research 17, 6437–6447 (2011). 
11. Zein, N., Sinha, A. M., McGahren, W. J. & Ellestad, G. A. Calicheamicin 
gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site 
specifically. Science 240, 1198–1201 (1988). 
12. Godwin, C. D., Gale, R. P. & Walter, R. B. Gemtuzumab ozogamicin in acute 
myeloid leukemia. 31, 1855–1868 (2017). 
13. Strop, P. et al. Location Matters: Site of Conjugation Modulates Stability and 
Pharmacokinetics of Antibody Drug Conjugates. Chemistry & Biology 20, 
161–167 (2013). 
14. Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an 
antibody improves the therapeutic index. Nature Biotechnology 26, 925–932 
(2008). 
15. Lotze, J., Reinhardt, U., Seitz, O. & Beck-Sickinger, A. G. Peptide-tags for 
site-specific protein labelling in vitro and in vivo. Molecular BioSystems 12, 
1731–1745 (2016). 
16. Zhou, Z. et al. Genetically Encoded Short Peptide Tags for Orthogonal 
Protein Labeling by Sfp and AcpS Phosphopantetheinyl Transferases. ACS 
Chemical Biology 2, 337–346 (2007). 
 
 
187 
 
17. Rabuka, D. Chemoenzymatic methods for site-specific protein modification. 
Current Opinion in Chemical Biology 14, 790–796 (2010). 
18. Zimmerman, E. S. et al. Production of Site-Specific Antibody–Drug 
Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free 
Expression System. Bioconjugate Chemistry 25, 351–361 (2014). 
19. Hallam, T. J., Wold, E., Wahl, A. & Smider, V. V. Antibody Conjugates with 
Unnatural Amino Acids. Mol. Pharmaceutics 12, 1848–1862 (2015). 
20. Xiao, H. et al. Genetic Incorporation of Multiple Unnatural Amino Acids into 
Proteins in Mammalian Cells. Angewandte Chemie International Edition 52, 
14080–14083 (2013). 
21. Wang, K. et al. Optimized orthogonal translation of unnatural amino acids 
enables spontaneous protein double-labelling and FRET. Nature Chemistry 6, 
393–403 (2014). 
22. Cohen, J. D., Zou, P. & Ting, A. Y. Site-Specific Protein Modification Using 
Lipoic Acid Ligase and Bis-Aryl Hydrazone Formation. ChemBioChem 13, 
888–894 (2012). 
23. Jeger, S. et al. Site-Specific and Stoichiometric Modification of Antibodies by 
Bacterial Transglutaminase. Angewandte Chemie International Edition 49, 
9995–9997 (2010). 
24. Antos, J. M. et al. Site-Specific N- and C-Terminal Labeling of a Single 
Polypeptide Using Sortases of Different Specificity. Journal of the American 
Chemical Society 131, 10800–10801 (2009). 
25. Rush, J. S. & Bertozzi, C. R. New Aldehyde Tag Sequences Identified by 
Screening Formylglycine Generating Enzymes in Vitroand in Vivo. Journal 
of the American Chemical Society 130, 12240–12241 (2008). 
26. Zeglis, B. M. et al. Enzyme-Mediated Methodology for the Site-Specific 
Radiolabeling of Antibodies Based on Catalyst-Free Click Chemistry. 
Bioconjugate Chemistry 24, 1057–1067 (2013). 
27. Mahalingam, S. M. et al. Evaluation of a Centyrin-Based Near-Infrared Probe 
for Fluorescence-Guided Surgery of Epidermal Growth Factor Receptor 
Positive Tumors. Bioconjugate Chemistry 28, 2865–2873 (2017). 
28. Rossin, R. et al. In Vivo Chemistry for Pretargeted Tumor Imaging in Live 
Mice. Angewandte Chemie International Edition 49, 3375–3378 (2010). 
29. Adumeau, P. et al. Site-Specifically Labeled Antibody–Drug Conjugate for 
Simultaneous Therapy and ImmunoPET. Mol. Pharmaceutics 15, 892–898 
(2018). 
30. van Buggenum, J. A. G. L. et al. A covalent and cleavable antibody-DNA 
conjugation strategy for sensitive protein detection via immuno-PCR. 
Scientific Reports 6, 22675 (2016). 
31. Kazane, S. A. et al. Site-specific DNA-antibody conjugates for specific and 
sensitive immuno-PCR. Proceedings of the National Academy of Sciences 
109, 3731–3736 (2012). 
32. Baltimore, D. et al. A prudent path forward for genomic engineering and 
germline gene modification. Science 348, 36–38 (2015). 
33. Dowdy, S. F. Overcoming cellular barriers for RNA therapeutics. Nature 
Biotechnology 35, 222–229 (2017). 
 
 
188 
 
34. Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for 
treatment of neurological disorders. Nature Publishing Group 1–13 (2017). 
doi:10.1038/nrneurol.2017.148 
35. Opalinska, J. B. & Gewirtz, A. M. Nucleic-acid therapeutics: basic principles 
and recent applications. Nat Rev Drug Discov 1, 503–514 (2002). 
36. Muntoni, F. & Wood, M. J. A. Targeting RNA to treat neuromuscular disease. 
1–17 (2011). doi:10.1038/nrd3459 
37. Elbashir, S. M. et al. Duplexes of 21-Nucleotide RNAs Mediate RNA 
Interference in Cultured Mammalian Cells. Nature 411, 494–498 (2001). 
38. Fire, A. et al. Potent and specific genetic interference by double-stranded 
RNA in Caenorhabditis elegans. Nature 391, 806–811 (1998). 
39. Kenski, D. M. et al. siRNA-optimized Modifications for Enhanced In Vivo 
Activity. Molecular Therapy — Nucleic Acids 1, e5 (2012). 
40. Watts, J., Deleavy, G. & Damha, M. Chemically modified siRNA: tools and 
applications. Drug Discovery Today 13, 842–855 (2008). 
41. Robbins, M., Judge, A. & MacLachlan, I. siRNA and Innate Immunity. 
Oligonucleotides 19, 89–102 (2009). 
42. Eckstein, F. Nucleoside Phosphorothioates. Journal of the American 
Chemical Society 88, 4292–4294 (1966). 
43. Crooke, S. T., Wang, S., Vickers, T. A., Shen, W. & Liang, X.-H. Cellular 
uptake and trafficking of antisense oligonucleotides. Nature Biotechnology 
35, 230–237 (2017). 
44. Matsuda, S. et al. siRNA Conjugates Carrying Sequentially Assembled 
Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust 
Gene Silencing In Vivoin Hepatocytes. ACS Chemical Biology 10, 1181–1187 
(2015). 
45. Gilleron, J. et al. Image-based analysis of lipid nanoparticle&ndash;mediated 
siRNA delivery, intracellular trafficking and endosomal escape. Nature 
Biotechnology 31, 638–646 (2013). 
46. Wittrup, A. et al. Visualizing lipid-formulated siRNA release from endosomes 
and target gene knockdown. Nature Biotechnology 33, 870–876 (2015). 
47. Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids 
Research 44, 6518–6548 (2016). 
48. Stewart, M. P., Lorenz, A., Dahlman, J. & Sahay, G. Challenges in carrier-
mediated intracellular delivery: moving beyond endosomal barriers. WIREs 
Nanomed Nanobiotechnol 8, 465–478 (2015). 
49. Blain, J. C. & Szostak, J. W. Progress Toward Synthetic Cells. Annual Review 
of Biochemistry 83, 615–640 (2014). 
50. Varkouhi, A. K., Scholte, M., Storm, G. & Haisma, H. J. Endosomal escape 
pathways for delivery of biologicals. Journal of Controlled Release 151, 220–
228 (2011). 
51. Miller, D. K., Griffiths, E., Lenard, J. & Firestone, R. A. Cell killing by 
lysosomotropic detergents. The Journal of Cell Biology 97, 1841–1851 
(1983). 
52. Pack, D. W., Putnam, D. & Langer, R. Design of imidazole‐containing 
endosomolytic biopolymers for gene delivery. Biotechnology and 
Bioengineering 67, 217–223 (2000). 
 
 
189 
 
53. Moreira, C. et al. Improving chitosan-mediated gene transfer by the 
introduction of intracellular buffering moieties into the chitosan backbone. 
Acta Biomaterialia 5, 2995–3006 (2009). 
54. Marsh, M. & Helenius, A. in 36, 107–151 (Elsevier, 1989). 
55. Wiley, D. C. & Skehel, J. J. The Structure and Function of the Hemagglutinin 
Membrane Glycoprotein of Influenza Virus. Annual Review of Biochemistry 
56, 365–394 (1987). 
56. Horth, M. et al. Theoretical and functional analysis of the SIV fusion peptide. 
The EMBO Journal 10, 2747–2755 (1991). 
57. Maxfield, F. R. Weak bases and ionophores rapidly and reversibly raise the 
pH of endocytic vesicles in cultured mouse fibroblasts. The Journal of Cell 
Biology 95, 676–681 (1982). 
58. Cheng, J. et al. Structure−Function Correlation of Chloroquine and Analogues 
as Transgene Expression Enhancers in Nonviral Gene Delivery. Journal of 
Medicinal Chemistry 49, 6522–6531 (2006). 
59. Veldhoen, S., Laufer, S. D., Trampe, A. & Restle, T. Cellular delivery of 
small interfering RNA by a non-covalently attached cell-penetrating peptide: 
quantitative analysis of uptake and biological effect. Nucleic Acids Research 
34, 6561–6573 (2006). 
60. Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic 
peptide enhances escape of TAT-fusion proteins after lipid raft 
macropinocytosis. Nature Medicine 10, 310–315 (2004). 
61. Terwilliger, T. C. & Eisenberg, D. The Structure of Melittin (II. Interpretation 
of the Structure). Journal of Biological Chemistry (1981). 
doi:10.2210/pdb1mlt/pdb 
62. Dempsey, C. E. The actions of melittin on membranes. Biochimica et 
Biophysica Acta (BBA) - Reviews on Biomembranes 1031, 143–161 (1990). 
63. Othon, C. M., Kwon, O.-H., Lin, M. M. & Zewail, A. H. Solvation in protein 
(un)folding of melittin tetramer–monomer transition. Proceedings of the 
National Academy of Sciences 106, 12593–12598 (2009). 
64. Lee, M. T., Hung, W. C., Chen, F. Y. & Huang, H. W. Mechanism and 
kinetics of pore formation in membranes by water-soluble amphipathic 
peptides. Proceedings of the National Academy of Sciences 105, 5087–5092 
(2008). 
65. Goto, Y. & Hagihara, Y. Mechanism of the conformational transition of 
melittin. Biochemistry 31, 732–738 (2002). 
66. Ogris, M., Carlisle, R. C., Bettinger, T. & Seymour, L. W. Melittin Enables 
Efficient Vesicular Escape and Enhanced Nuclear Access of Nonviral Gene 
Delivery Vectors. Journal of Biological Chemistry 276, 47550–47555 (2001). 
67. Tan, Y.-X. et al. Truncated peptides from melittin and its analog with high 
lytic activity at endosomal pH enhance branched polyethylenimine-mediated 
gene transfection. J. Gene Med. 14, 241–250 (2012). 
68. Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of 
siRNA to hepatocytes. Proceedings of the National Academy of Sciences 104, 
12982–12987 (2007). 
69. Rozema, D. B., Ekena, K., Lewis, D. L., Loomis, A. G. & Wolff, J. A. 
Endosomolysis by Masking of a Membrane-Active Agent (EMMA) for 
 
 
190 
 
Cytoplasmic Release of Macromolecules. Bioconjugate Chemistry 14, 51–57 
(2003). 
70. Wong, S. C. et al. Co-Injection of a Targeted, Reversibly Masked 
Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-
Conjugated Small Interfering RNAs In Vivo. Nucleic Acid Therapeutics 22, 
1–11 (2012). 
71. Tweten, R. K., Parker, M. W. & Johnson, A. E. in Pore-Forming Toxins 257, 
15–33 (Springer, Berlin, Heidelberg, 2001). 
72. Heuck, A. P., Savva, C. G., Holzenburg, A. & Johnson, A. E. Conformational 
Changes That Effect Oligomerization and Initiate Pore Formation Are 
Triggered throughout Perfringolysin O upon Binding to Cholesterol. Journal 
of Biological Chemistry 282, 22629–22637 (2007). 
73. Rossjohn, J., Feil, S. C., McKinstry, W. J., Tweten, R. K. & Parker, M. W. 
Structure of a Cholesterol-Binding, Thiol-Activated Cytolysin and a Model of 
Its Membrane Form. Cell 89, 685–692 (1997). 
74. Koster, S. et al. Crystal structure of listeriolysin O reveals molecular details of 
oligomerization and pore formation. Nature Communications 5, 1–14 (2014). 
75. Pirie, C. M., Liu, D. V. & Wittrup, K. D. Targeted Cytolysins Synergistically 
Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin. Molecular Cancer 
Therapeutics 12, 1774–1782 (2013). 
76. Pirie, C. M., Hackel, B. J., Rosenblum, M. G. & Wittrup, K. D. Convergent 
Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, 
Antigens, and Targeting Moieties. Journal of Biological Chemistry 286, 
4165–4172 (2011). 
77. Yang, N. J. et al. Antibody-Mediated Neutralization of Perfringolysin O for 
Intracellular Protein Delivery. Mol. Pharmaceutics 12, 1992–2000 (2015). 
78. Yang, N. J. et al. Cytosolic delivery of siRNA by ultra-high affinity dsRNA 
binding proteins. Nucleic Acids Research 45, 7602–7614 (2017). 
79. Ecker, D. M., Jones, S. D. & Levine, H. L. The therapeutic monoclonal 
antibody market. mAbs 7, 9–14 (2014). 
80. Reichert, J. M., Rosensweig, C. J., Faden, L. B. & Dewitz, M. C. Monoclonal 
antibody successes in the clinic. Nature Biotechnology 23, 1073–1078 (2005). 
81. Marks, J. D. et al. By-passing Immunization: Human Antibodies from V-gene 
Libraries Displayed on Phage. Journal of Molecular Biology 1–17 (2003). 
82. McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage 
antibodies: filamentous phage displaying antibody variable domains. Nature 
348, 552–554 (1990). 
83. Bradbury, A. R. M. & Marks, J. D. Antibodies from phage antibody libraries. 
Journal of Immunological Methods 290, 29–49 (2004). 
84. Zahnd, C. et al. Directed in VitroEvolution and Crystallographic Analysis of a 
Peptide-binding Single Chain Antibody Fragment (scFv) with Low Picomolar 
Affinity. Journal of Biological Chemistry 279, 18870–18877 (2004). 
85. Hanes, J., Schaffitzel, C., Knappik, A. & Plückthun, A. Picomolar affinity 
antibodies from a fully synthetic naive library selected and evolved by 
ribosome display. Nature Biotechnology 18, 1287–1292 (2000). 
86. Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H. R. & Pluckthun, 
A. Ribosome display efficiently selects and evolves high-affinity antibodies in 
 
 
191 
 
vitro from immune libraries. Proceedings of the National Academy of 
Sciences 95, 14130–14135 (1998). 
87. Schaffitzel, C. et al. In vitro generated antibodies specific for telomeric 
guanine-quadruplex DNA react with Stylonychia lemnae macronuclei. 
Proceedings of the National Academy of Sciences 98, 8572–8577 (2001). 
88. Jermutus, L., Honegger, A., Schwesinger, F., Hanes, J. & Pluckthun, A. 
Tailoring in vitro evolution for protein affinity or stability. Proceedings of the 
National Academy of Sciences 98, 75–80 (2001). 
89. Boder, E. T., Midelfort, K. S. & Wittrup, K. D. Directed evolution of antibody 
fragments with monovalent femtomolar antigen-binding affinity. Proceedings 
of the National Academy of Sciences 97, 10701–10705 (2000). 
90. Boder, E. T. & Wittrup, K. D. Yeast surface display for screening 
combinatorial polypeptide libraries. Nature Biotechnology 15, 553–557 
(1997). 
91. Lonberg, N. Human antibodies from transgenic animals. Nature 
Biotechnology 23, 1117–1125 (2005). 
92. Green, L. L. et al. Antigen–specific human monoclonal antibodies from mice 
engineered with human Ig heavy and light chain YACs. Nature Genetics 7, 
13–21 (1994). 
93. Salles, G. et al. Phase 1 study results of the type II glycoengineered 
humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell 
lymphoma patients. Blood 119, 5126–5132 (2012). 
94. Dalle, S. et al. Preclinical Studies on the Mechanism of Action and the Anti-
Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. Molecular 
Cancer Therapeutics 10, 178–185 (2011). 
95. Cartron, G. et al. Obinutuzumab (GA101) in relapsed/refractory chronic 
lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 
124, 2196–2202 (2014). 
96. Bowles, J. A. et al. Anti-CD20 monoclonal antibody with enhanced affinity 
for CD16 activates NK cells at lower concentrations and more effectively than 
rituximab. Blood 108, 2648–2654 (2006). 
97. Lohse, S. et al. Recombinant Dimeric IgA Antibodies against the Epidermal 
Growth Factor Receptor Mediate Effective Tumor Cell Killing. The Journal 
of Immunology 186, 3770–3778 (2011). 
98. Dodev, T. S. et al. A tool kit for rapid cloning and expression of recombinant 
antibodies. Scientific Reports 4, (2014). 
99. Ilieva, K. M. et al. Functionally Active Fc Mutant Antibodies Recognizing 
Cancer Antigens Generated Rapidly at High Yields. Front. Immunol. 8, 4892–
18 (2017). 
100. Dall’Ozzo, S. et al. Rituximab-Dependent Cytotoxicity by Natural Killer 
Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect 
Relationship. Cancer Research 64, 4664–4669 (2004). 
101. Lefebvre, M.-L., Krause, S. W., Salcedo, M. & Nardin, A. Ex Vivo-activated 
Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the 
Presence of Rituximab: Mechanism of Antibody-dependent Cellular 
Cytotoxicity and Impact of Human Serum. Journal of Immunotherapy 29, 
388–397 (2006). 
 
 
192 
 
102. Hernandez-Ilizaliturri, F. J. et al. Neutrophils Contribute to the Biological 
Antitumor Activity of Rituximab in a Non-Hodgkin’s Lymphoma Severe 
Combined Immunodeficiency Mouse Model. Clinical Cancer Research 9, 
5866–5873 (2003). 
103. Beers, S. A. & Glennie, M. J. Neutrophils: ‘neu players’ in antibody therapy? 
Blood 122, 3093–3094 (2013). 
104. Sievers, E. L. & Senter, P. D. Antibody-Drug Conjugates in Cancer Therapy. 
Annual Review of Medicine 64, 15–29 (2013). 
105. Prescher, J. A. & Bertozzi, C. R. Chemistry in living systems. Nature 
Chemical Biology 1, 13–21 (2005). 
106. Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click Chemistry: Diverse 
Chemical Function from a Few Good Reactions. Angewandte Chemie 
International Edition 40, 2004–2021 (2001). 
107. Huisgen, R. 1,3-Dipolar Cycloadditions. Angewandte Chemie International 
Edition 2, 565–598 (1963). 
108. Blackman, M. L., Royzen, M. & Fox, J. M. Tetrazine Ligation: Fast 
Bioconjugation Based on Inverse-Electron-Demand Diels−Alder Reactivity. 
Journal of the American Chemical Society 130, 13518–13519 (2008). 
109. Shen, B.-Q. et al. Conjugation site modulates the in vivo stability and 
therapeutic activity of antibody-drug conjugates. Nature Biotechnology 30, 
184–189 (2012). 
110. Jeffrey, S. C. et al. A Potent Anti-CD70 Antibody–Drug Conjugate 
Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific 
Conjugation Technology. Bioconjugate Chemistry 24, 1256–1263 (2013). 
111. Voynov, V. et al. Design and Application of Antibody Cysteine Variants. 
Bioconjugate Chemistry 21, 385–392 (2010). 
112. Tian, F. et al. A general approach to site-specific antibody drug conjugates. 
Proceedings of the National Academy of Sciences 111, 1766–1771 (2014). 
113. VanBrunt, M. P. et al. Genetically Encoded Azide Containing Amino Acid in 
Mammalian Cells Enables Site-Specific Antibody–Drug Conjugates Using 
Click Cycloaddition Chemistry. Bioconjugate Chemistry 26, 2249–2260 
(2015). 
114. Puthenveetil, S., Liu, D. S., White, K. A., Thompson, S. & Ting, A. Y. Yeast 
Display Evolution of a Kinetically Efficient 13-Amino Acid Substrate for 
Lipoic Acid Ligase. Journal of the American Chemical Society 131, 16430–
16438 (2009). 
115. Lhospice, F. et al. Site-Specific Conjugation of Monomethyl Auristatin E to 
Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic 
Index in Rodent Models. Mol. Pharmaceutics 12, 1863–1871 (2015). 
116. Dennler, P. et al. Transglutaminase-Based Chemo-Enzymatic Conjugation 
Approach Yields Homogeneous Antibody–Drug Conjugates. Bioconjugate 
Chemistry 25, 569–578 (2014). 
117. Fontana, A., Spolaore, B., Mero, A. & Veronese, F. M. Site-specific 
modification and PEGylation of pharmaceutical proteins mediated by 
transglutaminase. Advanced Drug Delivery Reviews 60, 13–28 (2008). 
 
 
193 
 
118. Liu, D. S. et al. Computational design of a red fluorophore ligase for site-
specific protein labeling in living cells. Proceedings of the National Academy 
of Sciences 111, E4551–E4559 (2014). 
119. Uttamapinant, C. et al. A fluorophore ligase for site-specific protein labeling 
inside living cells. Proceedings of the National Academy of Sciences 107, 
10914–10919 (2010). 
120. Uttamapinant, C. et al. Fast, Cell-Compatible Click Chemistry with Copper-
Chelating Azides for Biomolecular Labeling. Angewandte Chemie 
International Edition 51, 5852–5856 (2012). 
121. Liu, D. S. et al. Diels–Alder Cycloaddition for Fluorophore Targeting to 
Specific Proteins inside Living Cells. Journal of the American Chemical 
Society 134, 792–795 (2011). 
122. Cohen, J. D., Thompson, S. & Ting, A. Y. Structure-Guided Engineering of a 
Pacific Blue Fluorophore Ligase for Specific Protein Imaging in Living Cells. 
Biochemistry 50, 8221–8225 (2011). 
123. Hildreth, J. E. K., Derr, D. & Azorsa, D. O. Characterization of a Novel Self-
Associating Mr 40,000 Platelet Glycoprotein. Blood 77, 121–132 (1991). 
124. Cox, E. C. et al. Antibody-mediated endocytosis of polysialic acid enables 
intracellular delivery and cytotoxicity of a glycan-directed antibody-drug 
conjugate. Cancer Research canres.3119.2018 (2019). doi:10.1158/0008-
5472.CAN-18-3119 
125. Bertelsen, V. & Stang, E. The Mysterious Ways of ErbB2/HER2 Trafficking. 
Membranes 4, 424–446 (2014). 
126. Pols, M. S. & Klumperman, J. Trafficking and function of the tetraspanin 
CD63. Experimental Cell Research 315, 1584–1592 (2009). 
127. Dozier, J. & Distefano, M. Site-Specific PEGylation of Therapeutic Proteins. 
IJMS 16, 25831–25864 (2015). 
128. Fire, A. et al. Potent and specific genetic interference by double-stranded 
RNA in Caenorhabditis elegans. Nature 391, 806–811 (1998). 
129. Davis, M. E. The First Targeted Delivery of siRNA in Humans via a Self-
Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to 
Clinic. Mol. Pharmaceutics 6, 659–668 (2009). 
130. Gonzalez, H., Hwang, S. J. & Davis, M. E. New Class of Polymers for the 
Delivery of Macromolecular Therapeutics. Bioconjugate Chemistry 10, 1068–
1074 (1999). 
131. Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. 
Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery 
of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of 
Metastatic Ewing's Sarcoma. Cancer Research 65, 8984–8992 (2005). 
132. Hwang, S. J., Bellocq, N. C. & Davis, M. E. Effects of Structure of β-
Cyclodextrin-Containing Polymers on Gene Delivery. Bioconjugate 
Chemistry 12, 280–290 (2001). 
133. Popielarski, S. R., Mishra, S. & Davis, M. E. Structural Effects of 
Carbohydrate-Containing Polycations on Gene Delivery. 3. Cyclodextrin 
Type and Functionalization. Bioconjugate Chemistry 14, 672–678 (2003). 
134. Pun, S. H. et al. Cyclodextrin-Modified Polyethylenimine Polymers for Gene 
Delivery. Bioconjugate Chemistry 15, 831–840 (2004). 
 
 
194 
 
135. Reineke, T. M. & Davis, M. E. Structural Effects of Carbohydrate-Containing 
Polycations on Gene Delivery. 1. Carbohydrate Size and Its Distance from 
Charge Centers. Bioconjugate Chemistry 14, 247–254 (2003). 
136. Hafez, I. M., Maurer, N. & Cullis, P. R. On the mechanism whereby cationic 
lipids promote intracellular delivery of polynucleic acids. Gene Therapy 8, 
1188–1196 (2001). 
137. Hafez, I. M., Ansell, S. & Cullis, P. R. Tunable pH-Sensitive Liposomes 
Composed of Mixtures of Cationic and Anionic Lipids. Biophysical Journal 
79, 1438–1446 (2000). 
138. Huang, L. & Liu, Y. In Vivo Delivery of RNAi with Lipid-Based 
Nanoparticles. Annu. Rev. Biomed. Eng. 13, 507–530 (2011). 
139. Jayaraman, M. et al. Maximizing the Potency of siRNA Lipid Nanoparticles 
for Hepatic Gene Silencing In Vivo. Angewandte Chemie International 
Edition 51, 8529–8533 (2012). 
140. Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. 
Proceedings of the National Academy of Sciences 107, 9915–9915 (2010). 
141. Mahon, K. P. et al. Combinatorial Approach to Determine Functional Group 
Effects on Lipidoid-Mediated siRNA Delivery. Bioconjugate Chemistry 21, 
1448–1454 (2010). 
142. Sato, Y. et al. A pH-sensitive cationic lipid facilitates the delivery of 
liposomal siRNA and gene silencing activity in vitro and in vivo. Journal of 
Controlled Release 163, 267–276 (2012). 
143. Xu, Y. & Szoka, F. C. Mechanism of DNA Release from Cationic 
Liposome/DNA Complexes Used in Cell Transfection †,‡. Biochemistry 35, 
5616–5623 (1996). 
144. Zhang, J., Fan, H., Levorse, D. A. & Crocker, L. S.  Ionization Behavior of 
Amino Lipids for siRNA Delivery: Determination of Ionization Constants, 
SAR, and the Impact of Lipid p K a on Cationic Lipid−Biomembrane 
Interactions. Langmuir 27, 1907–1914 (2011). 
145. Zhang, S., Zhi, D. & Huang, L. Lipid-based vectors for siRNA delivery. 
Journal of Drug Targeting 20, 724–735 (2012). 
146. Zimmermann, T. S. et al. RNAi-mediated gene silencing in non-human 
primates. Nature 441, 111–114 (2006). 
147. Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F. & Aigner, A. 
RNAi-mediated gene-targeting through systemic application of 
polyethylenimine (PEI)-complexed siRNA in vivo. Gene Therapy 12, 461–
466 (2004). 
148. Kichler, A. Gene transfer with modified polyethylenimines. J. Gene Med. 6, 
S3–S10 (2004). 
149. Kircheis, R., Wightman, L. & Wagner, E. Design and gene delivery activity of 
modified polyethylenimines. Advanced Drug Delivery Reviews 53, 341–358 
(2001). 
150. Richards Grayson, A. C., Doody, A. M. & Putnam, D. Biophysical and 
Structural Characterization of Polyethylenimine-Mediated siRNA Delivery in 
Vitro. Pharm Res 23, 1868–1876 (2006). 
 
 
195 
 
151. Thomas, M. et al. Full deacylation of polyethylenimine dramatically boosts its 
gene delivery efficiency and specificity to mouse lung. Proceedings of the 
National Academy of Sciences 102, 5679–5684 (2005). 
152. Werth, S. et al. A low molecular weight fraction of polyethylenimine (PEI) 
displays increased transfection efficiency of DNA and siRNA in fresh or 
lyophilized complexes. Journal of Controlled Release 112, 257–270 (2006). 
153. Wittrup, A. & Lieberman, J. Knocking down disease: a progress report on 
siRNA therapeutics. Nature Reviews Genetics 16, 543–552 (2015). 
154. Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for 
therapeutic mRNA delivery. Nature Publishing Group 2, 1–17 (2017). 
155. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors Affecting 
the Clearance and Biodistribution of Polymeric Nanoparticles. Mol. 
Pharmaceutics 5, 505–515 (2008). 
156. Nielsen, C., Kjems, J., Sørensen, K. R., Engelholm, L. H. & Behrendt, N. 
Advances in targeted delivery of small interfering RNA using simple 
bioconjugates. Expert Opinion on Drug Delivery 11, 791–822 (2014). 
157. Nair, J. K. et al. Multivalent N -Acetylgalactosamine-Conjugated siRNA 
Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing. 
Journal of the American Chemical Society 136, 16958–16961 (2014). 
158. McNamara, J. O. et al. Cell type–specific delivery of siRNAs with aptamer-
siRNA chimeras. Nature Biotechnology 24, 1005–1015 (2006). 
159. Wheeler, L. A. et al. Inhibition of HIV transmission in human cervicovaginal 
explants and humanized mice using CD4 aptamer-siRNA chimeras. Journal 
of Clinical Investigation 121, 2401–2412 (2011). 
160. Berezhnoy, A., Castro, I., Levay, A., Malek, T. R. & Gilboa, E. Aptamer-
targeted inhibition of mTOR in T cells enhances antitumor immunity. Journal 
of Clinical Investigation 124, 188–197 (2013). 
161. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs 
via cell-surface receptors. Nature Biotechnology 23, 709–717 (2005). 
162. Baumer, S. et al. Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo 
Overcomes Therapy Resistance in Colon Cancer. Clinical Cancer Research 
21, 1383–1394 (2015). 
163. Sugo, T. et al. Development of antibody-siRNA conjugate targeted to cardiac 
and skeletal muscles. Journal of Controlled Release 237, 1–13 (2016). 
164. Ma, Y. et al.  Humanized Lewis-Y Specific Antibody Based Delivery of 
STAT3 siRNA. ACS Chemical Biology 6, 962–970 (2011). 
165. Cuellar, T. L. et al. Systematic evaluation of antibody-mediated siRNA 
delivery using an industrial platform of THIOMAB-siRNA conjugates. 
Nucleic Acids Research 43, 1189–1203 (2014). 
166. Baumer, N. et al. Antibody-coupled siRNA as an efficient method for in vivo 
mRNA knockdown. Nature Protocols 11, 22–36 (2015). 
167. Peer, D., Zhu, P., Carman, C. V., Lieberman, J. & Shimaoka, M. Selective 
gene silencing in activated leukocytes by targeting siRNAs to the integrin 
lymphocyte function-associated antigen-1. Proceedings of the National 
Academy of Sciences 104, 4095–4100 (2007). 
 
 
196 
 
168. Yao, Y. D. et al. Targeted Delivery of PLK1-siRNA by ScFv Suppresses 
Her2  Breast Cancer Growth and Metastasis. Science Translational Medicine 
4, 130ra48–130ra48 (2012). 
169. Kumar, P. et al. T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection 
in Humanized Mice. Cell 134, 577–586 (2008). 
170. Kingston, R. E., Chen, C. A. & Rose, J. K. Calcium Phosphate Transfection. 
Current Protocols in Molecular Biology 63, 9.1.1–9.1.11 (2003). 
171. Parmar, R. et al. 5′-( E)-Vinylphosphonate: A Stable Phosphate Mimic Can 
Improve the RNAi Activity of siRNA-GalNAc Conjugates. ChemBioChem 
17, 985–989 (2016). 
172. Layzer, J. M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 
766–771 (2004). 
173. Matias, C. et al. Citrate and albumin facilitate transferrin iron loading in the 
presence of phosphate. Journal of Inorganic Biochemistry 168, 107–113 
(2017). 
174. Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide 
therapies of clinical utility. Nature Biotechnology 35, 238–248 (2017). 
175. Zak, O. et al. Iron Release from Recombinant N-lobe and Mutants of Human 
Transferrin. Biochemistry 34, 14428–14434 (1995). 
176. Zelikin, A. N., Ehrhardt, C. & Healy, A. M. Materials and methods for 
delivery of biological drugs. Nature Chemistry 8, 997–1007 (2016). 
177. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: 
advances in siRNA delivery. Nat Rev Drug Discov 8, 129–138 (2009). 
178. Schellinger, J. G. et al. Melittin-grafted HPMA-oligolysine based copolymers 
for gene delivery. Biomaterials 34, 2318–2326 (2013). 
179. Bettinger, T., Carlisle, R. C., Read, M. L., Ogris, M. & Seymour, L. W. 
Peptide-mediated RNA delivery: a novel approach for enhanced transfection 
of primary and post-mitotic cells. Nucleic Acids Research 29, 3882–3891 
(2001). 
180. Boeckle, S., Wagner, E. & Ogris, M. C- versus N-terminally linked melittin-
polyethylenimine conjugates: the site of linkage strongly influences activity of 
DNA polyplexes. J. Gene Med. 7, 1335–1347 (2005). 
181. Chen, C.-P., Kim, J.-S., Steenblock, E., Liu, D. & Rice, K. G. Gene Transfer 
with Poly-Melittin Peptides. Bioconjugate Chemistry 17, 1057–1062 (2006). 
182. Meyer, M. et al. Synthesis and Biological Evaluation of a Bioresponsive and 
Endosomolytic siRNA−Polymer Conjugate. Mol. Pharmaceutics 6, 752–762 
(2009). 
183. Melikov, K. & Chernomordik, L. V. Arginine-rich cell penetrating peptides: 
from endosomal uptake to nuclear delivery. Cell. Mol. Life Sci. 62, 2739–
2749 (2005). 
184. Nagahara, H. et al. Transduction of full-length TAT fusion proteins into 
mammalian cells: TAT-p27Kip1 induces cell migration. Nature Medicine 4, 
1449–1452 (1998). 
185. Margus, H., Padari, K. & Pooga, M. Cell-penetrating Peptides as Versatile 
Vehicles for Oligonucleotide Delivery. Molecular Therapy 20, 525–533 
(2016). 
 
 
197 
 
186. Najjar, K. et al. Unlocking Endosomal Entrapment with Supercharged 
Arginine-Rich Peptides. Bioconjugate Chemistry 28, 2932–2941 (2017). 
187. Mandal, M. & Lee, K.-D. Listeriolysin O-liposome-mediated cytosolic 
delivery of macromolecule antigen in vivo: enhancement of antigen-specific 
cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochimica 
et Biophysica Acta (BBA) - Biomembranes 1563, 7–17 (2002). 
188. Saito, G., Amidon, G. L. & Lee, K.-D. Enhanced cytosolic delivery of 
plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate 
utilizing cellular reducing potential. Gene Therapy 10, 72–83 (2003). 
189. Werkmeister, J. A., Hewish, D. R., Kirkpatrick, A. & Rivett, D. E. Sequence 
requirements for the activity of membrane‐active peptides. The Journal of 
Peptide Research 60, 232–238 (2002). 
190. Phan, N. N., Li, C. & Alabi, C. A. Intracellular Delivery via Noncharged 
Sequence-Defined Cell- Penetrating Oligomers. Bioconjugate Chemistry 29, 
2628–2635 (2018). 
191. Verherstraeten, S. et al. Perfringolysin O: The Underrated Clostridium 
perfringens Toxin? Toxins 7, 1702–1721 (2015). 
192. Polekhina, G., Giddings, K. S., Tweten, R. K. & Parker, M. W. Insights into 
the action of the superfamily of cholesterol-dependent cytolysins from studies 
of intermedilysin. Proceedings of the National Academy of Sciences 102, 
600–605 (2005). 
193. Liu, D. V., Yang, N. J. & Wittrup, K. D. A Nonpolycationic Fully 
Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA. 
Molecular Therapy — Nucleic Acids 3, e162 (2014). 
194. Rozema, D. B. et al. Protease-triggered siRNA delivery vehicles. Journal of 
Controlled Release 209, 57–66 (2015). 
195. Naganawa, A., Ichikawa, Y. & Isobe, M. Synthetic studies on tautomycin: 
Synthesis of 2,3-Disubstituted Maleic Anhydride Segment. Tetrahedron 50, 
8969–8982 (1994). 
196. Xing, Y., Smith, A. M., Agrawal, A., Ruan, G. & Nie, S. Molecular profiling 
of single cancer cells and clinical tissue specimens with semiconductor 
quantum dots. International Journal of Nanomedicine 1, 473–481 (2006). 
197. Mayor, S. & Pagano, R. E. Pathways of clathrin-independent endocytosis. 
Nature Reviews Molecular Cell Biology 8, 603–612 (2007). 
198. Doronina, S. O. et al. Development of potent monoclonal antibody auristatin 
conjugates for cancer therapy. Nature Biotechnology 778–784 (2003). 
199. Hamblett, K. J. et al. Effects of Drug Loading on the Antitumor Activity of a 
Monoclonal Antibody Drug Conjugate. Clinical Cancer Research 7063–7070 
(2004). 
200. Patterson, J. T., Asano, S., Li, X., Rader, C. & Barbas, C. F., III. Improving 
the Serum Stability of Site-Specific Antibody Conjugates with Sulfone 
Linkers. Bioconjugate Chemistry 25, 1402–1407 (2014). 
201. Thompson, P. et al. Hydrolytically Stable Site-Specific Conjugation at the N-
Terminus of an Engineered Antibody. Bioconjugate Chemistry 26, 2085–2096 
(2015). 
 
 
198 
 
202. Lac, D. et al. Covalent Chemical Ligation Strategy for Mono- and Polyclonal 
Immunoglobulins at Their Nucleotide Binding Sites. Bioconjugate Chemistry 
27, 159–169 (2016). 
203. Zuberbühler, K., Casi, G., Bernardes, G. J. L. & Neri, D. Fucose-specific 
conjugation of hydrazide derivatives to a vascular-targeting monoclonal 
antibody in IgG format. Chemical Communications 48, 7100–3 (2012). 
204. Ekholm, F. S. et al. Introducing Glycolinkers for the Functionalization of 
Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. 
ChemMedChem 11, 2501–2505 (2016). 
205. Okeley, N. M. et al. Metabolic Engineering of Monoclonal Antibody 
Carbohydrates for Antibody–Drug Conjugation. Bioconjugate Chemistry 24, 
1650–1655 (2013). 
206. Zhou, Q. et al. Site-Specific Antibody–Drug Conjugation through 
Glycoengineering. Bioconjugate Chemistry 25, 510–520 (2014). 
207. Li, X., Fang, T. & Boons, G.-J. Preparation of Well-Defined Antibody-Drug 
Conjugates through Glycan Remodeling and Strain-Promoted Azide-Alkyne 
Cycloadditions. Angewandte Chemie International Edition 53, 7179–7182 
(2014). 
208. Qasba, P. K. Glycans of Antibodies as a Specific Site for Drug Conjugation 
Using Glycosyltransferases. Bioconjugate Chemistry 26, 2170–2175 (2015). 
209. van Geel, R. et al. Chemoenzymatic Conjugation of Toxic Payloads to the 
Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and 
Highly Efficacious Antibody–Drug Conjugates. Bioconjugate Chemistry 26, 
2233–2242 (2015). 
210. Bryant, P. et al. In Vitro and In Vivo Evaluation of Cysteine Rebridged 
Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-
Antibody Ratios. Mol. Pharmaceutics 12, 1872–1879 (2015). 
211. Behrens, C. R. et al. Antibody–Drug Conjugates (ADCs) Derived from 
Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and 
Other Pharmacological Properties over Conventional Heterogeneous ADCs. 
Mol. Pharmaceutics 12, 3986–3998 (2015). 
212. Maruani, A. et al. A plug-and-play approach to antibody-based therapeutics 
via a chemoselective dual click strategy. Nature Communications 6, 6645 
(2015). 
213. Harmand, T. J. et al. One-Pot Dual Labeling of IgG 1 and Preparation of 
C‑to‑C Fusion Proteins Through a Combination of Sortase A and Butelase 1. 
Bioconjugate Chemistry 1–5 (2018). doi:10.1021/acs.bioconjchem.8b00563 
214. Beerli, R. R., Hell, T., Merkel, A. S. & Grawunder, U. Sortase Enzyme-
Mediated Generation of Site-Specifically Conjugated Antibody Drug 
Conjugates with High In Vitro and In Vivo Potency. PLoS ONE 10, 
e0131177–17 (2015). 
215. Hu, C.-M. J. & Zhang, L. Nanoparticle-based combination therapy toward 
overcoming drug resistance in cancer. Biochemical Pharmacology 83, 1104–
1111 (2012). 
216. Maruani, A., Richards, D. A. & Chudasama, V. Dual modification of 
biomolecules. Org. Biomol. Chem. 14, 6165–6178 (2016). 
 
 
199 
 
217. Levengood, M. R. et al. Orthogonal Cysteine Protection Enables 
Homogeneous Multi-Drug Antibody-Drug Conjugates. Angew. Chem. 129, 
751–755 (2016). 
218. Adumeau, P. et al. Site-Specifically Labeled Antibody–Drug Conjugate for 
Simultaneous Therapy and ImmunoPET. Mol. Pharmaceutics 15, 892–898 
(2018). 
219. Spycher, P. R. et al. Dual, Site-Specific Modification of Antibodies by Using 
Solid-Phase Immobilized Microbial Transglutaminase. ChemBioChem 18, 
1923–1927 (2017). 
220. Wollschlaeger, C. et al. Simultaneous and Independent Dual Site-Specific 
Self-Labeling of Recombinant Antibodies. Bioconjugate Chemistry 1–9 
(2018). doi:10.1021/acs.bioconjchem.8b00545 
221. Sorkin, M. R., Walker, J. A., Brown, J. S. & Alabi, C. A. Versatile Platform 
for the Synthesis of Orthogonally Cleavable Heteromultifunctional Cross-
Linkers. Bioconjugate Chemistry 28, 907–912 (2017). 
222. Lee, B.-C. et al. FRET Reagent Reveals the Intracellular Processing of 
Peptide-Linked Antibody–Drug Conjugates. Bioconjugate Chemistry 29, 
2468–2477 (2018). 
223. Anami, Y. et al. Enzymatic conjugation using branched linkers for 
constructing homogeneous antibody–drug conjugates with high potency. Org. 
Biomol. Chem. 15, 5635–5642 (2017). 
224. Dubowchik, G. M. et al. Cathepsin B-Labile Dipeptide Linkers for Lysosomal 
Release of Doxorubicin from Internalizing Immunoconjugates:  Model 
Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer 
Activity. Bioconjugate Chemistry 13, 855–869 (2002). 
225. Turk, B. E., Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of 
protease cleavage site motifs using mixture-based oriented peptide libraries. 
Nature Biotechnology 19, 661–667 (2001). 
226. Chau, Y., Tan, F. E. & Langer, R. Synthesis and Characterization of 
Dextran−Peptide−Methotrexate Conjugates for Tumor Targeting via 
Mediation by Matrix Metalloproteinase II and Matrix Metalloproteinase IX. 
Bioconjugate Chemistry 15, 931–941 (2004). 
227. Uttamapinant, C., Sanchez, M. I., Liu, D. S., Yao, J. Z. & Ting, A. Y. Site-
specific protein labeling using PRIME and chelation-assisted click chemistry. 
Nature Protocols 8, 1620–1634 (2013). 
228. Salomon, P. L. & Singh, R. Sensitive ELISA Method for the Measurement of 
Catabolites of Antibody–Drug Conjugates (ADCs) in Target Cancer Cells. 
Mol. Pharmaceutics 12, 1752–1761 (2015). 
 
